A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Phase: PHASE1
Conditions: Lymphoma, Non-Hodgkin, Neoplasms
Sponsor: Celgene

Official Title of Study: 
A Phase 1, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and 
Preliminary Efficacy of CC-90011 in Subjects with Relapsed and/or Refractory Solid Tumors and Non-
Hodgkin’s Lymphomas 
 
 
NCT Number: NCT02875223 
Document Date (Date in which document was last revised): 05 Nov 2021 
 
 
 

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
1
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
TITLE PAGE
A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY TO ASSESS 
THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND 
PRELIMINARY EFFICACY OF CC-90011 IN SUBJECTS WITH 
RELAPSED AND/OR REFRACTORY SOLID TUMORS AND 
NON-HODGKIN’S LYMPHOMAS
INVESTIGATIONAL PRODUCT (IP):
CC-90011 (also known as BMS-986363)
PROTOCOL NUMBER:
CC-90011-ST-001
DATE FINAL:
19 April 2016
AMENDMENT No. 1 DATE
15 June 2016
AMENDMENT No. 1.1 DATE
12 August 2016
AMENDMENT No. 2 DATE
01 November 2016
AMENDMENT No. 3 DATE
23 June 2017
AMENDMENT No. 4 DATE
12 September 2017
AMENDMENT No. 5 DATE
30 March 2018
AMENDMENT No. 6 DATE
05 October 2019
AMENDMENT No. 7 DATE
06 February 2020
AMENDMENT No. 8 DATE
01 July 2020
AMENDMENT No. 9 DATE
22 December 2020
AMENDMENT No. 10 DATE
05 November 2021
EudraCT NUMBER:
2015-005243-13
IND NUMBER:
Not Applicable
SPONSOR NAME/ ADDRESS:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or 
consultant for review by you, your staff, and ethics committee/institutional 
review board.  The information contained in this document is regarded as 
confidential and, except to the extent necessary to obtain informed consent, may 
not be disclosed to another party unless such disclosure is required by law or 
regulations.  Persons to whom the information is disclosed must be informed 
that the information is confidential and may not be further disclosed by them.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
2
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
 
Address: Celgene International, Route de Perreux 1, 2017 Boudry, Switzerland
Phone:
E-mail:
Contact Information:
Name:
Title:
 
Address: Centre for Innovation and Translational Research Europe, Seville, Spain
Phone:
E-mail:
Note: The back-up 24-hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact Call Center: 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
3
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head
dd mmm yyyy
 
 
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
4
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representatives, the Declaration of Helsinki, International Council for
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations 
governing the conduct of clinical studies.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
5
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
6
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
PROTOCOL SUMMARY
Study Title
A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics
and Preliminary Efficacy of CC-90011 in Subjects with Relapsed and/or Refractory Solid 
Tumors and Non-Hodgkin’s Lymphomas.
Indication
Relapsed and/or refractory advanced unresectable solid tumors (enriched for grade 2 
neuroendocrine neoplasms [NEN] and grade 2 [G2] neuroendocrine tumors [NETs] and 
neuroendocrine carcinomas [NEC]) and relapsed and/or refractory (R/R) advanced Non-
Hodgkin’s lymphomas (NHLs) (ie, diffuse large B-cell lymphoma [DLBCL] and follicular 
lymphoma [FL] and marginal zone lymphoma [MZL]).
Part B will enroll relapsed and/or refractory advanced unresectable low/intermediate-grade lung 
NETs (typical and atypical carcinoid), prostate NECs (NEPCs) and R/R NHL.
Parts C and D will enroll subjects with advanced unresectable solid tumors.
Objectives Part A and Part B
Primary Objectives:

To determine the safety and tolerability of CC-90011

To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose 
(RP2D) of CC-90011 
Secondary Objectives:

To provide information on the preliminary efficacy of CC-90011

To characterize the pharmacokinetics (PK) of CC-90011
Objectives Part C and Part D
Primary Objectives:

To evaluate the effect of rifampicin, a strong cytochrome P450 (CYP) 3A and P-
glycoprotein (P-gp) inducer, on the PK of CC-90011 (Part C)

To evaluate the effect of itraconazole, a strong CYP3A and P-gp inhibitor on the PK 
of CC-90011 (Part D)
Secondary Objectives:

To characterize the PK parameters of a single dose of CC-90011 alone and in
combination with rifampicin (Part C) or itraconazole (Part D)

To assess the safety and tolerability of a single dose of CC-90011 alone and in 
combination with rifampicin (Part C) or itraconazole (Part D)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
7
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Exploratory Objectives
All exploratory objectives are outlined in Section 2.
Study Design
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-
Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors
(enriched for grade 2 NENs, grade 2 NETs and NECs) and R/R NHL (MZL, including 
extranodal MZL [EMZL], splenic MZL [SMZL], nodal MZL [NMZL], and histologic 
transformation of MZL). The dose escalation part (Part A) of the study will explore escalating 
oral doses of CC-90011 to estimate the MTD of CC-90011. A Bayesian logistic regression 
model (BLRM) utilizing escalation with overdose control (EWOC) (Babb, 1998; 
Neuenschwander, 2008) will help guide CC-90011 dose escalation and dose frequency decisions,
with the final decisions made by a safety review committee (SRC). The expansion part (Part B) 
will further evaluate the safety and efficacy of CC-90011 administered at or below the MTD in 3
selected expansion cohorts of approximately 10-20 evaluable subjects each, in order to further 
define the RP2D. The Drug-Drug Interaction (DDI) cohorts will evaluate the effect of multiple 
doses of rifampicin (Part C) and itraconazole (Part D) on CC-90011 by comparison of the PK 
parameters of a single dose of CC-90011 alone and in combination with rifampicin or 
itraconazole. Parts A and B will consist of 3 periods: Screening, Treatment, and Follow-up 
periods (refer to Figure 2). Part C and D will consist of 4 periods: Screening, DDI evaluation, 
Treatment and Follow-up periods (refer to Figure 3).
Screening Period
The Screening Period starts 28 days (± 3 days) prior to first dose of CC-90011. The informed 
consent form (ICF) must be signed and dated by the subject and the administering staff prior to 
the start of any other study procedures. All screening tests and procedures must be completed 
within the 28 days (± 3 days) prior to the first dose of CC-90011.
Treatment Period
Parts A and B
During the Treatment Period, CC-90011 will initially be administered orally once weekly in each 
4-week (28-day) Cycle in Part A. Alternative dosing schedules (eg, once every other week or 
twice weekly) may be evaluated based on the review of available safety, PK, PD, and efficacy 
data by the SRC. Once the MTD has been established for a once weekly schedule, and if the 
pharmacokinetics and clinical safety data in man suggest more frequent dosing might be 
appropriate, and if the SRC is supportive, alternative more frequent dosing schedules may be 
explored. In Part A, the window for evaluation of dose-limiting toxicity (DLT) will be 28 days (4 
weeks) during Cycle 1. 
In September 2018, after completion of Part A, the SRC determined the RP2D to be 60 mg
CC-90011 once weekly (QW) in each 28-day cycle. In Part B, 3 cohorts, of approximately 10-20 
(MZL, including EMZL, SMZL, NMZL and histologic transformation of MZL) evaluable 
subjects each, with advanced low/intermediate-grade lung NETs, NEPCs, R/R NHL will receive 
the RP2D to further evaluate safety, PK, PD and preliminary efficacy.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
8
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
The enrollment of subjects with bronchial NET, prostate NEC and MZL was closed due to 
Company’s strategic decisions and not due to any safety concern. The RP2D established during 
Part A, was confirmed to be safe and tolerable during Part B.
Parts C and D
The DDI cohorts will consist of a nonrandomized, fixed-sequence, crossover, two-period design 
that will evaluate the effect of multiple doses of rifampicin (Part C) and itraconazole (Part D) on 
CC-90011 PK parameters in approximately 16 subjects with advanced unresectable solid tumors. 
The DDI evaluation for both Parts C and D will be conducted across 2 study periods (hereafter 
referred to as Period 1 and Period 2) followed by a CC-90011 treatment period in which subjects 
will receive CC-90011 at the RP2D of 60 mg QW in 28-day cycles. Both Part C and Part D will 
have a 14-day washout interval between Period 1 and Period 2 and the total duration of the DDI 
evaluation period (Period 1 + Period 2) will be 40 days. Overnight stay for subjects can be 
arranged or subjects can be hospitalized at any time point due to study procedures, without this 
constituting a serious adverse event (SAE), if the treating physician considers this appropriate for 
an individual subject. Blood samples and urine will be collected at prespecified time points for 
PK analyses. Blood samples will also be collected at prespecified time points for PD analyses.
Follow-up Period
In the Follow-up Period, all subjects will be followed for 28 days (± 3 days) after the last dose of 
CC-90011 (in Parts A and B) and after the last dose of any study treatment, whichever is the 
latest (in Parts C and D) for safety. 
Subjects who discontinue treatment for reasons other than disease progression, start of a new 
anticancer therapy, or withdrawal of consent from the entire study will have disease assessments 
performed according to the specified tumor assessment schedule until progression and/or 
initiation of new systemic anticancer therapies. This does not apply to subjects who discontinue 
during the DDI evaluation period in Part C and Part D.
After the Safety Follow-up visit, subjects will be followed every subsequent 3 months, 
(± 2 weeks) for survival follow-up, for up until 2 years or until death, lost to follow-up, or the 
End of Trial, whichever occurs first. This does not apply to subjects who discontinue during the 
DDI evaluation period in Part C and Part D.
Subjects who discontinue treatment during the DDI evaluation in Parts C and D may be replaced
if not DDI evaluable.
Part A-Dose Escalation
A minimum of 3 subjects will be enrolled at each dose level. The initial CC-90011 dose was 1.25 
mg once per week. The BLRM with EWOC will incorporate available prior safety information 
and update the model parameters after each new cohort of subjects completes Cycle 1. The 
decision for the next dose will be made by the SRC based on a calculation of risk assessment 
using the BLRM, and available safety (ie, DLT and non-DLT safety data), PK, PD, and 
preliminary efficacy information. In addition, relevant non-clinical data (eg, GLP (good 
laboratory practice) toxicity studies, in vivo pharmacology from xenograft models, etc) may be 
utilized in the assessment. Details of the statistical methodology are provided in Appendix E.
At all decision time points, the BLRM permits alterations in the dose increments based on the 
observed DLTs; however, the dose for the next cohort will not exceed a 100% increase from the 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
9
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
prior dose. The MTD is the highest dose for which less than 33% of the population (not sample 
from the population) treated with CC-90011 suffer a DLT in the first cycle with at least 
6 evaluable subjects having been treated at this dose. The SRC will make the final decision 
regarding the CC-90011 dose for each cohort.
During dose escalation, a CC-90011 dose can be declared the MTD after meeting the following 
conditions: 

at least 6 evaluable subjects have been treated at the dose, 

the posterior probability that the DLT rate lying in the target interval (16-33%) at the 
dose exceeds 60% or a sufficient number of subjects have been entered into the study 
to ensure the precision of the MTD estimate, as the posterior probability approaches 
but fails to exceed 60%, and

the dose is recommended according to the BLRM and is approved by SRC.
Dose escalation may be terminated by SRC at any time based on emerging safety concerns 
without establishing the MTD. The SRC will include Investigators (and/or designated 
representatives), the Sponsor’s study physician, safety physician, study statistician, and the study 
manager.  Ad hoc attendees may include the study pharmacokineticist, the study biomarker 
scientist, and the study clinical scientist. Other internal and external experts may be consulted by 
the SRC, as necessary.  
All decisions made at the SRC meetings will be formally documented (via SRC meeting 
minutes) and circulated to all sites in writing.  No dose escalation, de-escalation, change to 
dosing schedule, or expansion of existing dose cohorts will commence prior to a written 
notification being sent to all participating sites of the respective SRC decision.
The decision to evaluate additional subjects within a dose cohort, a higher dose cohort, 
intermediate dose cohorts, smaller dose increments, alternative dosing schedules (eg, once every 
other week or twice weekly), or declare a MTD will also be determined by the SRC, based on the 
BLRM assessment and their review of available safety (ie, DLT and non-DLT data), PK, PD, 
and preliminary efficacy information. The final decision will be made by the SRC.
After the first dose is administered in any cohort during dose escalation, subjects in each cohort 
are observed for 28 days (Cycle 1, DLT window) before the next dose cohort can begin. A 
subject evaluable for DLT is defined as one that: 

Has received ≥ 75% of the total planned dose amount of CC-90011 during Cycle 1 
without experiencing a DLT,
or

Experienced a DLT after receiving at least one dose of CC-90011.  
Subjects non-evaluable for DLT will be replaced.
During the initial dose levels, subjects with relapsed and/or refractory advanced unresectable 
solid tumors and R/R NHL will be enrolled until the 2nd occurrence of a Grade ≥ 2, study drug-
related toxicity in Cycle 1 which fall under the adverse event terms of thrombocytopenia/platelet 
count decrease, anaemia/red blood cell count decrease, neutropenia/white blood cell count 
decrease, and/ or gastrointestinal tract toxicities. Then, enrollment in Part A will be restricted to 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
10
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
subjects with grade 2 (G2) neuroendocrine neoplasms (NEN)/neuroendocrine tumors (NETs), 
small cell lung cancer (SCLC), and other neuroendocrine carcinomas (NEC) which may secrete 
neuroendocrine markers such as Pro-GRP, CgA, or calcitonin (only in Part A).
Intra-subject dose escalation will not be allowed during the DLT assessment period; however, in 
Cycles ≥ 3, subjects without evidence of disease progression who are tolerating their assigned 
dose of CC-90011 may (at the Investigator’s discretion and in consultation and agreement with 
the Sponsor’s study physician) escalate to the highest dose level shown to be adequately 
tolerated by at least one cohort of subjects in this study (ie, overdose risk is less than 25% based 
on the BLRM assessment).
Part B-Cohort Expansion
Following completion of dose escalation (Part A), Part B (expansion) will enroll 3 cohorts, of 
approximately 10-20 evaluable subjects each, with advanced low/intermediate-grade lung NETs, 
NEPCs and R/R NHL (MZL, including EMZL, SMZL, NMZL and histologic transformation of 
MZL) will receive the RP2D to further evaluate the safety, PK, PD and preliminary efficacy.  
Expansion may occur at the MTD and schedule established in the dose escalation phase, and/or 
at an alternative tolerable dose and schedule, based on review of available safety, PK, PD, and 
efficacy data from Part A. The SRC will select the doses and schedules of interest for cohort 
expansion. One or more dosing regimens may be selected for cohort expansion. The SRC will 
continue to review safety data regularly throughout the study and make recommendations about 
study continuation and dose modification, as appropriate. The study will be conducted in 
compliance with International Council for Harmonisation (ICH)/Good Clinical Practices (GCPs).
In Part B of the study, SRC meetings will be held after at least 6 subjects have been recruited 
with at least 2 months of follow up; or after the number of subjects specified in the futility 
analyses has been reached; and/or ad-hoc as advised by emerging safety/efficacy data.
Part C and Part D- DDI Cohorts
Approximately 8 DDI evaluable subjects with advanced unresectable solid tumors will be 
enrolled in each part, leading to a total of up to 16 DDI evaluable subjects for Parts C and D.
DDI evaluable population is described in Section 9.2. Following confirmation of eligibility 
during screening, subjects will be alternatively enrolled in Part C or Part D. The DDI evaluation 
will be conducted across 2 study periods (Period 1 and Period 2), followed by a CC-90011 
treatment period in which subjects will receive CC-90011 at the RP2D of 60 mg QW of 28-day 
cycles. Overnight stay for subjects can be arranged or subjects can be hospitalized at any time 
point due to study procedures, without this constituting a serious adverse event (SAE), if the 
treating physician considers appropriate for an individual subject. Treatment in Part C and Part D 
are as described below. Both parts will have a 14-day washout interval between Period 1 and 
Period 2 and the total duration of the DDI evaluation period (Period 1 + Period 2) will be 40 
days:

Part C: Period 1 (Day 1 - Day 14) will consist of a single oral 60 mg CC-90011 dose 
administered on Day 1, followed by a washout interval of 14 days. 
Period 2 (Day 15 - Day 40) will consist of a total of 21 oral doses of rifampicin 600 
mg administered daily from Day 15 until Day 35, and a single oral 60 mg CC-90011 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
11
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
dose administered on Day 22, followed by a washout interval from Day 36 until Day 
39 (both included).

Part D: Period 1 (Day 1 - Day 14) will consist of single oral 20 mg CC-90011 dose 
administered on Day 1, followed by a washout interval of 14 days.
Period 2 (Day 15 - Day 40) will consist of a total of 17 oral doses of itraconazole 200 
mg administered daily from Day 15 until Day 31, and a single oral 20 mg CC-90011 
dose administered on Day 18, followed by a washout interval from Day 32 until Day 
39 (both included).
Following completion of DDI evaluation period, including a washout period of 5 days after the 
last dose of rifampicin (Part C) or 9 days following last dose of itraconazole (Part D), subjects 
will start CC-90011 dosing on Study Day 40 at the RP2D of 60 mg QW with 28-day cycles. 
Study Population
Men and women, 18 years or older, with relapsed and/or refractory advanced unresectable solid 
tumors (enriched for G2 NENs/NET, SCLC, and other NECs) and R/R NHL (including DLBCL 
and FL or MZL) will be enrolled in the study for Part A.
In Part B, 3 cohorts, of approximately 10-20 evaluable subjects each, with advanced 
low/intermediate-grade lung NETs, NEPCs and R/R NHL (MZL, including EMZL, SMZL, 
NMZL and histologic transformation of MZL) will receive the RP2D to further evaluate safety, 
PK, PD and preliminary efficacy.
In Parts C and D, approximately 16 DDI evaluable subjects with advanced unresectable solid 
tumors will be enrolled.
Length of Study
Enrollment is expected to take approximately 67 months to complete (24 months for dose 
escalation and 24 to 43 months for expansion). Completion of active treatment and post-
treatment follow-up is expected to take an additional 4 to 28 months. Enrollment and DDI 
evaluation in Parts C and D is expected to take 12 to 15 months. Completion of treatment and 
post-treatment follow-up is expected to take an additional 6 to 24 months. The entire study is 
expected to last approximately 9-10 years.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as prespecified in the protocol, 
whichever is the later date.
Study Treatments
Part A and Part B
Celgene Corporation (Celgene) will supply the investigational product (IP), CC-90011 in Parts A 
and B (containing only the active pharmaceutical ingredient at dosage strengths of 0.50 mg, 0.75 
mg, and 2.00 mg, 5.00 mg, and 15 mg) capsules for oral administration, labeled appropriately for 
investigational use as per the regulations of the relevant country health authority.
Study treatment may be discontinued if there is evidence of clinically significant disease 
progression, unacceptable toxicity or subject/physician decision to withdraw.  
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
12
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Part C and Part D
Celgene Corporation (Celgene) will supply the IP, CC-90011 capsules [available as Blend in 
Capsule (BIC, Gen 2) with 20 mg, 40 mg or 60 mg strengths] for oral administration. Rifampicin
and itraconazole may be obtained through the local hospital pharmacy at the sites or licensed 
distributor in Spain, where both drugs are commercially available. All study drugs supplied by 
Celgene will be labeled appropriately for investigational use as per the regulations of the relevant 
country health authorities.
During the DDI evaluation periods:
CC-90011 will be given orally on Days 1 and 22 at a dose of 60 mg (Part C) or on Days 1 and 18 
at a dose of 20 mg (Part D).
Rifampicin will be orally administered, once daily, at a dose of 600 mg (2 tablets of 300 mg) 
from Day 15 until Day 35 (21 doses in total).
Itraconazole will be orally administered, once daily, at a dose of 200 mg (2 capsules of 100 mg) 
from Day 15 until Day 31 (17 doses in total).
Dose modifications or interruptions are not allowed during the DDI evaluation period. It is 
highly recommended to consult with the Sponsor Study Physician prior to interrupting doses for 
DDI cohorts. In case of safety concerns, the physician may interrupt treatment to protect the 
safety of the subject. Such subjects will become non-evaluable for DDI assessment and will need 
to be replaced.
During the CC-90011 Treatment period:
CC-90011 will be given orally at the RP2D of 60 mg once weekly in 28 -days cycles. Dose 
modifications or interruptions are allowed, after discussion and agreement by the Study Sponsor 
Physician.
Study treatment may be discontinued if there is evidence of clinically significant disease 
progression, unacceptable toxicity or subject/physician decision to withdraw.  
Overview of Key Efficacy Assessments
Subjects will be evaluated for efficacy after every 2 cycles through Cycle 6, and then every 3 
cycles thereafter. All subjects who discontinue treatment for reasons other than disease 
progression, start of a new anticancer therapy, or withdrawal of consent from the entire study 
will be followed until progression and/or initiation of new systemic anticancer therapies.
Tumor response will be determined by the Investigator.  For solid tumors, assessment will be 
based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer, 2009). For 
NHLs, assessment will be based on the Lugano Classification (Cheson, 2014).
[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) or FDG PET/CT imaging 
is required to confirm a complete response in subjects with FDG-avid tumors. For prostate 
cancer (PC) and neuroendocrine prostate carcinoma (NEPC), response assessment will be based 
on the PCWG3 criteria (Scher, 2016). For hepatotocellular carcinoma (HCC) and 
neuroendocrine hepatocellular carcinoma (NEHCC), response will be based on the mRECIST 
criteria (Lencioni, 2010). Neuroendocrine neoplasms G2, G2 NETs and neuroendocrine 
carcinomas will additionally have levels of neuroendocrine markers assessed at baseline and on 
study.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
13
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
In Parts C and D, a CT/MRI will be performed at the end of the DDI evaluation period, before 
starting CC-90011 treatment period, that will be considered as the baseline. 
Overview of Key Safety Assessments
The safety variables for this study include adverse events, safety clinical laboratory variables, 
12-lead electrocardiograms, Eastern Cooperative Oncology Group Performance Status, left 
ventricular ejection fraction assessments, physical examinations, vital signs, exposure to study 
treatment, assessment of concomitant medications, and pregnancy testing for females of child 
bearing potential. The PK profiles of CC-90011 will be determined from serial blood collections. 
Overview of Pharmacokinetic Assessments
For Parts A and B, the plasma PK parameters determined for CC-90011 will be maximum 
observed plasma concentration (Cmax), area under the plasma concentration time-curve (AUC), 
time to maximum plasma concentration (Tmax), terminal half-life (t1/2), apparent clearance 
(CL/F), and apparent volume of distribution (Vz/F). Exposure-response analyses may be 
conducted, as appropriate, to assist in identification of the dosing regimen for Part B or Phase 2 
studies.
For Parts C and D, plasma PK parameters for CC-90011 will be determined as described above, 
in Period 1 (CC-90011 single dose administration) and Period 2 [CC-90011 in combination with 
rifampicin (Part C) or itraconazole (Part D)].
Additionally, in Parts C and D, PK parameters will also be determined for CC-90011 in urine, 
and for metabolite CC7108272 (M1) and possibly other metabolites in plasma and urine, as 
exploratory assessments, described in Section 9.9.2.
Overview of Exploratory Pharmacodynamic Assessments
Pharmacodynamic assessments are described in Section 0.
Statistical Methods for Part A
Part A and Part B Adverse Events
The primary objectives of this study are to evaluate the safety and tolerability of treatment with 
CC-90011, including the determination of the MTD. The analysis method for estimating the 
MTD is the BLRM guided by the EWOC principle (Babb, 1998; Neuenschwander, 2008).
Statistical analyses will be performed by dose level (Part A) and tumor cohort (Part B) as needed 
or applicable. All analyses will be descriptive in nature. All summaries of safety data will be 
conducted using subjects receiving any CC-90011 (the Treated Population). 
Study data will be summarized for disposition, demographic and baseline characteristics, 
exposure, efficacy, safety, PK, and PD. Categorical data will be summarized by frequency 
distributions (number and percentages of subjects) and continuous data will be summarized by 
descriptive statistics (mean, standard deviation, median, minimum, and maximum). 
Treatment-emergent adverse events (TEAEs) will be summarized by National Cancer Institute 
Common Terminology Criteria for Adverse Event (CTCAE) version 4.03 grades. The frequency 
of TEAEs will be tabulated by Medical Dictionary for Regulatory Activities system organ class 
and preferred term. Grade 3 or 4 TEAEs, TEAEs leading to discontinuation of CC-90011, study 
drug-related TEAEs, and SAEs will be tabulated separately. Changes from baseline in selected 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
14
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
laboratory analytes, vital signs, 12-lead ECGs, and ECHO/MUGA scans will be summarized. All 
data will be presented in by-subject listings.
Part C and Part D Adverse Events
TEAEs will be summarized by CTCAE version 4.03 grades. The frequency of TEAEs will be 
tabulated by Medical Dictionary for Regulatory Activities system organ class and preferred term. 
Grade 3 or 4 TEAEs, TEAEs leading to discontinuation of subjects during the DDI evaluation 
period, CC-90011-related TEAEs, rifampicin-related TEAEs, itraconazole-related TEAEs, 
TEAEs leading to discontinuation of CC-90011 during the treatment period, and SAEs will be 
tabulated separately. Changes from baseline in selected laboratory analytes and vital signs will 
be summarized. All data will be presented in by-subject listings.
Part A Efficacy
The primary efficacy variable for Part A is clinical benefit rate (CBR). CBR is defined as tumor 
responses (as assessed by the Investigators) of complete response (CR), partial response (PR)
and durable stable disease (SD) (SD of ≥ 4 months duration). Point estimates and 95% 
confidence intervals of CBR will be reported.  Objective response rate (defined as the percentage 
of subjects whose best response is complete response or partial response), duration of 
response/stable disease, progression-free survival, and overall survival will be summarized using 
frequency tabulations for categorical variables, or descriptive statistics for time to event 
variables.  Efficacy analysis will be repeated for the Treated Population and Efficacy Evaluable 
Population (subjects who received a baseline disease assessment evaluation, at least 75% of 
assigned doses in Cycle 1, and one on study disease assessment evaluation), with the result using 
the Treated Population considered primary.
Number of Subjects
During the Part A dose escalation, 50 subjects were enrolled. During the Part B dose expansion, 
17 subjects were enrolled. In Parts C and D, approximately 16 DDI evaluable subjects with 
advanced unresectable solid tumors will be enrolled, with approximately 8 subjects evaluable for 
each DDI assessment. The subjects may be replaced if not DDI evaluable.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
15
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................22
1.1.
Disease Background ...............................................................................................22
1.2.
Compound Background ..........................................................................................23
1.2.1.
Overview of CC-90011 Mechanism of Action and In vitro and In vivo 
Nonclinical Pharmacology......................................................................................23
1.2.1.1.
Overview of Nonclinical Pharmacokinetics ............................................................25
1.2.1.2.
Overview of Nonclinical Toxicology......................................................................27
1.2.1.3.
Summary of Clinical Data.......................................................................................29
1.2.1.4.
Summary of Clinical PK and PD Data ....................................................................30
1.2.2.
Safety Monitoring Plan...........................................................................................31
1.2.3.
Rifampicin and Itraconazole ...................................................................................36
1.3.
Rationale ................................................................................................................37
1.3.1.
Study Rationale and Purpose ..................................................................................37
1.3.2.
Rationale for Tumor Type Selection in Parts A and B.............................................38
1.3.2.1.
Rationale for Selection of NHL Tumors..................................................................39
1.3.2.2.
Rationale for Selection of Neuroendocrine Tumors.................................................40
1.3.3.
Rationale for Tumor Type Selection in Parts C and D.............................................42
1.3.4.
Rationale for the Study Design ...............................................................................42
1.3.5.
Rationale for Dose, Schedule and Regimen Selection (Part A and Part B)...............42
1.3.6.
Rationale for Drug-Drug Interaction Evaluation (Part C and Part D).......................43
1.3.6.1.
Rationale for DDI evaluation design.......................................................................44
1.3.6.2.
Rationale for Doses, Schedules and Regimen Selection in DDI cohorts ..................44
1.3.7.
Rationale for Pharmacodynamics and Biomarkers ..................................................46
2.
STUDY OBJECTIVES AND ENDPOINTS...........................................................47
3.
OVERALL STUDY DESIGN ................................................................................51
3.1.
Study Design ..........................................................................................................51
3.1.1.
Part A-Dose Escalation...........................................................................................53
3.1.2.
Part B-Cohort Expansion ........................................................................................55
3.1.3.
Part C and Part D- DDI Cohorts..............................................................................55
3.1.4.
Overview of Assessments.......................................................................................57
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
16
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
3.2.
Study Duration for Subjects....................................................................................58
3.3.
End of Trial ............................................................................................................58
4.
STUDY POPULATION.........................................................................................59
4.1.
Number of Subjects ................................................................................................59
4.2.
Inclusion Criteria....................................................................................................59
4.3.
Exclusion Criteria...................................................................................................64
5.
TABLE OF EVENTS (PART A AND PART B AND CC-90011 
TREATMENT PERIOD FOR PART C AND PART D).........................................68
6.
PROCEDURES......................................................................................................77
6.1.
Screening Period.....................................................................................................77
6.2.
Treatment Period ....................................................................................................80
6.2.1.
Concomitant Medication and Procedures................................................................80
6.2.2.
Adverse Event Monitoring......................................................................................80
6.2.3.
Weight....................................................................................................................80
6.2.4.
Vital Signs..............................................................................................................81
6.2.5.
Physical Examination and ECOG Performance Status ............................................81
6.2.6.
B Symptom Assessment (NHL Subjects only) ........................................................81
6.2.7.
12-Lead-Electrocardiograms...................................................................................81
6.2.8.
Left Ventricular Ejection Fraction...........................................................................82
6.2.9.
Pregnancy Test .......................................................................................................82
6.2.10.
Clinical Laboratory Tests........................................................................................83
6.2.11.
End of Treatment (EOT).........................................................................................84
6.3.
Follow-up Period....................................................................................................84
6.3.1.
Safety Follow-up ....................................................................................................84
6.3.2.
Survival Follow-up.................................................................................................84
6.4.
Efficacy Assessment...............................................................................................84
6.4.1.
Neuroendocrine Pharmacodynamic Markers...........................................................86
6.5.
Pharmacokinetics....................................................................................................86
6.6.
Biomarkers and Pharmacodynamics .......................................................................88
6.6.1.
Pharmacodynamic and Predictive Biomarkers (only Parts A and B)........................89
6.6.2.
Whole Blood samples for Anti-SARS-CoV-2 Serology ..........................................89
6.6.3.
Tumor Biopsies ......................................................................................................90
7.
DESCRIPTION OF STUDY TREATMENTS........................................................91
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
17
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.1.
Description of Investigational Product(s)................................................................91
7.1.1.
CC-90011...............................................................................................................91
7.1.2.
Rifampicin and Itraconazole ...................................................................................91
7.2.
Treatment Administration and Schedule .................................................................92
7.2.1.
CC-90011 Administration.......................................................................................92
7.2.1.1.
CC-90011, Rifampicin and Itraconazole Administration during DDI 
evaluation period in Part C and Part D....................................................................92
7.2.2.
Dose Escalation Process (Part A)............................................................................93
7.2.3.
Dose Escalation Decisions (Part A).........................................................................94
7.2.4.
Definition of a Subject Evaluable for DLT (Part A) ................................................94
7.2.5.
Definition of Maximum Tolerated Dose (MTD) (Part A)........................................95
7.2.6.
Definition of Dose-Limiting Toxicity (DLT) (Part A).............................................95
7.2.7.
Criteria for Dose Escalation in the Next Cohort of Subjects (Part A).......................96
7.2.8.
Permitted Study Drug Adjustments.........................................................................96
7.2.9.
Criteria for Dose Reduction ....................................................................................96
7.2.10.
Criteria for Dose Increase .......................................................................................97
7.2.11.
Treatment Interruption for Adverse Events .............................................................97
7.2.12.
Management of Select Adverse Events ...................................................................97
7.2.12.1.
Neutropenia, Thrombocytopenia, and Anemia ........................................................97
7.2.12.2.
Pain ........................................................................................................................98
7.2.12.3.
Gastrointestinal Effects...........................................................................................98
7.2.13.
Definition of Overdose ...........................................................................................99
7.3.
Method of Treatment Assignment...........................................................................99
7.4.
Packaging and Labeling..........................................................................................99
7.5.
Investigational Product Accountability and Disposal ..............................................99
7.6.
Investigational Product Compliance......................................................................100
8.
CONCOMITANT MEDICATIONS AND PROCEDURES..................................101
8.1.
Permitted Concomitant Medications and Procedures.............................................101
8.2.
Prohibited Concomitant Medications and Procedures............................................102
8.2.1.
Medications to be used with caution .....................................................................103
9.
STATISTICAL CONSIDERATIONS ..................................................................104
9.1.
Overview..............................................................................................................104
9.2.
Study Population Definitions ................................................................................104
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
18
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
9.3.
Sample Size and Power Considerations.................................................................105
9.4.
Background and Demographic Characteristics......................................................106
9.5.
Subject Disposition...............................................................................................106
9.6.
Efficacy Analysis..................................................................................................106
9.7.
Safety Analysis.....................................................................................................108
9.8.
Interim Analysis ...................................................................................................109
9.9.
Other Topics.........................................................................................................109
9.9.1.
Statistical Method for Dose Escalation (Part A only) ............................................109
9.9.2.
Assessment of Pharmacokinetics ..........................................................................111
9.9.3.
Assessment of Pharmacodynamics........................................................................112
10.
ADVERSE EVENTS............................................................................................113
10.1.
Monitoring, Recording and Reporting of Adverse Events .....................................113
10.2.
Evaluation of Adverse Events...............................................................................114
10.2.1.
Seriousness...........................................................................................................114
10.2.2.
Severity/Intensity..................................................................................................115
10.2.3.
Causality ..............................................................................................................116
10.2.4.
Duration ...............................................................................................................116
10.2.5.
Action Taken........................................................................................................116
10.2.6.
Outcome...............................................................................................................116
10.3.
Abnormal Laboratory Values................................................................................116
10.4.
Pregnancy.............................................................................................................117
10.4.1.
Females of Childbearing Potential: .......................................................................117
10.4.2.
Male Subjects.......................................................................................................118
10.5.
Reporting of Serious Adverse Events....................................................................118
10.5.1.
Safety Queries ......................................................................................................118
10.5.2.
Death Reports.......................................................................................................118
10.6.
Expedited Reporting of Adverse Events................................................................119
11.
DISCONTINUATIONS .......................................................................................120
11.1.
Treatment Discontinuation....................................................................................120
11.2.
Study Discontinuation ..........................................................................................120
12.
EMERGENCY PROCEDURES...........................................................................122
12.1.
Emergency Contact...............................................................................................122
12.2.
Emergency Identification of Investigational Products ...........................................122
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
19
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
13.
REGULATORY CONSIDERATIONS.................................................................123
13.1.
Good Clinical Practice..........................................................................................123
13.2.
Investigator Responsibilities .................................................................................123
13.3.
Subject Information and Informed Consent...........................................................124
13.4.
Confidentiality......................................................................................................124
13.5.
Protocol Amendments...........................................................................................124
13.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ..............................................................................................................125
13.7.
Ongoing Information for Institutional Review Board/ Ethics Committee ..............125
13.8.
Termination of the Study ......................................................................................125
14.
DATA HANDLING AND RECORDKEEPING...................................................127
14.1.
Data/Documents ...................................................................................................127
14.2.
Data Management.................................................................................................127
14.3.
Record Retention..................................................................................................127
15.
QUALITY CONTROL AND QUALITY ASSURANCE......................................129
15.1.
Study Monitoring and Source Data Verification....................................................129
15.2.
Audits and Inspections..........................................................................................129
15.3.
Product Quality Complaint ...................................................................................129
16.
PUBLICATIONS .................................................................................................131
17.
REFERENCES.....................................................................................................132
18.
APPENDICES......................................................................................................139
18.1.
Appendix A: Table of Abbreviations ...................................................................139
18.2.
Appendix B:  RECIST 1.1 ....................................................................................143
18.3.
Appendix C:  The Lugano Classification...............................................................147
18.4.
Appendix D:  Performance Status Criteria ............................................................148
18.5.
Appendix E:  Characteristics of the Bayesian Logistic Regression Model.............149
18.6.
Appendix F:  Recommendations for Management of Treatment-Induced 
Diarrhea................................................................................................................153
18.7.
Appendix G:  Management of Biologic Specimens...............................................154
18.8.
Appendix H: Child-Pugh Classification ................................................................156
18.8.1.
Child-Pugh Classification of Liver Failure............................................................156
18.9.
Appendix I: Modified RECIST (mRECIST) .........................................................157
18.10.
Appendix J: Prostate Cancer Clinical Trials Working Group (PCWG3)................158
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
20
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
LIST OF TABLES
......................................25
Table 2:
Proposed Clinical Starting Dose and Schedule of CC-90011 Based on the 
Severely Toxic Dose in 10% of the Mice and the Highest Non-severely 
Toxic Dose in Dogs from Pivotal 4-Week Toxicity Studies ....................................43
Table 3:
Study Objectives.....................................................................................................47
Table 4:
Study Endpoints .....................................................................................................48
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part 
C and Part D)..........................................................................................................68
Table 6:
Table of Events for DDI Evaluation Period (Part C and Part D)..............................75
Table 7:
Blood Pharmacokinetic sampling Schedule for Part A and Part B, Cycle 1 .............86
Table 8:
Blood Pharmacokinetic Sampling Schedule for CC-90011 and metabolites 
for Part C................................................................................................................87
Table 9:
Blood Pharmacokinetic Sampling Schedule for CC-90011 and metabolites 
for Part D................................................................................................................88
Table 10:
Urine Sampling Schedule for CC-90011 and metabolites for Parts C and D............88
Table 11:
Biomarker Sampling schedule for Anti-SARS-CoV-2-Serology .............................90
Table 12:
Precision and Intrasubject Standard Deviation ......................................................106
Table 13:
Prior Parameters for Bivariate Normal Distribution of Model Parameters .............109
Table 14:
Abbreviations and Specialist Terms......................................................................139
Table 15:
Time Point Response: Subjects With Target (± Non-target) Disease .....................145
Table 16:
Time Point Response: Subjects With Non-target Disease Only .............................146
Table 17:
Eastern Cooperative Oncology Group (ECOG) Performance Status......................148
Table 18:
P(DLT) for Five Simulated Scenarios with Numbers in Grey Indicating 
Doses with True P(DLT) within the Target Toxicity Interval [16%, 33%].............149
Table 19:
Summary Metrics of Simulation for BLRM and Comparison with 3+3.................150
Table 20:
Possible Scenarios Up to the Third Dosing Cohort with Three Subjects per 
Cohort ..................................................................................................................151
Table 21:
Child-Pugh Classification .....................................................................................156
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
21
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
LIST OF FIGURES
Figure 1:
CC-90011 Dose Responsive CellTiter 96® Aqueous Assay Results.........................24
Figure 2:
Overall Study Design (Part A and Part B)...............................................................51
Figure 3:
Study Design Part C and Part D..............................................................................52
Figure 4:
Overall Study Design for Part C..............................................................................56
Figure 5:
Overall Study Design for Part D .............................................................................57
Figure 6:
Probability of DLT According to Prior Distribution..............................................110
Figure 7:
Dose Toxicity Curves for Simulation....................................................................150
Figure 8:
Recommendations for management of Treatment-Induced Diarrhea .....................153
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
22
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
1.
INTRODUCTION 
Epigenetic dysregulation is an important mechanism in the initiation and progression of cancer 
(Mohammad, 2015). Mechanisms that control DNA and histone modifications have become a 
major focus for targeted therapy. CC-90011 is a reversible, potent, and selective inhibitor of the 
epigenetic target, lysine-specific demethylase 1A (LSD1/KDM1A). LSD1 is a histone-modifying 
enzyme that removes methyl groups and hence regulates the expression of many genes important 
in cancer progression and cell proliferation (Scoumane, 2007; Hoffmann, 2012; Lynch, 2012). It 
also plays a part in cellular differentiation, regulation of epithelial-to-mesenchymal transition,
and stem cell maintenance (Adamo, 2011; McDonald, 2011).
Inhibition of LSD1 reduces cell proliferation and stem cell maintenance and promotes cell 
differentiation (Harris, 2012), as well as delaying or inhibiting tumor growth, in a range of 
human solid tumor xenografts (Maes, 2010; Mohammad, 2015; DC QC6688 2015;
Sankar, 2014; Thiesen, 2014).
1.1.
Disease Background 
The epigenetic code determines if, when, and where specific genes are expressed. It is a dynamic 
and reversible process written, erased, and read by families of enzymes. Initiation and 
progression of cancer has increasingly been linked to misreading, miswriting or miserasing of 
histone modifications (Chi, 2010).
LSD1 is an eraser of the epigenetic code. It is a member of the flavin adenine dinucleotide 
(FAD) dependent amine oxidase family of demethylases and has substrate affinity for mono- and 
dimethylated lysines (Shi, 2004; Lynch, 2012). LSD1 is typically found associated with protein 
complexes that act as transcription repressors. For example, it catalyses the demethylation of 
monomethyl and dimethyl histone H3 lysine 4 (H3K4), which are marks of active transcription 
states (Lynch, 2012). However, it associates with different complexes and can function as a     
co-activator or co-repressor in a target-specific manner (Amente, 2013). For example, LSD1 
binds to hormone receptors such as the estrogen or androgen receptors and catalyses the 
demethylation of both monomethyl and dimethyl histone H3 lysine 9 (H3K9). Monomethyl 
H3K9 is associated with active transcription states whereas dimethyl H3K9 is associated with 
repressed transcription states (Barski, 2007).  LSD1 also demethylates other non-histone proteins 
such as p53 (Huang, 2007), DNA methytransferase 1 (DNMT1) (Wang, 2009), and E2F1 
(Helen, 2013), and has been reported to bind the oncogene MYC (Amente, 2010).
LSD1 knockout mice are embryonically lethal and LSD1 is essential for mammalian 
development (Wang, 2007). LSD1 is involved in many biological processes, including 
proliferation, differentiation, gene activation and repression and regulation of epithelial-to-
mesenchymal transition (Scoumane, 2007; Wang, 2007; Adamo, 2011; Lv, 2012). Additionally,
LSD1 has been shown to be an essential regulator of leukemia stem cell potential (Harris, 2012) 
and stem cell maintenance (Adamo, 2011).
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
23
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
 
 Studies involving knock down 
of LSD1 have suggested that loss of LSD1 expression reduces the growth of cancer cells as well 
as their potential for migration and invasion (Mohammad, 2015). Inhibition of LSD1 also 
significantly delayed or inhibited tumor growth in a number of solid tumor xenografts, including 
colon cancer, endometrial carcinoma, Ewing’s sarcoma, and SCLC (Maes, 2010; Mohammad,
2015, DC QC6688 2015; Sankar, 2014; Thiesen, 2014).
LSD1 expression is observed in approximately 25.5% of mature B-cell non-Hodgkin’s 
lymphoma (B-NHL) cases and it is highly expressed in germinal centers (Neibel 2014), 
however, the role of LSD1 in germinal center formation has only recently been elucidated
(Haines, 2018; Hatzi, 2019).  
Hence, LSD1 appears to play a significant role in the development and progression of 
malignancy and investigation of the LSD1 inhibitor CC-90011 is warranted.
1.2.
Compound Background
Please refer to the Investigator’s Brochure (IB version V6.0, dated 15 Feb 2021) for detailed 
information concerning the available pharmacology, toxicology, pharmacokinetics, and drug 
metabolism profile of the investigational product (IP).
1.2.1.
Overview of CC-90011 Mechanism of Action and In vitro and In vivo 
Nonclinical Pharmacology
LSD1 was the first lysine demethylase to be discovered and, unlike the Jumonji class of 
demethylases, belongs to the broad family of monoamine oxidases that uses FAD as a cofactor in 
its enzymatic demethylase activity (DC QC6688, 2015). 
The importance of LSD1 in development is exemplified by the embryonic lethality seen in 
knockout mice (Wang, 2007). shRNA knockdown experiments in human embryonic stem (ES) 
cell lines show that suppression of LSD1 activity decreases the proliferation and self-renewal 
ability of ES cells while promoting differentiation towards endoderm and mesoderm lineages 
(DC QC6688, 2015). In the adult setting, LSD1 is necessary for normal hematopoiesis through 
interaction and modulation of GFI1b transcriptional programs and loss of LSD1 results in 
impaired hematopoiesis through a block in differentiation (Mohammad, 2015). The importance 
of LSD1 in normal differentiation suggests that aberrant gene expression resulting from 
dysregulation of LSD1 may result in alterations in pathways associated with a stem-cell like 
phenotype.
In prior studies, proliferation screens of cell lines representing a number of tumor types indicated 
that SCLC is sensitive to LSD1 inhibition (Mohammad, 2015). In SCLC, LSD1 and H3K4 
methylation are associated with regions of chromatin that are implicated in the regulation of cell 
state. Inhibition of LSD1 increases methylation and LSD1 enrichment at these sites.  While 
differentiation of SCLC is not well understood, LSD1 positioning at genes associated with 
neuronal differentiation and transcriptional regulation may suggest that inhibition of LSD1 will 
promote alterations in expression programs associated with differentiation of this tumor type 
(Mohammad, 2015). 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
24
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
CC-90011, previously known as QC6688, is an extremely potent and selective inhibitor of LSD1
(DC QC6688, 2015). The inhibitory mechanism of CC-90011 against LSD1 was studied at 
various concentrations, and the linear correlation between the IC50 and S/Km indicates that 
CC-90011 is a competitive inhibitor of LSD1. The selectivity of CC-90011 for LSD1 over other 
FAD containing enzymes (LSD2, MAO-A, and MAO-B) is greater than 60,000-fold.
CC-90011 demonstrated potent anti-proliferative activity in a Kasumi-1 cell line model of acute 
myeloid leukemia (AML), with an IC50 of 0.0024 µM and showed no effect (IC50 of >10 µM) in 
a normal human fibroblast cell model (Figure 1).
Figure 1:
CC-90011 Dose Responsive CellTiter 96® Aqueous Assay Results
Many growth modulatory factors are expressed by SCLC, and are felt to contribute to the 
aggressive nature of the tumor. One such peptide growth factor is gastrin-releasing peptide 
(GRP), which functions as an autocrine growth factor in SCLC (Campbell, 2002). Prior work 
with another LSD1 inhibitor showed loss of expression of GRP in SCLC xenografts
(Mohammad, 2015), which being a neuroendocrine marker may be suggestive of a change in the 
cell state, similar to the pro-differentiation effect seen in leukaemia with LSD1 inhibition 
(Harris, 2012). 
 
 
 
 
 
 
 
 
 
Kasumi-1, 11/07/2014, Cell-MTS
QC106688.005
0.0001
0.01
Normalized % DMSO
-20
20
60
100
140
IMR-90 (Normal Fibroblast), 4/25/2014, Cell-MTS
QC106688.001
0.0001
0.01
1
Normalized % DMSO
-20
20
60
100
140
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
25
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
1.2.1.1.
Overview of Nonclinical Pharmacokinetics 
In preclinical species, CC-90011 demonstrated moderate (mouse, dog, and monkey) to high (rat) 
systemic clearance and extensive (12- to 43-fold of total body water) volume of distribution. 
Terminal half-lives were considerably different between rodents (2 to 4 hours) and non-rodents 
(12 to 20 hours). Upon oral dosing, CC-90011 was well absorbed with oral bioavailability 
ranging from 28% to 74% in rodents and from 82% to 100% in dogs and monkeys. In vitro data 
indicate that CC-90011 is a P-glycoprotein (P-gp) substrate, and a weak breast cancer resistance 
protein (BCRP) substrate, but these properties have not limited its oral availability or absorption. 
Due to the disparate half-lives between mice and dogs, repeat-dose toxicity studies were 
conducted using different dosing regimens in either mice (5 days on/2 days off [QDx5/week] for 
4 weeks, and QD for up to 3 months) or dogs (QW, BIW, or once every 2 weeks [Q2W] for 4 
weeks, and QW for 3 months). In the 3-month toxicology studies, systemic exposure to CC-
90011 in mice increased in a greater than dose-proportional manner from 1 to 3 mg base/kg/day 
and in an approximately dose-proportional manner from 3 to 10 mg base/kg/day, while in dogs 
the increase in exposure was approximately dose-proportional in the dose range 0.10 to 0.25 mg 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
26
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
base/kg/week. No consistent sex differences and no accumulation in toxicokinetics (TK) were 
noted.
CC-90011 was moderately to highly bound to plasma protein binding (approximately 83% to 
92%) in preclinical species and humans with no notable differences in free fraction among 
species. 
After oral administration of [14C]CC-90011 to mice, radioactivity was widely distributed and 
then rapidly eliminated from most tissues by 48 hours. Distribution of radioactivity in the uveal 
tract and pigmented skin in CB63F1 (pigmented) mice, as compared to CD-1 (non-pigmented) 
mice, suggest an affinity for melanin-containing tissues.
The in vitro metabolism of CC-90011 was characterized using hepatocytes from various species 
(mouse, rat, rabbit, dog, monkey, and human). In hepatocytes, CC-90011 showed minimal 
turnover in human, dog, monkey, and mouse, moderate metabolism in female rabbit, and was 
extensively metabolized in rats. In hepatocytes, the biotransformation pathways of CC-90011 
across all species included oxidative deamination, piperidine hydroxylation and subsequent ring-
opened carboxylation, demethylation as well as glucuronidation and sulfation of oxidized species 
and a combination of these pathways. No unique human metabolites were found. All metabolites 
observed in humans were also found in mouse and dog, supporting the use of these species for 
toxicology testing.
The absorption, metabolism, and excretion of [14C]CC-90011 following oral administration has 
been studied in mice and dogs. Metabolic pathways were qualitatively similar in mice and dogs, 
with no major sex differences in metabolism observed. The primary metabolic pathways in mice 
and dogs were similar to those observed in vitro and included deamination, dealkylation 
followed by glucuronidation (or sulfation, in dogs only), oxidations/carboxylation, hydrolysis 
and combinations of these pathways. In mouse and dog plasma, CC-90011 was the predominant 
drug-related component and M1 (CC7108272, a deamination product) was a prominent 
circulating metabolite 
A study was conducted to profile and identify CC-90011 metabolites in human plasma samples 
and to estimate exposure coverage of any major metabolites in the toxicity species (CC-90011-
DMPK-3367). After oral administration of unlabeled CC-90011 to human patients, parent drug 
and metabolite CC7108272 were the prominent drug-related components in human plasma. 
Other metabolites were only detectable at trace levels and no unique human metabolites were 
found in human plasma. Based on an exploratory quantitative assessment, the weekly exposure 
of CC7108272 in mice at a dose of 3 mg/kg/day QD and dogs at a dose of 0.25 mg/kg QW (the 
NOAEL doses in the 3 month toxicology studies), was approximately 2.9- to 3.4-fold and 0.27-
to 0.28-fold, respectively of the human exposure at a dose of 60 mg QW.
In rats, CC-90011 may be eliminated primarily via metabolism, since following an IV bolus 
dose, the amount of intact drug excreted in bile and urine was 17.8% and 8.5%, respectively. 
Following oral administration of [14C]CC-90011 to mice and dogs, feces was the primary route 
for excretion of radioactivity. Approximately 29% and 54% of the [14C]CC-90011 dose was
absorbed in bile duct-cannulated (BDC) mouse and dog, respectively. The absorbed CC-90011 
was primarily eliminated by direct urinary excretion and metabolism in mouse, and by 
metabolism and direct biliary excretion in dog. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
27
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
In vitro studies suggest that CC-90011 does not inhibit or induce major CYP enzymes and is not 
an inhibitor of major uptake and efflux drug transporters at clinically relevant concentrations and 
thus CC-90011 has minimal potential to cause drug-drug interactions with co-administered drugs 
that are CYP or transporter substrates. CC-90011 was not a substrate of organic anion 
transporting polypeptide (OATP)1B1 and OATP1B3, multi-drug resistance protein (MRP)2, 
organic anion transporter (OAT)1 and OAT3, and organic cation transporter (OCT)2, and 
therefore, interactions with drugs that are inhibitors of these transporters are not expected. 
However, the metabolism of CC-90011 is governed primarily by cytochrome P450 (CYP) 3A4/5
and it was also an in vitro substrate of P-gp and BCRP transporters. Therefore, the exposure of 
CC-90011 may be affected when co-administered with drugs that are inhibitors or inducers of 
CYP3A and/or P-gp and BCRP.
1.2.1.2.
Overview of Nonclinical Toxicology
A series of exploratory and pivotal Good Laboratory Practice (GLP)-compliant toxicity studies 
in mice and dogs of up to 3 months, and 2 in vitro genetic toxicity studies were conducted to 
characterize the toxicity profile of CC-90011. In vivo studies were conducted using the oral route 
as it is the intended route of administration in clinical trials. Pivotal toxicity studies were 
conducted using a QD, QDx5/week, or every other day (QOD) 3 days per week (QODx3/week) 
dosing schedule in mice, and QW, BIW, or Q2W dosing in dogs. Pivotal toxicity studies were 
conducted in accordance with the requirements of the United States Food and Drug 
Administration (FDA) GLP Regulations for Nonclinical Laboratory Studies (21 CFR Part 58), 
the Organisation for Economic Cooperation and Development (OECD) Principles of GLP, 
ENV/MC/CHEM(98)17 (revised in 1997, issued January 1998), and the International Council on 
Harmonisation (ICH) S9 guideline, 2009.
The doses and schedules for the pivotal toxicity studies were selected based on data from 
pharmacology studies and exploratory repeat-dose toxicity studies in mice and dogs. The pivotal 
toxicity studies were conducted in Crl:CD1(ICR) mice and Beagle dogs. Dose levels were 0, 5, 
15, or 45 mg base/kg/dose QDx5/week or 25 mg base/kg/dose QODx3/week in the mouse 
pivotal 4-week oral toxicity study with a 4-week recovery period, and 0, 1, 3, or 10 mg/kg/day 
QD in the mouse 3-month study. Dose levels in the initial dog pivotal 4-week oral toxicity study 
(with a 4-week recovery period) were 0, 0.375, 0.75, or 1.5 mg base/kg/dose QW, or 0.375 mg 
base/kg/dose BIW. Since a QW nonseverely toxic dose was not identified in this study, a second 
pivotal dog study at lower dose levels of 0, 0.125 or 0.25 mg base/kg/dose QW, or 0.5 mg 
base/kg/dose Q2W was conducted (no recovery period). A study was also conducted in dogs 
using doses of 0, 0.10, and 0.25 mg/kg QW for 3 months (total of 14 doses). 
In 4-week toxicity studies, treatment-related mortality was observed at 45 mg base/kg/dose in 
mice following a QDx5/week dose schedule; and at ≥ 0.375 mg base/kg/dose in dogs following a 
QW dose schedule. The cause of mortality in mice was not determined; the moribund condition 
of dogs was due to CC-90011-related gastrointestinal (GI) toxicity and ensuing septicemia. 
In mice dosed at up to 45 mg base/kg/dose for 4 weeks, there was dose-proportional marrow 
toxicity, evidenced by a myeloid shift and/or marrow hypocellularity. The marrow space was 
replaced by fibrosis in the sternum and/or femur, with hyperostosis of endosteal, periosteal, and 
trabecular bone surfaces of affected sternebrae. Collectively, these changes persisted through a 
recovery period at the highest dose only. Some increase in marrow megakaryocytes (without 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
28
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
peripheral correlate) was noted at all doses, also persisting at the highest dose. Marrow toxicity 
occurred in concert with declines in peripheral red cell mass (red blood cell [RBC] count, 
hemoglobin, and hematocrit), and declines in platelet, reticulocyte and/or leukocyte counts along 
with significant increases in splenic extramedullary hematopoiesis at all doses (a reactive change 
to which mice are particularly sensitive). Depletion of splenic marginal zone lymphocytes was 
observed in all but the lowest dose groups but did not persist through a recovery period. 
In dogs dosed for 4 weeks, findings were more clearly inflammatory in nature. The predominant 
finding centered on GI inflammation which in some instances was ulcerative and associated with 
secondary septicemia and mortality at higher doses. Changes in the bone marrow reflected 
peripheral demand, with myeloid hypercellularity and variable evidence of marrow toxicity 
reflected in the peripheral blood as either a decrease or increase in peripheral leukocyte numbers; 
unlike mice, no reactive bone alterations were noted. 
In one 4-week dog study, there was mortality at ≥ 0.375 mg base/kg/dose, with morbidity 
generally attributed to gastric inflammation and/or ulceration. Slight to marked, acute to subacute 
inflammation was observed variably in the esophagus, stomach, small and/or large intestines, 
and/or rectum of dogs dying early. Findings that correlated with these microscopic changes 
included dehydration, abnormal feces (liquid, red), red vomitus, decreased food consumption and 
body weight, hypoactivity, fever, and/or GI tract discomfort. Related clinical pathology findings 
included decreased albumin, albumin:globulin ratio, calcium, and inorganic phosphorous; 
increased monocytes, large unstained cells, and neutrophils; and decreased red cell mass, 
platelets, reticulocytes, and eosinophils. Other findings in these animals were attributed to 
generalized inflammation and/or septicemia secondary to mucosal ulceration in the GI tract 
(inflammation in multiple lymph nodes, subcutaneous edema, acute inflammation in the heart or 
liver), and/or physiologic stress, including extramedullary hematopoiesis in the spleen and an 
increased myeloid:erythroid ratio in the sternal marrow. In surviving animals, only minimal to 
moderate acute inflammation of the intestines and/or rectum was observed at ≤ 0.75 mg/kg/dose, 
with complete recoverability following a 4-week non-dosing interval.
In a 4-week study at lower doses (0.125 or 0.25 mg base/kg/dose QW or 0.5 mg/kg/dose Q2W), 
there was no mortality, and findings were of lower severity, with acute inflammation in the 
cecum, ileum, and/or gut-associated lymphoid tissue of dogs from the highest dose-groups from 
each dosing-interval. Changes were minimal when dosed Q2W, becoming marked when dosed 
QW. Other findings included minimal extramedullary hematopoiesis in animals from the highest 
dose groups of either dosing regimen.
All CC-90011-related findings in mice and dogs treated for 4 weeks demonstrated evidence of 
partial to complete reversibility following a 4-week treatment-free period.
In mice dosed daily for up to 3 months at up to 10 mg/kg/dose, further evidence of CC-90011-
related systemic inflammation was observed. Inflammation affected multiple tissues, with 
instances of mortality (10 mg/kg/dose level) being associated with more severe inflammatory 
foci. Specifically, scattered neutrophilic inflammatory cell infiltrates occurred at 10 mg/kg/day in 
the heart valve, epididymides, eye sclera, and/or periocular tissue. Some instances of periocular 
inflammation were clearly an extension of peripheral glandular inflammation and, in general, the 
interior of the eye was unaffected. At 3 mg/kg/day, such infiltrates became minimal and were 
restricted to the periocular tissues; no such findings were seen at the 1 mg/kg/day. At the 
nontolerated dose level, ophthalmology examination revealed hyporeflection and reduced pallor 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
29
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
in the fundus of the eye. Also, at 10 mg/kg/day, mortality was associated with focal abscessation 
in the Harderian glands and/or skin/subcutis. Reactive alterations in affected dose groups 
included increased (myeloid) marrow cellularity, and extramedullary hematopoiesis in the liver 
(with some necrosis at the highest dose), spleen and/or adrenal glands.
In dogs dosed QW for 3 months, CC-90011 was well tolerated up to 0.25 mg/kg/dose, the 
highest dose level administered, with no signs of toxicity.
CC-90011 was not mutagenic based on the negative results from the in vitro mutagenicity 
assays.
Overall, CC-90011 exhibits an acceptable safety profile in preclinical species for a clinical drug 
candidate in an advanced oncology setting and the toxicology program for CC-90011 adequately 
supports the conduct of clinical trials in oncology subjects.
1.2.1.3.
Summary of Clinical Data
As of 11 Sep 2020, 50 subjects were enrolled in Part A of the study and received escalating oral 
doses of CC 90011 QW at 9 dose levels from 1.25 mg to 120 mg/dose and 17 subjects (14 
subjects with low/intermediate-grade lung NETs [typical and atypical carcinoid], 2 subjects with 
prostate NEC and 1 subject with MZL) were enrolled in Part B of the study and received oral 
CC-90011 QW at 60 mg. The Part A of the study has been completed and the primary objectives 
were met. The nontolerated dose (NTD) was determined to be 120 mg, the MTD was 80 mg, and 
the RP2D was 60 mg, QW of 28-day cycles. Thrombocytopenia, an on target effect, was the only 
dose limiting toxicity (DLT); these events occurred mainly at the highest dose levels and were 
successfully managed with dose interruption for a week and/or dose reduction. CC-90011 has 
been generally well tolerated with the majority of treatment-emergent adverse events (TEAEs) 
being reversible and manageable by dose adjustments and/or supportive treatments.
In Part A of the study (N = 50), the most frequently reported TEAEs (in at least 10% of subjects) 
were thrombocytopenia (46.0%), anemia and vomiting (28.0% each), fatigue (26.0% ), nausea, 
constipation and asthenia (22.0% each),  diarrhea, pyrexia, and decreased appetite (20.0% each), 
musculoskeletal pain (16.0%), back pain (14.0%), neutropenia, abdominal pain, increased 
alanine aminotransferase (ALT), increased aspartate aminotransferase (AST)and cough (12.0% 
each), and tumor pain, headache, and dyspnea (10.0% each). Overall, 24 (48.0%) subjects 
experienced at least one Grade 3 or 4 TEAE and the most frequently reported Grade 3 or 4 
TEAEs (in at least 2 subjects) were thrombocytopenia (24.0%), neutropenia (8.0%), anemia 
(6.0%), and general physical health deterioration, increased ALT, increased blood bilirubin, 
increased lipase, and hypophosphatemia (4.0% each). Grade 3 or 4 thrombocytopenia occurred 
from the dose level of 40 mg and Grade 3 or 4 neutropenia occurred from the dose level of 80 
mg and only after clinically significant thrombocytopenia. Overall, 34 (68.0%) subjects 
experienced at least one TEAE assessed as related to the study treatment by the investigator and 
the most frequently reported treatment-related TEAEs (in at least 5% of subjects) were 
thrombocytopenia (40.0%), neutropenia (12.0%), fatigue (10.0%), and vomiting and asthenia 
(6.0% each). No death due to drug-related toxicity occurred during the study. Overall, 23 
(46.0%) subjects experienced at least one serious TEAE, and the most frequently reported 
serious TEAEs (in at least 2 subjects) were thrombocytopenia (8.0%) and general physical health 
deterioration (4.0%).
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
30
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
CC-90011 demonstrated preliminary evidence of antitumor activity in this difficult-to-treat 
patient population with very few treatment options. Among 27 NEN subjects, 7 subjects have 
demonstrated prolonged stabilization of disease (stable disease [SD] > 4 months). Notably, 3 
subjects with bronchial NEN had prolonged SD of > 6 months and 2 subjects with prostate NEN 
remained on study treatment for over 6 months due to clinical benefit. The R/R NHL subject 
(transformed MZL) experienced a complete metabolic response (see IB version V6.0, dated 15
Feb 2021) and currently is on-going in Cycle 49.
In Part B of the study (N = 17), the most frequently reported TEAEs (in at least 10% of subjects) 
were thrombocytopenia (70.6%), asthenia (41.2%), anemia (35.3%), constipation, diarrhea, and 
nausea (29.4% each), neutropenia and dysgeusia (23.5% each), decreased appetite, arthralgia, 
musculoskeletal pain, cough and epistaxis (17.6% each), and leucopenia, stomatitis, vomiting, 
fatigue, hepatic pain, bronchitis, lipase increased, hypokalemia, bone pain, neck pain, dizziness,  
peripheral sensory neuropathy, sciatica, confusional state, dyspnea and pruritus (11.8% each). 
Overall, 13 (76.5%) subjects experienced at least one Grade 3 or 4 TEAE and the most 
frequently reported Grade 3 or 4 TEAEs (in at least 2 subjects) were thrombocytopenia (35.3%), 
and neutropenia (17.6%) and asthenia (11.8%). Overall, 16 (94.1%) subjects experienced at least 
one TEAE assessed as related to the study treatment by the investigator, and the most frequently 
reported treatment-related TEAEs (in at least 2 subjects) were thrombocytopenia (70.6%), 
asthenia (29.4%), anemia and neutropenia (23.5% each), diarrhea, and nausea (17.6% each), and 
leucopenia and dysgeusia (11.8% each). No death due to drug-related toxicity occurred during 
the study. Overall, 6 (35.3%) subjects experienced at least one serious TEAE and serious TEAEs 
occurred in one subject each.
In the 14 subjects with low/intermediate-grade lung NET, a best response of SD was observed in 
10 (71.4%) subjects, including 7 (50.0%) subjects with SD ≥ 4 months. The 2 subjects with 
prostate NEC and the MZL subject progressed.
1.2.1.4.
Summary of Clinical PK and PD Data 
Pharmacokinetic data from Part A of Study CC-90011-ST-001 are available for 50 subjects who 
received escalating oral doses of CC-90011 QW at 9 dose levels from 1.25 mg to 120 mg/dose 
(see IB version V6.0, dated 15 Feb 2021). Following oral administration of CC-90011, geometric 
mean exposure to CC-90011, based on Cmax and AUC, generally increased with dose on Day 1 
(single dose) and Day 22 (repeated weekly administration), in a manner approximately 
proportional with dose. Maximum observed plasma concentrations were observed a few hours 
after dosing, with median time to peak plasma concentration (tmax) ranging from 2.0 to 4.6 hours 
postdose across all dose levels and both dosing occasions. Half-life was generally similar across 
the dose levels (2.5 to 80 mg) and on both occasions, ranging from approximately 50 to 78 hours. 
Apparent clearance and volume of distribution ranged from 57.5 to 95.7 L/h and 5506 to 8077 L, 
respectively, across the 5 to 120 mg dose range. Results suggest an overall negligible 
accumulation after weekly dosing of CC-90011 between 2.5 mg to 80 mg, with accumulation 
ratios for Cmax and AUC from 0 to the last quantifiable concentration (AUCLST) ranging from 
0.66 to 1.57. The interindividual variability (geometric coefficient of variation %) values ranged 
from 19.3% to 136.7% on Day 1 and 8.6% to 92.4% on Day 22 across Cmax and AUC 
parameters.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
31
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Preliminary PK data from Part B of Study CC-90011-ST-001 and Study CC-90011-SCLC-001
suggest an overall similarity of PK parameters to the respective doses from Part A of Study 
CC-90011-ST-001. These preliminary data suggest that PK profile of CC-90011 is similar 
between subgroups of solid tumor subjects including lung NET, prostate NEC, and SCLC. 
Additionally, coadministration of cisplatin, or carboplatin, and etoposide does not appear to 
impact the PK profile of CC-90011 in SCLC subjects.
Preliminary PD analyses from Part A of Study CC-90011-ST-001 revealed a decrease in 
chromogranin A (CgA) neuroendocrine marker levels in response to CC-90011 at doses as low 
as 2.5 mg QW in subjects with NENs. Additionally, CC-90011 decreased expression of 
monocyte to macrophage differentiation-associated (MMD) ribonucleic acid (RNA) by ≥50% in 
subject blood samples at doses ≥ 60 mg QW. In Part B of the study, MMD suppression was 
consistent with the dose effects observed in Part A of Study CC-90011-ST-001. These 
preliminary findings indicate that downregulation of MMD is a potential marker for PD by 
CC-90011 in the clinical setting. In Study CC-90011-SCLC-001, preliminary PD analysis 
showed a ≥ 50% decrease of MMD expression in available samples from patients receiving CC-
90011 (20 mg, 40 mg) plus Etoposide/Cisplatin and CC-90011 (20 mg) plus
Etoposide/Carboplatin in 1L Extensive Stage (ES) SCLC patients.
Although the biomarker analyses in the current trial are exploratory in nature, they could reveal 
associations between biomarkers and responses that could provide a basis for future 
diagnostically-driven studies. Refer to Section 0 for additional information.
1.2.2.
Safety Monitoring Plan
Thrombocytopenia is an on-target effect of LSD1 inhibition. Knockdown of LSD1 causes a 
block in the terminal platelet maturation step leading to thrombocytopenia with accumulation of 
megakaryocytes in the bone marrow (Sprussel, 2012).
Information from a First-In-Human study of the LSD-1 inhibitor ORY-1001 in refractory or 
relapsed Acute Leukemia resulted in predicted toxicities that included thrombocytopenia and 
anemia (Somervaille, 2016; Maes, 2018).
As of the 11 Sep 2020 data cutoff date, current experience with CC-90011 in humans is based 
on 3 ongoing clinical Phase 1 studies, CC-90011-ST-001 (monotherapy) CC-90011-SCLC-001 
(combination therapy) and CC-90011-ST-002 (combination therapy) (see IB version V6.0, dated 
15 Feb 2021).  
Study CC-90011-ST-001
As of 11 Sep 2020, 50 subjects were enrolled in Part A of the study and received escalating oral 
doses of CC-90011 QW at 9 dose levels from 1.25 mg to 120 mg/dose and 17 subjects 
(14 subjects with low/intermediate-grade lung NETs [typical and atypical carcinoid], 2 subjects 
with prostate NEC and 1 subject with MZL) were enrolled in Part B of the study and received 
oral CC-90011 QW at 60 mg. The Part A of the study has been completed and the primary 
objectives were met. The nontolerated dose (NTD) was determined to be 120 mg, the MTD was 
80 mg, and the RP2D was 60 mg, QW of 28-day cycles. Thrombocytopenia, an on-target effect, 
was the only dose-limiting toxicity (DLT); these events occurred mainly at the highest dose 
levels and were successfully managed with dose interruption for a week and/or dose reduction. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
32
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
CC-90011 has been generally well tolerated with the majority of TEAEs being reversible and 
manageable by dose adjustments and/or supportive treatments.
In Part A of the study (N = 50), the most frequently reported TEAEs (in at least 10% of subjects) 
were thrombocytopenia (46.0%), anemia and vomiting (28.0% each), fatigue (26.0% ), nausea, 
constipation and asthenia (22.0% each),  diarrhea, pyrexia, and decreased appetite (20.0% each), 
musculoskeletal pain (16.0%), back pain (14.0%), neutropenia, abdominal pain, increased 
alanine aminotransferase (ALT), increased aspartate aminotransferase (AST),  and cough (12.0% 
each), and tumor pain, headache, and dyspnea (10.0% each). Overall, 24 (48.0%) subjects 
experienced at least one Grade 3 or 4 TEAE and the most frequently reported Grade 3 or 4 
TEAEs (in at least 2 subjects) were thrombocytopenia (24.0%), neutropenia (8.0%), anemia 
(6.0%), and general physical health deterioration, increased ALT, increased blood bilirubin,
increased lipase, and hypophosphatemia (4.0% each). Grade 3 or 4 thrombocytopenia occurred 
from the dose level of 40 mg and Grade 3 or 4 neutropenia occurred from the dose level of 
80 mg and only after clinically significant thrombocytopenia. Overall, 34 (68.0%) subjects 
experienced at least one TEAE assessed as related to the study treatment by the investigator and 
the most frequently reported treatment-related TEAEs (in at least 5% of subjects) were 
thrombocytopenia (40.0%), neutropenia (12.0%), fatigue (10.0%), and vomiting and asthenia 
(6.0% each). No death due to drug-related toxicity occurred during the study. 
Overall, 23 (46.0%) subjects experienced at least one serious TEAE, and the most frequently 
reported serious TEAEs (in at least 2 subjects) were thrombocytopenia (8.0%) and general 
physical health deterioration (4.0%).
CC-90011 demonstrated preliminary evidence of antitumor activity in this difficult-to-treat 
patient population with very few treatment options. Among 27 NEN subjects, 7 subjects have 
demonstrated prolonged stabilization of disease (stable disease [SD] > 4 months). Notably, 
3 subjects with bronchial NEN had prolonged SD of > 6 months and 2 subjects with prostate 
NEN remained on study treatment for over 6 months due to clinical benefit. The R/R NHL 
subject (transformed MZL) experienced a complete metabolic response.
In Part B of the study (N = 17), the most frequently reported TEAEs (in at least 10% of subjects) 
were thrombocytopenia (70.6%), asthenia (41.2%), anemia (35.3%), constipation, diarrhea, and 
nausea (29.4% each), neutropenia and dysgeusia (23.5% each),  decrease appetite, arthralgia, 
musculoskeletal pain, cough and epistaxis (17.6% each), and leucopenia, stomatitis, vomiting, 
fatigue, hepatic pain, bronchitis, lipase increased, hypokalemia, bone pain, neck pain, dizziness,  
peripheral sensory neuropathy, sciatica, confusional state, dyspnea and pruritus (11.8% each). 
Overall, 13 (76.5%) subjects experienced at least one Grade 3 or 4 TEAE and the most frequently 
reported Grade 3 or 4 TEAEs (in at least 2 subjects) were thrombocytopenia (37.5%), and 
neutropenia (17.6%) and asthenia (11.8%). Overall, 16 (94.1%) subjects experienced at least one 
TEAE assessed as related to the study treatment by the investigator, and the most frequently 
reported treatment-related TEAEs (in at least 2 subjects) were thrombocytopenia (70.6%), 
asthenia (29.4%), anemia and neutropenia (23.5% each), diarrhea and nausea (17.6% each), and 
leucopenia and dysgeusia (11.8% each). No death due to drug-related toxicity occurred during the 
study. Overall, 6 (37.5%) subjects experienced at least one serious TEAE and serious TEAEs 
occurred in one subject each.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
33
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
In the 14 subjects with low/intermediate-grade lung NET, a best response of SD was observed in 
10 (71.4%) subjects, including 7 (50.0%) subjects with SD ≥ 4 months. The 2 subjects with 
prostate NEC and the MZL subject progressed. 
Study CC-90011-SCLC-001
Study CC-90011-SCLC-001 is an open-label, Phase 1b, multicenter, dose-finding study to assess 
the safety, tolerability, PK, PD, and preliminary efficacy of CC-90011 given in combination with 
cisplatin or carboplatin and etoposide, defined as Chemotherapy, followed by CC-90011 single 
agent in maintenance, and CC-90011 given in combination with Chemotherapy plus nivolumab 
followed by CC-90011 plus nivolumab in maintenance, to adult subjects with first line, extensive 
stage (ES) SCLC. As of 11 Sep 2020, safety and efficacy data are available for 19 enrolled 
subjects with first line ES SCLC, who received escalating doses of oral CC-90011 at 20 mg 
(Cohort 1; N = 8),  40 mg (Cohort 2; N = 7) and 60 mg (Cohort 3; N = 4) in combination with 
etoposide plus cisplatin and 5 enrolled subjects with first line ES SCLC, who received escalating 
doses of oral CC-90011 at 20 mg (Cohort 1; N = 3) and 40 mg (Cohort 2; N = 2), in combination 
with etoposide plus carboplatin. Twelve subjects from the CC-90011 plus Cisplatin/Etoposide
treatment arm and 3 subjects from the CC-90011 plus Carboplatin/Etoposide treatment arm
received CC-90011 at 60 mg in the Maintenance Treatment Period.
CC-90011 plus Etoposide/Cisplatin Treatment Arm (N = 19)
One subject, who received CC-90011 20 mg and 2 subjects, who received CC-90011 60 mg plus 
Cisplatin/Etoposide, experienced a DLT during the Chemotherapy Treatment Period. No DLT 
was observed in the 6 evaluable subjects treated at the dose of 40 mg CC-90011 plus 
Cisplatin/Etoposide. CC-90011 at 60mg plus Cisplatin/Etoposide was determined as the NTD 
and CC-90011 at 40 mg on Days 1 and 8 of each 21-day chemotherapy cycle plus 
Cisplatin/Etoposide was determined as the RP2D of the combination. 
During the dose escalation Chemotherapy Treatment Period (N = 19), the most frequently 
reported TEAEs (in at least 20% of subjects) were anemia (78.9%), thrombocytopenia and 
neutropenia (68.4% each), asthenia (52.6%), nausea (42.1%), constipation (31.6%), increased 
blood alkaline phosphatase (ALP) (26.3%), and mucosal inflammation, pyrexia, diarrhea, 
decreased appetite, hyponatremia, dyspnea and alopecia (21.1% each). Overall, 
16 (84.2%) subjects experienced at least one Grade 3 or 4 TEAE and the most frequently 
reported Grade 3 or 4 TEAEs (in at least 2 subjects) were neutropenia (63.2%), 
thrombocytopenia (42.1%), febrile neutropenia (15.8%) and anemia (10.5%). Seventeen 
(89.5%) subjects experienced at least one TEAE assessed as related to CC-90011 treatment by 
the investigator, and the most frequently reported treatment-related TEAEs (in at least 2 subjects) 
were anemia and neutropenia (57.9% each), thrombocytopenia (52.6%), and febrile neutropenia, 
asthenia, and decreased appetite (10.5% each). No death due to drug-related toxicity occurred 
during the study. Overall, 4 (21.1%) subjects experienced at least one serious TEAE, each 
serious TEAE occurring in one subject each. The CC-90011 RP2D of 40 mg was well tolerated; 
the most frequent TEAEs assessed as related to CC-90011 treatment (in at least 2 subjects) were 
neutropenia (42.9%), and thrombocytopenia and anemia (28.6% each), with only 2 (28.6%) 
subjects, who experienced Grade 3 or 4 TEAEs related to CC-90011 treatment (neutropenia 
only). One subject experienced a serious TEAE, assessed as not related to CC-90011 treatment. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
34
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
During the Maintenance Treatment Period (N = 12), the most frequently reported TEAEs (in at 
least 2 subjects) were thrombocytopenia (91.7%), anemia (50.0%), neutropenia and nausea 
(33.3%), dysgeusia (25.0%), asthenia, noncardiac chest pain, vomiting, gastro-esophageal reflux 
disease, back pain, headache, dizziness, peripheral sensory neuropathy, pruritus, and 
hypertension (16.7% each). Six (50.0%) subjects experienced at least one Grade 3 or 4 TEAE
and the most frequently reported Grade 3 or 4 TEAEs (in at least 2 subjects) were
thrombocytopenia (41.7%) and hypertension (16.7%). Seven (58.3%) subjects experienced at 
least one TEAE assessed as related to CC-90011 treatment by the investigator and the most 
frequently reported treatment-related TEAEs (in at least 2 subjects) were thrombocytopenia 
(41.7%), anemia (25.0%), and neutropenia (16.7%). Two (16.7%) subjects experienced at least 
one serious TEAE during the Maintenance Treatment Period, each serious TEAE occurring in 
one subject each.
As of 11 Sep 2020, a best objective response was partial response (PR) for 16 out of 19 treated 
subjects (3 non evaluable subjects). 
CC-90011 plus Carboplatin/Etoposide Treatment Arm (N = 5)
One subject, who received CC-90011 40 mg plus Carboplatin/Etoposide experienced a DLT 
during the Chemotherapy Treatment Period.
During the Chemotherapy Treatment Period (N = 5), the most frequently reported TEAEs (in at 
least 2 subjects) were thrombocytopenia (80.0%), and anemia and neutropenia (60.0% each). 
Overall, 4 (80.0%) subjects experienced at least one Grade 3 or 4 TEAE and the most frequently 
reported Grade 3 or 4 TEAEs (in at least 2 subjects) were thrombocytopenia (80.0%) and 
neutropenia (40.0%). All subjects experienced at least one TEAE assessed as related to 
CC-90011 treatment by the investigator, and the most frequently reported treatment-related 
TEAEs (in at least 2 subjects) were thrombocytopenia (80.0%), and anemia and neutropenia 
(60.0% each). No death due to drug-related toxicity occurred during the study. One (20.0%) 
subject treated at 40 mg experienced 2 serious TEAEs (Grade 4 hyponatremia and Grade 3 
ischemic stroke, assessed as not related to CC-90011 treatment).
During the Maintenance Treatment Period (N = 3), the most frequently reported TEAEs (in at 
least 2 subjects) were thrombocytopenia, anemia, and constipation (66.7% each). Two (66.7%) 
subjects experienced at least one Grade 3 or 4 TEAE with thrombocytopenia, aphasia, and 
inadequate analgesia in one subject each. One (33.3%) subject experienced Grade 2 asthenia 
assessed as related to CC-90011 treatment. Two (66.7%) subjects experienced at least one 
serious TEAE (Grade 3 and Grade 5 aphasia, secondary to progression of brain metastases, and 
Grade 3 inadequate analgesia) assessed as not related to study treatment.
As of 11 Sep 2020, the best objective response was PR for 4 out of the 5 treated subjects (1 non 
evaluable subject).
Study CC-90011-ST-002
CC-90011-ST-002 study is a Phase 2, multicenter, open-label, multi-cohort study to assess safety 
and efficacy of CC-90011 in combination with nivolumab in adult subjects with SCLC and 
squamous non-small cell lung cancer (sqNSCLC) who have progressed after 1 or 2 lines of 
therapy. As of 11 Sep 2020, 5 subjects with SCLC (4 subjects in Cohort A and 1 subject in 
Cohort B) were treated in the study. Three serious TEAEs (2 Grade 4 thrombocytopenia, 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
35
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
assessed as related to study treatments by the investigator and 1 Grade 3 muscular weakness, 
assessed as not related to study treatments) were reported in the first 2 subjects treated with CC-
90011 at the dose of 60 mg QW (plus nivolumab at 480 mg Q4W). The initial dose of CC-90011 
was further amended and reduced to 40 mg due to the occurrence of Grade 4 thrombocytopenia
in 2 of the subjects.
Monitor for discomfort in left upper quadrant and bone pain. Analgesics such as paracetamol 
should be administered as necessary, but NSAIDS and aspirin should be avoided, if possible in 
view of the potential thrombocytopenia. If discomfort in the upper left quadrant is reported, 
subjects will be examined for any evidence of splenomegaly and monitored closely.
Frequent early monitoring of subjects’ weight, hydration status, serum electrolytes, the incidence 
and severity of diarrhea and emesis, as well as episodes of abdominal pain (gastric, intestinal) are 
critical components of the safety monitoring plan and implementation of aggressive supportive 
care measures for the early onset (ie, Grade 1) of nausea, vomiting or diarrhea are highly 
recommended.  Based on the morphologic changes, mucosal ulcerations, and acute inflammation 
observed in the GI tract of dogs, subjects with active ulcer/gastritis, malabsorption syndromes, or 
recurring episodes of GI bleeding will be excluded from enrollment. Mucosa coating agents for 
protection of esophageal/gastric mucosa will be recommended as well as monitoring subjects for 
GI bleeding. Subjects will be encouraged to report episodes of GI discomfort or pain, appetite 
loss, frequency of diarrhea or blood in stool. 
Bone marrow hypocellularity findings in GLP toxicity studies emphasize the importance of 
frequent blood count monitoring, including platelet counts and white blood cell (WBC) 
differential. Similarly, the presence of increased size of megakaryocytes and/or megakaryocyte
numbers emphasizes the importance of closely monitoring the platelet counts. Subjects will be 
monitored for possible toxicity through standard and specialized laboratory tests including 
complete blood counts, prothrombin time (PT)/activated partial thromboplastin time 
(APTT)/international normalized ratio (INR), and serum chemistries. 
Serum chemistry findings such as decreased total protein, albumin, albumin:globulin (A:G) ratio, 
and increased cholesterol and alkaline phosphatase (ALP) will necessitate a more conservative 
eligibility criteria for total albumin and initial weekly monitoring of the serum chemistry in 
subjects.
Decrease in the weight of the seminal vesicles, testes, and uterus was seen in studies in mice.  All 
changes observed during and/or at the end of treatment were partially or completely recovered by 
4 weeks after treatment.  No such changes were seen in dogs.
Fertility counseling for men: Subjects will be informed that the effects of CC-90011 on 
spermatogenesis are unknown and they will be encouraged to collect and bank sperm if 
appropriate, prior to taking CC-90011.
These findings warrant prohibition of semen donation and fathering children for male subjects 
and conceiving for female subjects for the duration of the clinical study as well as for at least 105 
days after the last study dose. There were no histologic lesions in reproductive organs of female 
and male animals in the nonclinical studies. The significance of this pre-clinical finding and the 
potential and relative clinical risk is unknown at this time. Developmental and reproductive 
toxicology studies have not been conducted with CC-90011. Subjects will be required to follow 
the pregnancy prevention guidelines as described in Section 6.2.9.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
36
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
As this is an FIH study, subjects with a history of heart failure, ischemic heart disease, 
uncontrolled hypertension, serious cardiac arrhythmias, or long QT interval on ECG will be 
excluded from enrollment. All study subjects will require documentation of adequate left 
ventricular ejection fraction (> 45%) at baseline.
Comprehensive studies to evaluate the phototoxicity potential of CC-90011 have not been 
conducted. As a precautionary measure, it is recommended that subjects avoid prolonged 
exposure to ultraviolet (UV) light, wear protective clothing and sunglasses, and use UV-blocking 
topical preparations while taking CC-90011.
The global coronavirus disease 2019 (COVID-19) pandemic has been identified as a potential 
risk to clinical trial subjects in general. Whether CC-90011, rifampicin or itraconazole
administration increases the risk for contracting SARS-CoV-2 infection or increases the severity 
or duration of symptoms is currently unknown. This unknown risk must be considered when 
enrolling a subject. 
No additional safety monitoring or routine screening tests will be required due to the SARS-
CoV-2 pandemic. Subjects with recent or acute infections will be excluded or delay start of 
treatment as defined in Section 4.3. If a subject has a confirmed SARS-CoV-2 infection while on 
study treatment, dose delay or interruption of study treatment is required as described in 
Section 7.2. An exploratory analysis of the impact of SARS-CoV-2 serologic status on subjects 
receiving CC-90011 may be performed.
The study has been designed with study visits that allow for close monitoring of subjects’ safety 
throughout the clinical trial (Section 6), and subjects are encouraged to contact the investigator if 
an intercurrent illness develops between study visits. Testing for COVID-19 to inform decisions 
about clinical care during the study should follow local standard practice.
Non-live COVID-19 vaccination is considered a simple concomitant medication within the 
study. However, the efficacy and safety of non-live vaccines (including non-live COVID-19 
vaccines) in subjects receiving CC-90011, rifampicin or itraconazole is unknown.
1.2.3.
Rifampicin and Itraconazole
Drug metabolizing enzymes and transporters affected by rifampicin include CYP 1A2, 2B6, 
2C8, 2C9,2C19, and 3A/5, UDP-glucuronyltransferases (UGT), sulfotransferases, 
carboxylesterases, and transporters including P-gp and multidrug resistance-associated protein 2 
(MRP2). Most drugs are substrates for one or more of these enzyme or transporter pathways, and 
these pathways may be induced concurrently by rifampicin capsules. Therefore, rifampicin
capsules may accelerate the metabolism and reduce the activity of certain co-administered drugs, 
and has the potential to perpetuate clinically important drug-drug interactions against many drugs 
and across many drug classes. Rifampicin should be withdrawn if clinically significant changes 
in hepatic function occur. Some severe cutaneous adverse reactions have been reported with a 
not known frequency in association with rifampicin. Early manifestations of hypersensitivity, 
such as fever, lymphadenopathy or biological abnormalities may be present even though rash is 
not evident. If such signs or symptoms are present, the subject should be advised to consult 
immediately their physician. Importantly, rifampicin treatment reduces the systemic exposure of 
oral contraceptives. Diabetes may become more difficult to control. Rifampicin may accelerate 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
37
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
the metabolism and reduce the activity of certain co-administered drugs. To maintain optimum 
therapeutic blood levels, dosages of drugs may require adjustment.
Itraconazole is a potent CYP3A4 inhibitor and a P-gp inhibitor. The most serious adverse drug 
reaction (ADRs) with itraconazole are serious allergic reactions, cardiac failure/congestive heart 
failure/pulmonary oedema, pancreatitis, serious hepatotoxicity (including some cases of fatal 
acute liver failure), and serious skin reactions. Caution should be exercised when itraconazole is 
administered in subjects with hepatic impairment. Itraconazole should not be used in patients 
with congestive heart failure or with a history of congestive heart failure. When using 
concomitant medication together with itraconazole, it is recommended that the corresponding 
label be consulted for information on the route of metabolism and the possible need to adjust 
dosages.
Please refer to the Summary of Product Characteristics (SmPC) for more details on formulations, 
storage conditions (eg, refrigeration), known precautions, warnings, interactions, and adverse 
reactions for these drugs (Rifampicin SmPC) (Itraconazole SmPC).
1.3.
Rationale
1.3.1.
Study Rationale and Purpose
LSD1 is an eraser of the epigenetic code thereby regulating the expression of many genes 
important in cancer progression and cell proliferation (Scoumane, 2007; Hoffmann, 2012;
Lynch, 2012). LSD1 over-expression promotes proliferation, migration, and tumor invasion (Lv,
2012) and has been documented in many human solid tumors including bladder, breast, 
colorectal, prostate and SCLC (Kahl, 2006; Kauffman, 2011; Hayami, 2010; Serce, 2012). 
Moreover, LSD1 over-expression has been correlated with poor prognosis in hepatocellular 
carcinoma, neuroblastoma, prostate cancer, non-small cell lung cancer, and ER negative breast 
cancer (Kahl, 2006; Schulte, 2009; Lv, 2012; Lim, 2010; Zhao, 2012; Chen, 2015).
LSD1 is required for normal differentiation in adult as well as embryonic cells (Wang, 2007). It 
controls the balance between H3K4 and H3K27 methylation, thereby regulating
differentiation-associated genes (Adamo, 2011). It is required for normal hematopoiesis through 
interaction and modulation of GFI1b transcriptional programs and loss of LSD1 impairs 
hematopoiesis, through a block in differentiation (Saleque, 2007; Sprussel, 2012). Indeed, LSD1 
expression is high in acute myeloid leukemia and correlates inversely with differentiation 
(Lynch, 2012). Furthermore, its expression increases as chronic phase myeloid leukemia 
progresses to blast phase. Additionally, LSD1 is over-expressed more commonly in high-grade 
ductal carcinoma of the breast than low grade ductal carcinoma in situ (Serce, 2012) and in 
subjects with a higher Gleason score in prostate cancer (Kahl, 2006). LSD1’s importance in 
normal differentiation suggests that aberrant gene expression resulting from dysregulation of 
LSD1 may result in alterations in pathways associated with a stem-cell like phenotype.
Moreover, LSD1 plays a part in stem cell maintenance, regulation of epithelial-to-mesenchymal 
transition (Adamo, 2011; McDonald, 2011), and has been shown to be an essential regulator of 
leukemia stem cell potential (Harris, 2012). shRNA knockdown experiments in human ES cell 
lines show that decreased LSD1 activity lessens the proliferation and self-renewal ability of ES 
cells while promoting differentiation (DC QC6688, 2015). Hence inhibition of LSD1 might be a 
useful therapeutic approach for tumors with cancer stem cell involvement such as SCLC.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
38
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
SCLC is one of the most genetically complex cancers. Additionally, epigenetic changes such as 
histone modification occur, including methylation regulation of key SCLC genes, such as 
over-expression of B-cell lymphoma 2 (BCL2) and silencing of the retinoblastoma (RB1) gene
(Peifer, 2012; Poirier, 2015; Stewart, 2015). SCLC is a poorly differentiated tumor 
(Rechtman, 2010), believed to be derived from self-renewing pulmonary neuroendocrine 
progenitors (Park, 2011; Sutherland, 2011). The SCLC cell line (NCI-H446) has been shown to 
share the phenotypic characteristics of both neuroectoderm and mesoderm lineages with the cells 
possessing high stemness, tumorigenicity, and plasticity (Zhang, 2013). Indeed, SCLC retains 
stem cell markers such as CD133, Oct4, Sal4, PODXL-1, and Bmi-1 (Sarvi, 2014; Koch L-K,
2008; Zhang, 2013).
LSD1 over-expression has also been reported in other neuroendocrine tumours, including 
gastrointestinal neuroendocrine carcinomas (NECs) (Magerl, 2009). Furthermore, the stem cell 
marker, SOX2, is over-expressed in large cell neuroendocrine carcinoma (LCNEC), 
neuroendocrine prostate cancer (NEPC), and Merkel cell carcinoma (Laga, 2010; Sholl, 2010;
Yu, 2014). Strong SOX2 expression was found in only 23% of low grade pulmonary 
neuroendocrine tumors such as carcinoid but in 72% of NEC.  Hence, G2 NENs/NETs, SCLC,
and other NECs with their documented cancer stem cell involvement seem appropriate tumors in 
which to investigate CC-90011.
Similarly, LSD1 expression has been reported in non-Hodgkin’s lymphoma (Niebel, 2014) and 
appears to play a part in B cell differentiation (Hatzi, 2013; Haines, 2018; Haines, 2019). Hence,
NHL subjects will also be enrolled.
CC-90011 is a new investigational product (IP) that has a strong biological rationale for the 
treatment of subjects with relapsed and/or refractory advanced unresectable solid tumors 
(including G2 NENs/NETs, SCLC, and other NECs) and R/R NHL (MZL, including EMZL, 
SMZL, NMZL and histologic transformation of MZL) (refer to Section 1.3). The safety and 
tolerability of CC-90011 in humans, as well as the biologic and clinical activity, will be 
evaluated in this study. The study will be conducted in 4 parts: dose escalation (Part A), dose 
expansion (Part B) and DDI evaluation (Parts C and D).
1.3.2.
Rationale for Tumor Type Selection in Parts A and B
After the second Grade ≥ 2 study drug-related toxicity, which fall under the adverse event terms 
of thrombocytopenia/platelet count decrease, anaemia/red blood cell count decrease, 
neutropenia/white blood cell count decrease, and/ or gastrointestinal tract toxicities in Cycle 1
occurs, enrollment will be restricted to subjects with G2 NENs/NETs, SCLC, and other NECs
which may secrete neuroendocrine markers such as Pro-GRP, CgA or calcitonin which 
expression is regulated by LSD1 (Takagi, 2017; Jotatsu, 2016; Mohammad, 2015). LSD1 
binding has been demonstrated at possible regulatory sites for the gastrin releasing peptide 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
39
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
(GRP) locus and is consistent with GRP expression being directly regulated by LSD1(CC-90011 
Pharmacology Report). Additionally,
 
in mouse xenograft SCLC models. Hence GRP seems to be a 
relevant PD marker for LDS1 inhibition. Pro-GRP is more stable than GRP and therefore is a 
more robust biomarker and will be used rather than GRP. Also, chromatin immunoprecipitation 
(ChIP) studies demonstrated binding of LSD1 to enhancer elements near the Chromogranin A 
(CgA) gene locus in SCLC cell lines.
 
.
Medullary thyroid carcinoma (MTC) is a NEC associated with raised calcitonin levels. RREB1 
(RAS responsive element binding protein) is a component of the multiprotein corepressor 
complex containing the c terminal binding protein and LSD1, which interacts with a Ras-
responsive element in the calcitonin gene promoter (Ray, 2014). 
Enrolling such subjects at a biologically active dose will also provide preliminary data in tumors 
of highest interest, to guide selection of Part B expansion cohorts.
In part B, the enrollment will be restricted to subjects with advanced low/intermediate-grade lung 
NETs, NEPCs and R/R NHL (MZL, including EMZL, SMZL, NMZL and histologic 
transformation of MZL) based on results from Part A of the study, pre-clinical efficacy data (for 
data in PDX models of SCLC tumors, see Section 1.2.2 and Section 1.2.1) and supportive 
literature. 
1.3.2.1.
Rationale for Selection of NHL Tumors
LSD1 expression is observed in approximately 25.5% of mature B-cell non-Hodgkin’s 
lymphoma (B-NHL). Low-grade B-NHLs expressed LSD1 less often (12.9%) than did high-
grade B-NHLs (39.7%) (Neibel, 2014). 
LSD1 is highly expressed in germinal centers, indeed both transcripts and protein levels are 
induced during the transition from naïve to germinal center B cell state (Hatzi, 2013). Moreover, 
LSD1 has been shown to be necessary for proliferation and differentiation of naïve B cells and to 
regulate marginal zone B cell (MZB) development (Haines, 2018; Haines, 2019), however, the 
role of LSD1 in germinal center formation and BCL6-driven lymphomagenesis has only recently 
been elucidated.  BCL6, a key regulator of germinal center function that is frequently 
translocated and constitutively expressed in B-cell lymphoma (Basso, 2010), was shown to 
physically interact with and recruit LSD1 to its target genes, indicating that LSD1 acts in concert 
with BCL6 to facilitate proliferation.  Blocking LSD1 enzymatic activity was insufficient to 
suppress BCL6-driven lymphoma cell proliferation; the LSD1 domain required for protein–
protein interaction was required for lymphoma cell proliferation (Hatzi, 2019).   In vitro 
experiments have shown an extensive overlap of BCL6 and LSD1 binding sites and that genes 
bound or associated with BCL6-LSD1 complexes were significantly enriched in pathways such 
as B cell activation and cell cycle control among others (Hatzi, 2013). Taken together these 
results, suggest that LSD1 might act as a BCL6 co-repressor in germinal center being an 
essential transcriptional regulator for B cell differentiation. Due to the high LSD1 expression in 
lymphoma cells, targeting LSD1 might potentially be a good therapy for lymphoma.  Notably, 
there is yet no predictive biomarker to differentiate BCL6-dependent and BCL6-independent 
lymphomas (Cardenas, 2016).  BCL6 expression does not correlate with response to genetic or 
pharmacologic BCL6 inhibition.  Further, tumors not typically classified as germinal center 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
40
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
derived, such as ABC subtype DLBCL, appear BCL6-dependent and exquisitely responsive to 
investigational BCL6 inhibitors.
Clinical experience with LSD1-targeted agents in lymphoma is thus far limited.  The single 
subject 
 with tMZL enrolled in Part A of the current study experienced a durable CR 
to single-agent CC-90011 treatment. The subject, 
 with tMZL, received 6 lines 
of therapy prior to study enrollment, including involved field radiotherapy, 4 lines of 
combination chemotherapy, and an investigational agent.  Disease regression (↓38%) was 
observed after 2 cycles of treatment with 80 mg QW of CC-90011, and a complete metabolic 
response was reported after cycle 5. Subject is currently ongoing in C49 with very good
tolerability, without dose reductions, or evidence for disease progression. Like most cases of 
tMZL (Flossbach, 2011), this subject’s disease was found to overexpress BCL6 by 
immunohistochemistry, but a corresponding chromosomal translocation was not identified. A 
chromosomal abnormality in BCL2 was also identified; LSD1 expression has not been assessed. 
Dysregulation of c-MYC is essential in the pathogenesis of a number of B-cell NHLs, generally 
due to an overexpression of c-MYC by loss of the tight control of its expression rather than 
oncogenic mutations or fusion proteins seen in many other oncogenes (Nguyen, 2017). LSD1
inhibition significantly reduce transcription of MYC target genes (Amente, 2010; Ambrosio, 
2017; Li, 2016) and, conversely, LSD1 expression is induced by c-MYC generating a positive 
feedback mechanism (Nagasaka, 2019).
The observed durable CR and the potential role for LSD1 in lymphomagenesis provide rationale 
for further exploration of CC-90011 in B-NHL within the ongoing study.
1.3.2.2.
Rationale for Selection of Neuroendocrine Tumors
Neuroendocrine tumors (NET) arise from cells of the endocrine (hormonal) and nervous 
systems. The most common NETs are originating from lungs and gastrointestinal tract. Lung 
NETs can be classified into four subtypes: well differentiated, low-grade typical carcinoids 
(TCs) (2% of primary lung neoplasms); well-differentiated, intermediate-grade atypical 
carcinoids (ACs) (<1%); poorly differentiated, high-grade large cell neuroendocrine carcinomas 
(LCNECs) (3%); and poorly differentiated, high-grade SCLCs (20%) (Rechtman, 2010; Travis, 
2015). Well-differentiated lung NETs comprise approximately 27% of all NETs (Yao, 2008; 
Modlin, 2003) and 1% to 2% of all primary lung cancers (Rechtman, 2010) with estimated age-
adjusted incidence rates of 0.2 to two cases per 100,000 in the United States and Europe (Caplin, 
2015). Although rare, the prevalence of well differentiated lung NET has increased by 
approximately 6% per year over the last 30 years in both men and women (Modlin, 2008;
Gustafsson, 2008). Most well differentiated lung NETs are located centrally in the main (10%) or 
lobar bronchi (75%), with the remainder located in the peripheral lung (Yao, 2008; Oberg, 2012). 
As a result, symptoms usually reflect tumor location, with centrally located tumors (primarily 
TCs) often presenting with obstructive respiratory symptoms related to tumor mass, including 
cough, hemoptysis, dyspnea, chest pain, wheezing, and pneumonitis (Oberg, 2012; Caplin, 2015;
Gustafsson, 2008; Fisseler-Eckhoff, 2012).
The availability of effective treatment options for patients with advanced/metastatic 
low/intermediate-grade lung NETs (typical carcinoid and atypical carcinoid) are limited.
Platinum based doublets, mostly combinations with etoposide, are commonly used despite poor 
response rates and treatment outcomes since typical and atypical carcinoids tend to be less 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
41
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
chemo-sensitive than SCLC. While clinical data for these tumor types are limited because they 
have not been studied independently of other neuroendocrine neoplasms, temozolomide has 
shown activity. Results from a published phase II 36-patient neuroendocrine study with oral 
temozolomide given for 5 consecutive days every 28 days yielded 4 partial responses (31%) and 
4 stable diseases (31%) among typical and atypical carcinoids (Ekeblad, 2007). Until recently, 
there has been no clinical data for targeted therapy in patients with lung NENs. RADIANT-4, the 
first phase III trial which randomized 302 patients with advanced lung carcinoids and 
gastrointestinal neuroendocrine tumors, recently reported a PFS benefit with everolimus (PFS 
was significantly prolonged by 7.1 months and the risk of progression of the disease was reduced 
by 52% in everolimus-treated patients), resulting in its approval by the FDA as the first treatment 
for adult patients with advanced, well-differentiated, nonfunctional lung NETs (Yao, 2016).  
After progression to first-line therapy, there is no standard treatment and patients may be offered 
a variety of treatments as palliative care.
NETs are a heterogenous group of tumors, which until recently have remained largely intractable 
to genetic characterization, with many research studies being performed with a small number of 
samples leading to the identification of low-frequency mutations, which do not appear to have 
significant prognostic or therapeutic impact, suggesting the presence of alternative pathogenic 
drivers (Yoshimoto, 1992; Yashiro, 1993; Chung, 1997). 
There is a significant positive correlation between LSD1 and the expression of neuroendocrine 
differentiation genes in human cancer cell lines (Jotatsu, 2016). In addition, an alternative splice 
variant of LSD1, LSD1+8a, has been reported to be restricted expressed in neural tissues. 
Suppression of LSD1 led to inhibition of cell proliferation in SCLC in vitro and in vivo (Jotatsu, 
2016; Mohammad, 2015). Moreover, a DNA hypomethylation signature was able to identify 
SCLC PDXs sensitive to LSD1 inhibition (Mohammad, 2015).
Deregulated Notch signaling has been shown in many solid tumors. In some tumors, Notch 
signaling prevents differentiation, while in others, the oncogenic role of Notch is likely due to 
inhibition of apoptosis. LSD1 act as a corepressor of the Notch signaling which is involved in the 
acquisition or maintenance a partially differentiated neuroendocrine phenotype while retaining 
the ability to proliferate (Crabtree, 2016).
CC-90011 has demonstrated preliminary evidence of antitumor activity in neuroendocrine 
tumors. Among 27 NEN subjects in Part A, 7 subjects have demonstrated prolonged stabilization 
of disease (stable disease [SD] > 4 months). Notably, 3 subjects with bronchial NEN had 
prolonged SD of > 6 months and 2 subjects with prostate NEN remained on study treatment for 
over 6 months due to clinical benefit. In Part B, the 14 subjects with low/intermediate-grade lung 
NET, a best response of SD was observed in 10 (71.4%) subjects, including 7 (50.0%) subjects 
with SD ≥ 4 months. The 2 subjects with prostate NEC and the MZL subject progressed (see IB 
version V6.0, dated 15 Feb 2021).
The unmet medical need for advanced NETs, and the observed preliminary antitumoral activity 
in neuroendocrine subjects in Part A of the study, provide rationale for further exploration of 
CC-90011 in NENs/NECs within the ongoing study.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
42
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
1.3.3.
Rationale for Tumor Type Selection in Parts C and D
As of 11 Sep 2020, in CC-90011-ST-001 study, 67 subjects have been treated with a number of 
malignancies at different dose levels. 40 subjects received doses from 20 mg CC-90011 weekly 
or higher. Two durable responses were observed (a CR and a PR in a R/R NHL and a low- grade 
rare type of sarcoma/solitary fibrous tumour, respectively). In addition, 10 more subjects 
experienced SD > 6 months under CC-90011 monotherapy. All these subjects had low-grade 
NETs (G1/G2 of various anatomical origin as bronchial, renal, paraganglioma and 
pheochromocytoma) and were clearly progressing at study entry. Our targeted population is 
based on our observation that CC-90011 confers a benefit in suppressing tumor growth in slow 
growing tumor types. We will prioritize unresectable solid tumors with no available established 
therapeutic alternatives which have a slow growth pattern.
1.3.4.
Rationale for the Study Design
In Part A, this study will utilize a BLRM which is a well-established method to estimate the 
MTD and/or RP2D in cancer subjects. The adaptive BLRM will be guided by the EWOC 
principle to control the risk of DLT in future subjects on study. This method is more likely to 
assign fewer subjects to either sub-therapeutic or severely toxic dose levels and estimate the 
MTD with smaller average bias and error than the up-and-down methods such as 3+3. The use of 
Bayesian response adaptive models for small datasets has been accepted by EMA (“Guideline on 
clinical trials in small populations” February 1, 2007) and endorsed by numerous publications 
(Babb, 1998; Neuenschwander, 2008; Neuenschwander, 2010), and its development and 
appropriate use is one aspect of the FDA’s Critical Path Initiative.
In Part A, during the initial dose levels, subjects with relapsed and/or refractory advanced 
unresectable solid tumors and R/R NHL will be enrolled until the 2nd occurrence of a Grade ≥ 2, 
study drug-related toxicity, which fall under the adverse event terms of thrombocytopenia/
platelet count decrease, anaemia/red blood cell count decrease, neutropenia/white blood cell 
count decrease, and/ or gastrointestinal tract toxicities in Cycle 1. At this point, the enrollment 
will be restricted to subjects with G2 NENs/NETs, SCLC, and other NECs likely to secrete,
Pro-GRP, CgA or calcitonin, because these subjects may be more likely to gain clinical benefit 
and may provide evidence of a pharmacodynamic effect through changes in the baseline and on 
treatment levels of secreted neuropeptides.
In Part B, 3 cohorts, of approximately 10-20 evaluable subjects each, with advanced 
low/intermediate-grade lung NETs, NEPCs and R/R NHL (MZL, including EMZL, SMZL, 
NMZL and histologic transformation of MZL) will receive the RP2D to further evaluate safety, 
PK, PD and preliminary efficacy.  
1.3.5.
Rationale for Dose, Schedule and Regimen Selection (Part A and Part B)
The CC-90011 GLP 4-week toxicity studies were conducted in mice dosed on schedules that 
included QDx5/week, and in Beagle dogs dosed on schedules that included QW.  Based on the 
doses and exposures at which the principal treatment-related effects occurred in the 
GLP-compliant 4-week mouse and dog studies, the dog is considered of greater sensitivity to the 
toxicities associated with CC-90011 administration. The proposed human starting dose was 1.25 
mg CC-90011 based on a QW schedule. Alternative dosing schedules (eg, once every other 
week) may be evaluated based on the review of available safety, PK, PD, and efficacy data by 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
43
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
the SRC. This CC-90011 dose was calculated using the approach described in the ICH S9 
Guideline entitled “Nonclinical Evaluation for Anticancer Pharmaceuticals (ICH, 2009) and is 
summarized in Table 2.
The proposed starting dose in humans was lower than 1/10th the STD10 in mice, less than 1/6th 
the HNSTD in dogs, and was considered likely to be safe based on multiples of exposure (as 
measured by AUC) in mice and dogs relative to the predicted human exposure at a dose of 1.25 
mg CC-90011 base on a QW schedule. As noted in Table 2, the human exposure (AUC) at a 1.25 
mg base QW dose was predicted to be 29 ng•hr/mL; this value is approximately 4785-fold lower 
than the mean exposure corresponding to the predicted weekly mouse STD10 exposure (138750
ng•hr/mL) and approximately 10-fold lower than the mean exposure corresponding to the dog
QW HNSTD (287 ng•hr/mL). Based on these toxicokinetic data, the proposed human starting 
dose of 1.25 mg CC-90011 base was expected to be safe.
Table 2:
Proposed Clinical Starting Dose and Schedule of CC-90011 Based on the 
Severely Toxic Dose in 10% of the Mice and the Highest Non-severely Toxic 
Dose in Dogs from Pivotal 4-Week Toxicity Studies
Species
Mouse 
STD10 or 
Dog HNSTD 
(mg 
base/kg/dose)
HED (mg 
base/kg/dose)
HED (mg 
base/dose)
Safety 
Factor
HED/Safety 
Factor (mg 
base/dose)
a
Proposed 
Clinical Starting 
Dose and 
Schedule
b
Mouse
45
3.66
219.6
10
22
1.25 mg 
base/dose, QW
Dog
0.250
0.139
8.34
6
1.4
HED = human equivalent dose; HNSTD = highest non-severely toxic dose; STD10 = severely toxic dose in 10% of 
the animals.
a Based on HED conversion factor for a 60-kg person from the FDA Guidance for Industry entitled "Estimating the 
Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers" (FDA, 2005) 
and the ICH S9 Guideline entitled “Nonclinical Evaluation for Anticancer Pharmaceuticals” (ICH, 2009).
b Using allometry derived plasma clearance (9.4 mL/min/kg) and volume of distribution (17.6 L/kg) estimates and 
assuming 80% oral bioavailability, the predicted Cmax and AUC24h at the intended human starting dose of 1.25 mg 
are approximately 0.8 ng/mL and 29 ng•h/mL, respectively.
Refer to the Investigator’s Brochure for detailed information.
For the summary of clinical data, see Section 1.2.1.3 of the protocol and current IB (version 6.0, 
dated 15 Feb 2021).
Part B (expansion) of the study enrolled the first subject on 23 Oct 2018 within the advanced 
low/intermediate-grade lung NET cohort with CC-90011 at the RP2D of 60mg QW. No safety 
concerns were observed in the 17 treated subjects (14 Bronchial, 2 Prostate and 1 MZL) 
receiving 60 mg CC-90011 QW. 
1.3.6.
Rationale for Drug-Drug Interaction Evaluation (Part C and Part D)
The available preclinical data suggest that CC-90011 may be substantially eliminated via 
CYP3A4/5-mediated metabolism in humans. Studies using recombinant human CYP enzymes, 
human liver microsomes (HLMs), and CYP-selective monoclonal antibodies have shown that 
CYP3A4/5 appears to be predominantly responsible for the oxidative metabolism of CC-90011 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
44
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
(Report QC6688-ADME-2006, Report CC-90011-DMPK-2332). In bile duct cannulated (BDC)
rats, following IV dosing of nonradiolabeled CC-90011, an average of 26.3% of the dose (8.5% 
of dose in urine and 17.8% of dose in bile) was excreted intact in the 24-hour period postdose
(Report QC6688-ADME-2008). Furthermore, following oral administration of [14C]CC-90011 to 
BDC dogs, less than half of the absorbed dose was recovered as unchanged parent drug (22.8% 
of the administered radioactivity was recovered in urine and bile as parent drug vs. 54% 
recovered as total radioactivity), while in BDC rats, approximately 68% of the absorbed dose 
was recovered as unchanged parent drug (19.6% of the administered radioactivity was recovered 
in urine and bile as parent drug vs. 29% as total radioactivity). Taken together, these data suggest 
that metabolism likely plays a significant role in the elimination of CC-90011 (Report QC6688-
ADME-2008; Report CC-90011-DMPK-3315; Report CC-90011-DMPK-3369).
In addition, CC-90011 is a P-gp substrate as suggested by the in vitro cell-based permeability 
assay findings (Report QC6688-ADME-2003; Report CC-90011-DMPK-2450). Therefore, Parts 
C and D are designed to evaluate the effect of a strong CYP3A and P-gp inhibitor or inducer on 
the PK of CC-90011. 
1.3.6.1.
Rationale for DDI evaluation design
The overall study design of Parts C and D allows for the evaluation of the effect of a strong 
CYP3A and P-gp inhibitor or inducer on the PK of CC-90011, consistent with the EMA 
Guideline on the investigation of drug interactions (EMA, 2012References) and FDA Guidance 
for industry: clinical drug interaction studies (FDA, 2020). CC-90011. Rifampicin and 
Itraconazole will be administered in a fasted state as the potential effect of food on the PK of 
CC-90011 has not been evaluated, and this may represent an additional variable in this PK 
evaluation.

Part C is designed to evaluate the potential for PK DDI between CC-90011 and 
rifampicin, a potent CYP3A inducer (EMA, 2012 and FDA, 2020) and based on 
published literature reports as a P-gp inducer (Elmeliegy, 2020).

Part D is designed to evaluate the potential for PK DDI between CC-90011 and 
itraconazole, a potent CYP3A and P-gp inhibitor (EMA, 2012 and FDA,2020).
The key endpoints of the DDI cohorts are plasma PK parameters of CC-90011 with and without 
coadministration of rifampicin (Part C) or itraconazole (Part D). The fixed-sequence, crossover 
design used in Parts C and D is typical for DDI studies. A relatively small number of subjects are 
required, as this design minimizes inter-subject variability in the treatment comparison. The 
number of participating subjects is considered sufficient to achieve the objectives of the 
evaluation and is based on statistical calculations on precision and intrasubject standard 
deviation.
1.3.6.2.
Rationale for Doses, Schedules and Regimen Selection in DDI cohorts
Thrombocytopenia, an on-target effect, was the only DLT reported in Part A of the CC-90011-
ST-001 study. LSD1-inhibition affects the budding of platelets from the megakaryocytes (Rinske 
van Oorschot, 2019). This effect is completely reversable with one week interruption of
treatment (see IB version V6.0, dated 15 Feb 2021). These events occurred mainly at the highest 
dose levels (80 mg QW and 120 mg QW) and were successfully managed with dose interruption 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
45
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
for a week (majority cases) and/or dose reduction (rare cases). CC-90011 has been generally well 
tolerated with the majority of treatment-emergent adverse events (TEAEs) reversible and 
manageable by dose adjustments and/or supportive treatments (see IB version V6.0, dated 15 
Feb 2021). The RP2D of CC-90011 monotherapy was established at 60 mg QW administered on 
Days 1, 8, 15, and 22 of 28-day cycles. At this dose level (60 mg QW), thrombocytopenia is the 
only clinically significant (CS) toxicity observed. Around 40% of patients experience CS, mainly 
asymptomatic Grade 2/Grade 3 thrombocytopenia. Only 10% of patients experience Grade 4 
thrombocytopenia. The thrombocytopenia follows a cyclical pattern within the 28 days cycle 
with a nadir on day 14 of each cycle and self-recovery by day 21. Drug management guidelines 
include dose reduction to 40 mg QW in cases of Grade 4 thrombocytopenia and interruption of 
dosing for a week in cases of Grade 2/Grade 3 thrombocytopenia. No treatment related deaths 
nor hospitalizations due to toxicity have occurred during the expansion Part B at 60 mg QW of 
CC-90011 in around 60 patients treated on different cohorts/studies (G2 NET, Prostate NEC, 
R/R Marginal Zone NHL, SCLC maintenance). Single agent CC-90011 decreased expression of 
target gene MMD by ≥ 50% in patient blood samples at doses ≥ 60 mg QW MMD suppression in 
part B is consistent with same dose effects in Part A. 
The 60 mg CC-90011 dose level was selected for evaluation of CC-90011 DDI in combination 
with rifampicin, a potent CYP3A inducer, whereas the 20 mg CC-90011 dose level was selected 
for DDI evaluation in combination with itraconazole, a potent CYP3A and P-gp inhibitor. A 60 
mg dose of CC-90011 administered twice within the 40 days of the DDI evaluation in 
combination with rifampicin is expected to result in a lower risk of thrombocytopenia. If 
thrombocytopenia occurs, it is expected to appear around 14/21 days after the first dose of the 
combination which would require observation/drug interruption if platelets fall below G2 levels. 
Platelet levels are expected to self-recover in around one week´s time from nadir. Platelet levels 
and a coagulation panel will be closely monitored during the study as described in Table 6. 
A physiology based pharmacokinetic (PBPK) model projected that the maximum impact (worst 
case scenario) from coadministration of a strong index CYP3A inducer is ~ 80% decrease in CC-
90011 AUC (internal data). Assuming 4- to 5-fold reduction in exposure, the resulting CC-90011 
plasma concentrations are still expected to be quantifiable and expected to correspond to 
approximately 12 mg monotherapy dose of CC-90011. During the dose escalation (Part A) of the 
current study, exposures to CC-90011were well characterized following doses lower than 12 mg
of CC-90011.
In Part D (CC-90011 coadministration with itraconazole) of this study, coadministration of a 
strong CYP3A and P-gp inhibitor is expected to result in increased exposure to CC-90011. The 
PBPK model projected that the maximum impact (worst case scenario) from coadministration of 
a strong index CYP3A4 inhibitor is ~ 4.7-fold increase in CC-90011 AUC. The exposure to CC-
90011 resulting from this increase would be the equivalent of the exposure to CC-90011 
achieved with an ~80-90 mg monotherapy dose, and is well below the exposure to the non-
tolerated dose of 120 mg QW.
Based on the known human PK of CC-90011, and the fact that rifampicin could enhance CC-
90011 clearance by inducing CYP3A4 expression and itraconazole could diminish CC-90011 
clearance by inhibiting CYP3A4 expression, the sample collection timing and duration of Parts C 
and D of this study are considered adequate to achieve the objectives of Part C and D 
respectively.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
46
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Selection of rifampicin and itraconazole dosing regimen is based on a large body of published 
literature (Srinivas, 2016) (Liu, 2016) as well as DDI study designs utilized in the Sponsor’s
protocols.
Rationale for Washout Interval in Parts C and D
Based on the half-lives of CC-90011 and the study-specified perpetrator drugs, the inter-dose
washout intervals are considered sufficient to prevent carryover. For example, the geometric 
mean half-life of CC-90011 following single 20- or 60-mg dose administration is approximately 
65 hours. Thus, an inter-dose washout interval of 14 days (5 half-lives of CC-90011) between the 
Day 1 dose of CC-90011 in Period 1 and the first dose of study drug in Period 2 is expected to be 
sufficient.
In Part C, Period 2, a washout interval of 5 days between the last dose of rifampicin on Day 35
and start of CC-90011 treatment period on Day 40, is greater than 5 times rifampicin half-life of 
3.35 ± 0.66 hours (reference: SmPC). It is understood that restoration of baseline level of enzyme 
activity after rifampicin treatment may take longer than the washout period. However, initiation 
of CC-90011 treatment period on Day 40 is planned in the best interest of the subjects and is not 
considered to be a safety concern.
In Part D, Period 2, a 9-day washout interval between the last dose of itraconazole on Day 31 and 
start of CC-90011 treatment period on Day 40, is greater than 5 times itraconazole half-life of 16 
± 5 hours (reference: SmPC). Additionally, the PBPK model predicted mean and upper 95th 
percentile plasma CC-90011 concentrations on Day 40 were 0.52 ng/mL and 2.68 ng/mL, 
respectively, which represent the normal range of trough concentrations following 20 mg QW
dosing of CC-90011. Additionally, the predicted mean residual CC-90011 concentration on Day 
40 (0.52 ng/mL) was approx. 5% of the predicted mean CC-90011 Cmax in Period 2 (10.9 
ng/mL), indicating that the washout interval of 9 days between Period 2 and CC-90011 treatment 
period was adequate.
1.3.7.
Rationale for Pharmacodynamics and Biomarkers
A key exploratory objective of this study is to identify a dose and schedule of CC-90011 that is 
not only safe but that exhibits pharmacologic activity. 
 
 
 
 
 
 
 
 
 
 
 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
47
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
2.
STUDY OBJECTIVES AND ENDPOINTS
Table 3:
Study Objectives
Primary Objective
The primary objectives of the study are:
Parts A and B

To determine the safety and tolerability of CC-90011

To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of 
CC-90011  
Parts C and D

To evaluate the effect of rifampicin, a strong cytochrome P450 (CYP) 3A and P-glycoprotein (P-
gp) inducer, on the PK of CC-90011 (Part C)

To evaluate the effect of itraconazole, a strong CYP3A and P-gp inhibitor on the PK of CC-
90011 (Part D)
Secondary Objective(s)
The secondary objectives are:
Parts A and B

To provide information on the preliminary efficacy of CC-90011

To characterize the pharmacokinetics (PK) of CC-90011
Parts C and D

To characterize the PK parameters of a single dose of CC-90011 alone and in combination with 
rifampicin (Part C) or itraconazole (Part D)

To assess the safety and tolerability of a single dose of CC-90011 alone and in combination with 
rifampicin (Part C) or itraconazole (Part D) 
Exploratory Objective(s)
The exploratory objectives are:

To evaluate the PD effects of CC-90011 on gene expression in peripheral blood and if available, 
in tumor samples (in Parts A and B)

To evaluate the PD effects of CC-90011 on secreted neuropeptide (such as Pro-GRP, CgA and
calcitonin only in Part A) levels in blood from G2 NENs/NETs, SCLC, and other NEC subjects 
(in Parts A and B)

To explore the relationship among CC-90011 dose, plasma exposure (in all Parts), and selected 
clinical endpoints (in Parts A and B) (eg, measures of toxicities, preliminary activity, and/or 
biomarkers) 

To explore the relationship between baseline, on-treatment, and/or changes in gene expression in 
tumor samples (if available) and clinical response (in Parts A and B)

To characterize the metabolites of CC-90011 in plasma.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
48
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 3:
Study Objectives (Continued)
Exploratory Objective(s)

To assess the urinary excretion of CC-90011 and its M1 metabolite (CC7108272) following 
single oral dose of CC-90011 to cancer patients (Parts C and D).

Data from exploratory objectives may be included in the Clinical Study Report per SAP 
(Statistical analyses plan)
To assess the impact of SARS-CoV-2 serologic status on subjects with R/R NHL (MZL, 
including EMZL, SMZL, NMZL and histologic transformation of MZL) and on subjects with 
advanced unresectable solid tumors enrolled in Parts C and D, receiving CC-90011
Table 4:
Study Endpoints
Endpoint
Name
Description
Timeframe
Primary 
Safety endpoints
DLTs and MTD evaluated using the NCI 
CTCAE criteria, Version 4.03
Dose escalation
Effect of Rifampicin 
on CC-90011 PK 
(Part C)
Cmax, AUC0-∞, AUC0-t, AUC0- 168, for
CC-90011 with and without coadministration 
with Rifampicin
Ratio (CC-90011 + Rifampicin/
CC-90011 alone) of Cmax, AUC∞, AUC0-t,
AUC0-168; as well as the difference 
(CC-90011 + Rifampicin – CC-90011 alone) 
in Tmax.
At prespecified 
time points (Part 
C)
Effect of Itraconazole 
on CC-90011 PK 
(Part D)
Cmax, AUC0-∞, AUC0-t, AUC0- 168, for
CC-90011 with and without coadministration 
with Itraconazole
Ratio (CC-90011 + Itraconazole/
CC-90011 alone) of Cmax, AUC∞, AUC0-t,
AUC0-168; as well as the difference 
(CC-90011 + Itraconazole – CC-90011 alone) 
in Tmax.
At prespecified 
time points (Part 
D)
Secondary 
Preliminary efficacy
Clinical benefit rate (CBR) determined by 
response and stable disease rates by disease-
appropriate response criteria, ORR, DOR, 
and PFS
Dose escalation 
and expansion
Overall survival
From the first dose to death due to any cause
Dose escalation 
and expansion
PK endpoints
Maximum observed plasma concentration 
(Cmax), area under the plasma concentration 
time-curve (AUC), time to maximum plasma 
concentration (Tmax), terminal half-life (t1/2), 
apparent clearance (CL/F), and apparent 
volume of distribution (Vz/F) of CC-90011
Dose escalation 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
49
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 4:
Study Endpoints (Continued)
Endpoint
Name
Description
Timeframe
Effect of Rifampicin
on CC-90011 PK 
(Part C)
t½, CL/F, Vz/F for CC-90011
At prespecified 
time points (Part 
C)
Effect of Itraconazole 
on
CC-90011 PK (Part 
D)
t½, CL/F, Vz/F for CC-90011
At prespecified 
time points (Part 
D)
Exploratory
PD endpoints

Gene expression in peripheral blood 
cell components 

Gene expression in tumor tissue, if 
available

Secreted neuropeptides (such as Pro-
GRP, CgA and calcitonin only in part 
A) levels in blood from 
low/intermediate-grade lung NET and 
NEPCs subjects in expansion Part B.
Dose escalation 
and expansion
PK endpoints

Clinically relevant covariates of PK 
parameters

Identification of principal CC-90011 
metabolite(s) in plasma

Exposure-response relationships
Effect of Rifampicin
on CC-90011 PK 
(Part C)

Exploratory metabolite profiles in 
plasma and urine without 
coadministration of Rifampicin. 

Measurement of pharmacokinetic 
(PK) parameters in urine for the parent 
drug, metabolite CC7108272 (M1), 
and other metabolites as needed, 
without coadministration of 
Rifampicin.

Measurement of PK parameters in 
plasma for CC7108272 and other 
metabolites as needed, with and 
without coadministration of 
Rifampicin.
At prespecified 
time points (Part 
C)
Effect of Itraconazole 
on CC-90011 PK 
(Part D)

Exploratory metabolite profiles in 
plasma and urine without 
coadministration of Itraconazole. 
At prespecified 
time points (Part 
D)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
50
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 4:
Study Endpoints (Continued)
Endpoint
Name
Description
Timeframe

Measurement of PK parameters in 
urine for the parent drug, CC7108272, 
and other metabolites as needed, 
without coadministration of 
Itraconazole.

Measurement of PK parameters in 
plasma for M1 and other metabolites 
as needed, without coadministration of 
Itraconazole.
SARS-CoV-2 
serologic status

Exploratory measurements of SARS-
CoV-2 serology (anti-SARS-CoV-2 
total or IgG).
At prespecified 
time points.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
51
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
3.
OVERALL STUDY DESIGN
3.1.
Study Design
Study CC-90011-ST-001 is an open-label, Phase 1a, dose escalation and expansion, FIH clinical 
study of CC-90011 in subjects with relapsed and/or refractory advanced unresectable solid 
tumors (including G2 NENs/NETs, SCLC, and other NECs) and R/R NHL. The dose escalation 
part (Part A) of the study explored escalating oral doses of CC-90011 to estimate the 
RP2D/MTD of CC-90011. A Bayesian logistic regression model (BLRM) utilizing escalation 
with overdose control (EWOC) (Babb, 1998; Neuenschwander, 2008) helped guide CC-90011 
dose escalation decisions with the final decisions being made by an SRC. The expansion part 
(Part B) will further evaluate the safety and efficacy of CC-90011 administered at 60 mg QW in 
the selected expansion cohorts of R/R NHL (MZL, including EMZL, SMZL, NMZL and
histologic transformation of MZL), advanced unresectable low/intermediate-grade lung NETs
and NEPCs, which may secrete neuroendocrine markers such as Pro-GRP, CgA, or calcitonin, of 
approximately 10-20 evaluable subjects each in order to further define the RP2D. One or more 
dosing regimens may be selected for cohort expansion (Part B). Parts A and B will consist of 3 
periods: Screening, Treatment, and Follow-up periods (refer to Figure 2). The DDI cohorts will 
evaluate the effect of multiple doses of rifampicin (Part C) and itraconazole (Part D) on CC-
90011 by comparison of the PK parameters of a single dose of CC-90011 alone and in 
combination with rifampicin or itraconazole. Part C and D will consist of 4 periods: Screening, 
DDI Evaluation, Treatment and Follow-up periods (refer to Figure 3).
The study will be conducted in compliance with the International Council for Harmonisation 
(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
Figure 2:
Overall Study Design (Part A and Part B)
Screening Period
Day -28 to Day -1
(± 3 days)
Treatment Period
Part A: Dose escalation
Part B: Cohort expansion
CC-90011 administered in 
28-day cycles according to 
protocol- or SRC-approved 
dosing schedule. 
Possible reasons for 
discontinuation of treatment are 
described in Section 11.1.
Follow-up Period
Safety follow-up occurs 
within 28 days (± 3 
days) after last dose of 
CC-90011.  
Survival follow-up will 
be every 3 months (± 2 
weeks) for up to 2 years 
or until death, lost to 
follow-up, or the End of 
Trial, whichever occurs 
first. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
52
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Figure 2:
Overall Study Design (Continued)
Figure 3:
Study Design Part C and Part D
a Not applicable for subjects who discontinues during DDI evaluation period.
Screening 
Period
Day -28 to 
Day -1
(± 3 days)
DDI Evaluation 
Period
Part C: CC-90011 + 
Rifampicin
Part D: CC-90011 + 
Itraconazole
Period 1: D1-D14
Period 2: D15-D39
Details about CC-
90011, Rifampicin 
and Itraconazole 
administration are 
described in 
Section 7.2.1.1
Follow-up Period
Safety follow-up 
occurs within 
28 days (± 3 days) 
after last dose of 
study treatments.  
Survival follow-up 
will be every 3 
months (± 2 weeks) 
for up to 2 years or 
until death, lost to 
follow-up, or the 
End of Trial, 
whichever occurs 
first.a
CC-90011 
Treatment Period
CC-90011 
administered at 
RP2D (60 mg 
QW) in 28-day 
cycles. 
Possible reasons 
for discontinuation 
of treatment are 
described in 
Section 11.1.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
53
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Screening Period
The Screening Period starts 28 days (± 3 days) prior to first dose of CC-90011. The informed 
consent form (ICF) must be signed and dated by the subject and the administering staff prior to 
the start of any other study procedures. All screening tests and procedures must be completed 
within the 28 days (±3 days) prior to the first dose of CC-90011.
Treatment Period
During the Treatment Period, CC-90011 will initially be administered orally once weekly in each 
4-week (28 day) Cycle in Part A. Alternative dosing schedules (eg, once every other week or 
twice weekly) may be evaluated based on the review of available safety, PK, PD, and efficacy 
data by the SRC. In Part A, the window for evaluation of dose-limiting toxicity (DLT) will be 28 
days (4 weeks) during Cycle 1. Once the MTD has been established for a once weekly schedule, 
and if the pharmacokinetics and clinical safety data in man suggest more frequent dosing might 
be appropriate, and if the SRC is supportive, alternative more frequent dosing schedules may be 
explored.
The DDI cohorts will evaluate the effect of multiple doses of rifampicin (Part C) and 
itraconazole (Part D) on CC-90011 by comparison of the PK parameters of a single dose of CC-
90011 alone and in combination with rifampicin or itraconazole. The DDI evaluation period for 
each part will be conducted across 2 study periods (Period 1 and Period 2). Following 
completion of the DDI evaluation period, including a washout period of 5 days after the last dose 
of rifampicin (Part C) or 9 days after the last dose of itraconazole (Part D), subjects will start 
CC-90011 at the RP2D of 60 mg QW of 28-day cycles. 
Follow-up Period
In the Follow-up Period, subjects will be followed for 28 days (± 3 days) after the last dose of 
CC-90011 (in Parts A and B) and after the last dose of any study treatment, whichever is the 
latest (in Parts C and D) for safety. 
Subjects who discontinue treatment for reasons other than disease progression, start of a new 
anticancer therapy, or withdrawal of consent from the entire study will have disease assessments 
performed according to the specified tumor assessment schedule until progression and/or 
initiation of new systemic anticancer therapies. This does not apply to subjects who discontinue 
during the DDI evaluation period in Parts C and D.
After the Safety Follow-up visit, all subjects will be followed every subsequent 3 months (± 2 
weeks) for survival follow-up for up until 2 years or until death, lost to follow-up, or the End of 
Trial, whichever occurs first. This does not apply to subjects who discontinue during the DDI 
evaluation period in Parts C and D.
Subjects who discontinue treatment during the DDI evaluation may be replaced if not DDI 
evaluable.
3.1.1.
Part A-Dose Escalation
A minimum of 3 subjects will be enrolled at each dose level. The initial CC-90011 dose was 1.25 
mg once per week. The BLRM with EWOC will incorporate available prior safety information 
and update the model parameters after each new cohort of subjects completes Cycle 1. The 
decision for the next dose will be made by the SRC based on a calculation of risk assessment 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
54
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
using the BLRM, and available safety (ie, DLT and non-DLT safety data), PK, PD, and 
preliminary efficacy information. In addition, relevant non-clinical data (eg, GLP toxicity 
studies, in vivo pharmacology from xenograft models, etc) may be utilized in the assessment. 
Details of the statistical methodology are provided in Appendix E.
At all decision time points, the BLRM permits alterations in the dose increments based on the 
observed DLTs; however, the dose for the next cohort will not exceed a 100% increase from the 
prior dose. The MTD is the highest dose for which less than 33% of the population (not sample 
from the population) treated with CC-90011 suffer a DLT in the first cycle and at least 6 
evaluable subjects have been treated at this dose. The SRC will make the final decision regarding 
the CC-90011 dose for each cohort.
During dose escalation, a CC-90011 dose can be declared the MTD after meeting the following 
conditions: 

at least 6 evaluable subjects have been treated at the dose, 

the posterior probability that the DLT rate lying in the target interval (16-33%) at the 
dose exceeds 60% or a sufficient number of subjects have been entered into the study 
to ensure the precision of the MTD estimate, as the posterior probability approaches 
but fails to exceed 60%, and

the dose is recommended according to the BLRM and the SRC approves it.
Dose escalation may be terminated by SRC at any time based on emerging safety concerns 
without establishing the MTD. The SRC will include Investigators (and/or designated 
representatives), the Sponsor’s study physician, safety physician, study statistician, and the study 
manager.  Ad hoc attendees may include the study pharmacokineticist, the study biomarker- and 
study clinical scientists. Other internal and external experts may be consulted by the SRC, as 
necessary. 
All decisions made at the SRC meetings will be formally documented (via SRC meeting 
minutes) and circulated to all sites in writing.  No dose escalation, de-escalation, change to 
dosing schedule, or expansion of existing dose cohorts will commence prior to a written 
notification being sent to all participating sites of the respective SRC decision.
The decision to evaluate additional subjects within a dose cohort, a higher dose cohort, 
intermediate dose cohorts, smaller dose increments, alternative dosing schedules (eg, once every 
other week or twice weekly), or declare a MTD will also be determined by the SRC, based on the 
BLRM assessment and their review of available safety (ie, DLT and non-DLT data), PK, PD, 
and preliminary efficacy information. The final decision will be made by the SRC.
After the first dose is administered in any cohort during dose escalation, subjects in each cohort 
are observed for 28 days (Cycle 1, DLT window, as defined in Section 7.2.6) before the next 
dose cohort can begin. A subject evaluable for DLT is defined as one that: 

Has received ≥ 75% of the total planned dose amount of CC-90011 during Cycle 1 
without experiencing a DLT,
or

Experienced a DLT after receiving at least one dose of CC-90011.  
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
55
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Subjects not evaluable for DLT will be replaced.
During the initial dose levels, subjects with advanced unresectable solid tumors and R/R NHL 
will be enrolled until the 2nd occurrence of a Grade ≥ 2, study drug-related toxicity, which fall 
under the adverse event terms of thrombocytopenia/platelet count decrease, anaemia/red blood 
cell count decrease, neutropenia/white blood cell count decrease, and/ or gastrointestinal tract 
toxicities in Cycle 1.  At this point, the enrollment will be restricted to subjects with G2 
NENs/NETs, SCLC, or other NECs who may secrete Pro-GRP, CgA and calcitonin.
Intra-subject dose escalation will not be allowed during the DLT assessment period, however, in 
Cycles ≥ 3, subjects without evidence of disease progression who are tolerating their assigned 
dose of CC-90011 may (at the Investigator’s discretion and in consultation and agreement with 
the Sponsor’s study physician) escalate to the highest dose level shown to be adequately 
tolerated by at least one cohort of subjects in this study (ie, overdose risk is less than 25% based 
on the BLRM assessment).
3.1.2.
Part B-Cohort Expansion
Following completion of dose escalation (Part A), in Part B, 3 cohorts, of approximately 10-20 
evaluable subjects each, with advanced low/intermediate-grade lung NETs, NEPCs and R/R 
NHL (MZL, including EMZL, SMZL, NMZL and histologic transformation of MZL) will 
receive the RP2D to further evaluate safety, PK, PD and preliminary efficacy.  Expansion will
occur at the RP2D and schedule established in the dose escalation phase (60 mg QW), and/or at 
an alternative tolerable dose and schedule, based on review of available safety, PK, PD and 
efficacy data from Part A. The SRC will select the doses and schedules of interest for cohort
expansion. One or more dosing regimens may be selected for cohort expansion. The SRC will 
continue to review safety data regularly throughout the study and make recommendations about 
study continuation and dose modification, as appropriate.
In Part B of the study, SRC meetings will be held after at least 6 subjects have been recruited 
with at least 2 months of follow up; or after the number of subjects specified in the futility 
analyses has been reached; and/or ad-hoc as advised by emerging safety/efficacy data.
3.1.3.
Part C and Part D- DDI Cohorts
The DDI cohorts will consist of a nonrandomized, fixed-sequence, crossover, two-period design 
that will evaluate the effect of multiple doses of rifampicin (Part C) and itraconazole (Part D) on 
CC-90011 PK parameters in approximately 16 DDI evaluable subjects with advanced
unresectable solid tumors. The DDI evaluation period for each part will be conducted across 2 
study periods (Period 1 and Period 2) followed by a CC-90011 treatment period in which 
subjects will receive CC-90011 at the RP2D of 60 mg QW in 28-day cycles. Both Part C and 
Part D will have a 14-day washout interval between Day 2 and Day 14 (inclusive of Days 2 and 
14) and another washout interval after last dose of rifampicin on Day 35 (Part C) or Itraconazole 
on Day 31(Part D), before starting the CC-90011 treatment period. The total duration of DDI 
treatment period (Period 1 + Period 2) will be 40 days.
Blood samples and urine will be collected at prespecified times for PK analyses. Subject safety 
will be monitored throughout the study. Overnight stay for subjects can be arranged or subjects 
can be hospitalized at any time point due to study procedures, without this constituting a serious 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
56
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
adverse event (SAE), if the treating physician considers this appropriate for an individual 
subject. 
Following confirmation of eligibility during screening, subjects will be alternatively enrolled in 
Part C and Part D, respectively. In each part, approximately 8 DDI evaluable subjects will be 
enrolled, leading to a total of up to 16 DDI evaluable subjects for Parts C and D.
Part C and D are as described below:
Part C (CC-90011 and Rifampicin)
During Period 1, subjects will:

On Day 1: Receive a single oral dose of CC-90011 60 mg under fasting condition as 
described in Section 7.2.

On Days 2 to 14 inclusive: Observe a washout period
Blood samples and urine for measurement of CC-90011 and metabolites in plasma and urine will 
be collected at predose and postdose until 336 hours (D15), following 60 mg dose of CC-90011 
on Day 1.
During Period 2, subjects will:

On Days 15 to 21: Receive rifampicin oral dose of 600 mg once daily fasting under 
condition

On Day 22: Receive a single oral dose of CC-90011 60 mg coadministered with a 
single oral dose of rifampicin 600 mg under fasting condition

On Days 23 to 35: Receive rifampicin 600 mg once daily under fasting condition

On Days 36 to 39 inclusive: Observe a washout period
Blood samples, for measurement of plasma CC-90011 and metabolites, will be collected at 
predose and postdose until 432 hours, following 60 mg dose of CC-90011 on Day 22.
After Period 2 completion, on Day 40, subjects will start the CC-90011 Treatment Period, 
receiving CC-90011 at the RP2D of 60 mg QW in each 28-day cycle (Figure 4).
Figure 4:
Overall Study Design for Part C
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
57
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Part D (CC-90011 and Itraconazole)
During Period 1, subjects will:

On Day 1: Receive a single oral dose of CC-90011 20 mg under fasting conditions as 
described in Section 7.2

On Days 2 to 14 inclusive: Observe a washout period
Blood samples and urine for measurement of CC-90011 and metabolites in plasma and urine will 
be collected at predose and postdose to 336 hours (D15), following 20 mg dose of CC-90011 on 
Day 1.
During Period 2, subjects will:

On Days 15 to 17: Receive itraconazole 200 mg once daily under fasting conditions

On Day 18: Receive a single oral dose of CC-90011 20 mg coadministered with a 
single oral dose of Itraconazole 200 mg under fasting conditions

On Days 19 to 31: Receive itraconazole 200 mg once daily under fasting conditions

On Days 32 to 39 (inclusive): Observe a washout period
Blood samples for measurement of plasma CC-90011 will be collected at predose and postdose 
to 528 hours, following 20 mg dose of CC-90011 on Day 18. 
After Period 2 completion, on Day 40, subjects will start CC-90011 Treatment Period receiving 
CC-90011 at the RP2D of 60 mg QW in each 28-day cycle (Figure 5).
Figure 5:
Overall Study Design for Part D
3.1.4.
Overview of Assessments
The schedule of assessments is shown in Table 5 (for Parts A and B) and Table 6 (for Parts C 
and D)and assessments are described in Section 6 and Section 7. The safety variables for this 
study include adverse events, safety clinical laboratory variables, 12-lead electrocardiograms, 
Eastern Cooperative Oncology Group Performance Status, left ventricular ejection fraction 
assessments, physical examinations, vital signs, exposure to study treatment, assessment of 
concomitant medications, and pregnancy testing for females of child bearing potential.
Subjects will be evaluated for efficacy after every 2 cycles through Cycle 6, and then every 3 
cycles thereafter. Subjects with NENs/NETs, SCLC, and other NECs will have neuroendocrine 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
58
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
markers taken at the start of each cycle.  Tumor markers such as prostate-specific antigen (PSA) 
for prostate cancer (PC) and NEPC and alfa-fetoprotein (AFP) for hepatocellular carcinoma 
(HCC) and neuroendocrine hepatocellular carcinoma (NEHCC) will be taken on D1 of each 
cycle. All subjects who discontinue treatment for reasons other than disease progression, start of 
a new anticancer therapy, or withdrawal of consent from the entire study will be followed until 
progression and/or initiation of new systemic anticancer therapies.
Blood samples will be collected at specified time-points for determining the PK profiles of CC-
90011 and for exploratory PD assessments. Paired tumor biopsies for analysis of biomarkers of 
treatment activity will be collected whenever safe and feasible in the dose escalation phase and
during the dose expansion phase (Part B), unless exemption granted by Sponsor’s study 
physician in exceptional circumstances. For Part C and D, blood samples and urine will be 
collected at specified time-points for determining PK profiles of CC-90011 and metabolite
CC7108272 and possibly other metabolites.
The study will be conducted in compliance with the ICH of Technical Requirements for 
Registration of Pharmaceuticals for Human Use/GCP and applicable regulatory requirements.
3.2.
Study Duration for Subjects 
Enrollment is expected to take approximately 67 months to complete (24 months for dose 
escalation, and 24 to 43 months for expansion). Completion of active treatment and post-
treatment follow-up is expected to take an additional 4 to 28 months. Enrollment and DDI 
evaluation are expected to take 12 to 15 months. Completion of treatment and post-treatment 
follow-up is expected to take an additional 6 to 24 months. The entire study is expected to last 
approximately 9-10 years.
3.3.
End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
59
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
4.
STUDY POPULATION
4.1.
Number of Subjects 
This is a multicenter, open-label study in which approximately 50 evaluable subjects will be 
enrolled during Part A (dose escalation). During the Part B (dose expansion), approximately 20 
evaluable subjects may be enrolled in each of the selected dose expansion cohorts. Enrollment 
will occur at approximately 4 to 8 sites in Europe for Part A. Enrollment in Part B may include 
additional sites in Europe with approximately 12 sites for this part.
In Parts C and D, approximately 8 DDI evaluable subjects with advanced unresectable solid 
tumors will be enrolled in each part, leading to a total of up to 16 DDI evaluable subjects. 
Enrollment will occur at approximately 3 sites in Spain.
4.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:  
1. Subject is a man or woman ≥ 18 years of age, at the time of signing the informed consent 
form (ICF).
2. Subject must understand and voluntarily sign an ICF prior to any study-related
assessments or procedures being undertaken.
3. Subject is willing and able to adhere to the study visit schedule and other protocol 
requirements.
Entry Criteria Specific for Dose-Escalation Phase (Part A)
4. Subjects with histological or cytological confirmation of advanced unresectable solid 
tumors (including G2 NENs/NETs, SCLC, and other NECs) or R/R NHL (DLBCL and 
FL or MZL). Sporadic and familial NECs can be enrolled, as can endocrine-producing 
tumors or non-functioning NECs.
NECs and G2 NENs/NETs must have: 

Appropriate pathological features according to WHO classification (Rindi, 2010;
Travis, 2015)  

Expression of neuroendocrine markers (eg, synaptophysin or chromogranin-A) by 
immunohistochemistry

Mitotic count ≥ 2 per 10 HPF or ≥ 2 per 2mm2 and/or ≥ 3% Ki67 index (if 
reliably available)

Specific additional criteria for certain NEC tumor types are as follows:

Small Cell Lung Cancer (SCLC);

Histologic or cytologic confirmation of SCLC according to 2015 WHO 
classification (Travis, 2015)
or
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
60
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Immunohistochemistry suggestive of SCLC such as AE1/AE3 positive 
cytoplasmic staining, NCAM (CD56) positivity, chromogranin positivity, 
synaptophysin positivity, TTF1 positivity and high proliferation activity as 
demonstrated by Ki-67 in uncertain cases. Combined SCLC is permitted. 

Large Cell Neuroendocrine Carcinoma (LCNEC);

Histologic confirmation of LCNEC according to 2015 WHO classification 
(Brambilla, 2015)

Immunohistochemistry > 10% of tumor cells positive for CD56, chromogranin or 
synaptophysin. Combined LCNEC is permitted.

Neuroendocrine variant of EGFR mutant Lung Cancer;

Known EGFR mutation

Progression on/following prior EGFR inhibitor

Histologic or cytologic confirmation of SCLC according to 2015 WHO 
classification (Brambilla, 2015)

Immunohistochemistry suggestive of SCLC such as AE1/AE3 positive 
cytoplasmic staining, NCAM (CD56) positivity, chromogranin positivity, 
synaptophysin positivity, TTF1 positivity and high proliferation activity as 
demonstrated by Ki-67 in uncertain cases.

Subjects with mixed adenoneuroendocrine carcinoma (MANEC), which has at 
least 30% adenocarcinoma and 30% NEC, are eligible.

Medullary Thyroid Carcinoma (MTC);

Previously confirmed cytologic or histologic diagnosis of unresectable, locally 
advanced or metastatic hereditary or sporadic MTC

Immunochemistry suggestive of MTC including positive staining for calcitonin 
(Perros, 2014)

Documented disease progression following prior therapy with vandetanib and/or 
cabozantinib

Calcified lesions at baseline should not be used as a target lesion at baseline 
unless no other lesions are available. 

Calcitonin levels above the normal range

Neuroendocrine Prostate Cancer (NEPC);

Metastatic prostate cancer and at least one of
i. Histologic diagnosis of small cell or neuroendocrine prostate cancer, 
supported by immunochemistry
ii. Histologic diagnosis of prostate adenocarcinoma plus > 50% IHC staining for 
neuroendocrine markers (chromogranin, synaptophysin, CD56, or 
neuron-specific enolase (NSE))
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
61
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
iii. Development of liver metastases in the absence of PSA progression as 
defined by PCWG3 (Scher, 2016)

Subjects with histologic evidence of pure neuroendocrine or small cell carcinoma 
do not need to have received prior androgen deprivation therapy or castrate levels 
of testosterone, but their testosterone state should be maintained for the duration 
of the study. Other subjects must have undergone surgical or ongoing medical 
castration and have baseline serum testosterone levels <50 ng/dL or <1.73 
nmol/L.

Neuroendocrine Pancreatic Carcinoma;

Pathologic diagnosis of neuroendocrine pancreatic carcinoma (Klimstra WHO 
Classification 2010), with supportive immunochemistry

Evidence of radiologic disease progression ≤ 12 months prior to Cycle 1,
Day 1

No receptor-targeted radiolabeled therapy ≤ 3 months prior to Cycle 1, Day 1

No liver-directed therapy ≤ 4 weeks prior to Cycle 1, Day 1 

Subjects with mixed adenocarcinoma are eligible

Neuroendocrine Hepatocellular Carcinoma (NEHCC);

Histologically or cytologically-confirmed NEHCC, with supportive 
immunochemistry

Platelet count ≥ 75 x 109/L (≥ 75,000/mm3) if subject has portal hypertension, 
otherwise ≥ 100 x 109/L (≥ 100,000/mm3)

Child-Pugh score < 7 (ie, class A liver function) (Appendix H)

BCLC C Advanced stage disease (Llovet, 1999) 

At least 4 weeks from last dose of α-interferon and/or ribavirin

At least 4 weeks from prior percutaneous ethanol injection, radiofrequency 
ablation, transarterial embolization, or cryotherapy with documentation of 
progressive or recurrent disease  

Measurable disease per RECIST 1.1 outside the liver or measurable disease per 
RECIST 1.1 on triple phase contrast enhanced hepatic CT or MRI that is suitable 
for repeat measurement and shows intratumoral arterial enhancement. Poorly 
demarcated or lesions showing atypical enhancement in the liver should be 
recorded as non-target lesions

No prior liver transplant

No gastrointestinal or variceal bleed in the previous 3 months requiring 
transfusion or endoscopic or operative intervention  

No history of, or current, encephalopathy  

No current clinically significant ascites (ie, not easily controlled with diuretics) 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
62
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Other NECs such as Merkel cell carcinoma, neuroendocrine colorectal cancer, and 
neuroendocrine melanoma may be enrolled. Additionally, NEN/NET G2 (mitotic count 2 -
20 per 10 HPF or 2 - 20 per 2mm2 and/or 3- 20% Ki67 index) may be enrolled if they have 
documented progression on or following prior standard anticancer therapy as per institutional 
practice. However, pathology and immunochemistry must confirm the neuroendocrine 
element and pathologic diagnosis.
Entry Criteria Specific for Dose-Expansion Phase (Part B).
1. Neuroendocrine tumors  
Subjects with histological or cytological confirmation of advanced unresectable solid 
tumors (including low/intermediate-grade lung NETs and NEPCs) which fall under one 
of the following categories:

Lung NETs; 

The following 2 histologies Subjects with demonstrated tumor progression in the 
last 12 months on last prior therapy assessed by CT/MRI scan. 
i. Typical carcinoid (TC)
ii. Atypical carcinoid (AT)

Prostate NECs (NEPCs);

Appropriate pathological features according to WHO classification (Rindi, 2010, 
Travis, 2015)  

Expression of neuroendocrine markers (eg, synaptophysin or chromogranin-A)

Mitotic count ≥ 2 -10 per 10 HPF or ≥ 2-10 per 2mm2 and/or ≥ 3% Ki67 index (if 
reliably available)
2. R/R NHL;

Subjects with MZL (including EMZL, SMZL, NMZL and histologic transformation
of MZL), relapsed/refractory after ≥2 prior therapies and ineligible for potentially 
curative therapy with the adequate immunohistochemistry markers.
Local therapy such as surgery, radiotherapy accounts for a first line treatment. 
Regarding gastric EMZL, antibiotics only does not count for one line of treatment. 
Prior therapies must contain at least one prior line with anti-CD20 antibody. 
Subjects must have progressed on (or not been able to tolerate due to medical 
comorbidities or unacceptable toxicity), or following standard anticancer therapy or 
for whom no other approved conventional therapy exists or is acceptable.  
Entry Criteria Specific for DDI evaluation (Part C and Part D):
1. Advanced unresectable solid tumors including those who have progressed on (or not been 
able to tolerate due to medical comorbidities or unacceptable toxicity) standard 
anticancer therapy or for whom no other approved conventional therapy exists.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
63
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
2. Subject with solid tumor that has at least one site of measurable disease per RECIST 1.1, 
subjects with R/R NHL has at least one site of measurable disease per the Lugano 
Classification (Cheson, 2014)
3.
Tumor biopsies, wherever safe and feasible, will be collected in Part A and during cohort 
expansion (Part B), unless an exemption is granted by the Sponsor’s study physician in 
exceptional circumstances. Fresh biopsies will not be collected in Parts C and D.
4.
Subject has ECOG Performance Status of 0 to 1.
5.
Subjects must have the following laboratory values: 

Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 
7 days (14 days if subject received pegfilgastrim) (except Part B, NHL cohort)

ANC ≥ 1.0 x 109/L (Part B, NHL cohort)

Hemoglobin (Hgb) ≥ 10 g/dL (≥ 100 g/L or > 6.2 mmol/L)

Platelet Count

Platelet count (plt) ≥ 100 x 109/L (≥ 50 x 109/L for NHL subjects) or ≥75 x 
109/L for HCC or NEHCC subjects with portal hypertension without transfusion 
for 7 days (Part A).

Platelet count (plt) ≥ 150 x 109/L (Part B, solid tumor cohort in particular NET 
and CRPC, Part C and Part D).

Platelet count (plt) ≥ 50 x 109/L (Part B, NHL cohort)

Serum potassium concentration within normal range, or correctable with supplements
(Part A only)

Serum AST/SGOT and ALT/SGPT ≤ 3.0 x Upper Limit of Normal (ULN) or ≤ 5.0 x 
ULN if liver metastases are present

Serum total bilirubin ≤ 1.5 x ULN

Subjects must have serum albumin ≥3.0 g/dL

Adequate hepatic function for subjects with HCC or NEHCC includes (Part 
A only):

Serum AST and ALT ≤ 5 x ULN

Serum total bilirubin ≤ 3 mg/dL (≤51µmol/L)

Serum albumin ≥ 3.0 g/dL

Serum creatinine ≤ 1.5 x ULN, or measured glomerular filtration rate (GFR) ≥ 50 
mL/min/1.73m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr 
EDTA or 125I iothalamate. In cases where the serum Creatinine is < 1,5xULN, there is 
no need to calculate GFR.

PT (or INR) and activated partial thromboplastin time (APTT) 

within normal range (Part A)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
64
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

≤1.5 ULN (Parts B, C and D)
6. Females of childbearing potential (FCBP)1 must: 

Either commit to true abstinence2 from heterosexual contact (which must be reviewed 
on a monthly basis and source documented) or agree to use, and be able to comply 
with, at least two effective contraceptive methods (oral, injectable, or implantable 
hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with 
spermicide; or vasectomized partner), one of which must be barrier, from signing the 
ICF, throughout the study, and for up to 45 days following the last dose of CC-90011
(and for 1 week after last dose of rifampicin and 2 months after last dose of 
itraconazole in Parts C and D; and

Have two negative pregnancy tests as verified by the Investigator prior to starting 
CC-90011:  

a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at Screening

a negative serum or urine pregnancy test within 72 hours prior to Cycle 1 Day 1
of study treatment

Avoid conceiving for 45 days after the last dose of CC-90011 (and for one week after 
last dose of rifampicin and 2 months after last dose of itraconazole in Parts C and D).

Agree to ongoing pregnancy testing during the course of the study, and after the end 
of study treatment. This applies even if the subject practices true abstinence2 from 
heterosexual contact
7. Males must practice true abstinence2 (which must be reviewed on a monthly basis) or 
agree to use a condom (a latex condom is recommended) during sexual contact with a 
pregnant female or a FCBP and will avoid conceiving from signing the ICF, while 
participating in the study, during dose interruptions, and for at least 105 days following 
CC-90011 discontinuation, even if he has undergone a successful vasectomy
4.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. G1 neuroendocrine tumors (< 2 per HPF or < 2 per mm2 and/or ≤ 2% Ki67 index) such as 
carcinoid are excluded (Part A).
2. Subject has received anti-cancer therapy (either approved or investigational) ≤ 4 weeks or 
5 half-lives, whichever is shorter, prior to Cycle 1 Day 1.

< 42 days for prior nitrosureas or mitomycin C
                                               
1 A female of childbearing potential is a sexually mature woman who 1) has not undergone a hysterectomy (the 
surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or 2) has not been 
naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time during the preceding 
24 consecutive months).  
2 True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic 
abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable  
methods of contraception].
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
65
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
3. Toxicities resulting from prior systemic cancer therapies must have resolved to ≤ NCI 
CTCAE Grade 1 prior to starting CC-90011 treatment (with exception of grade 2 
peripheral neuropathy and alopecia).
4. Prior autologous stem cell transplant ≤ 3 months before first dose or those who have not 
recovered.
5. Prior allogeneic stem cell transplant with either standard or reduced intensity 
conditioning.
6. Subject has undergone major surgery ≤ 4 weeks or minor surgery ≤ 2 weeks prior to
Cycle 1 Day 1 or who have not recovered from surgery.
7. Subject has completed any radiation treatment < 4 weeks prior to Cycle 1 Day 1 or < 2 
weeks for palliative bone radiotherapy (single fraction). Subjects with > 25% of 
myelopoetic BM radiation are not allowed to be enrolled on this study.
8. Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or 
inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or 
any other significant GI disorder that could affect the absorption of CC-90011.
9. Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those 
with a history of and/or risk of perforation and GI tract hemorrhages.
10. Subject with any hemorrhage/bleeding event > CTCAE Grade 2 or haemoptysis > 1 
teaspoon within 4 weeks prior to the first dose
11. Symptomatic and untreated or unstable central nervous system (CNS) metastases.

Subject recently treated with whole brain radiation or stereotactic radiosurgery for 
CNS metastases must have completed therapy at least 4 weeks prior to Cycle 1, Day 1 
and have a follow-up brain CT or MRI demonstrating either stable or improving 
metastases 4 or more weeks after completion of radiotherapy (the latter to be obtained 
as part of the Screening Assessments, refer to Section 6.1)

Subject must be asymptomatic and off steroids or on stable dose of steroids for at 
least 4 weeks (≤10 mg/day prednisone equivalent)
12. Subject with SCLC that has history of interstitial lung disease (ILD) OR a history of 
pneumonitis that has required oral or IV steroids
13. Subject has known symptomatic acute or chronic pancreatitis. 
14. Subject has impaired cardiac function or clinically significant cardiac diseases, including 
any of the following:

LVEF < 45% as determined by multiple gated acquisition scan (MUGA) or 
echocardiogram (ECHO)  

Complete left bundle branch or bifascicular block  

Congenital long QT syndrome  

Persistent or clinically meaningful ventricular arrhythmias or atrial fibrillation.  

QTcF ≥ 480 msec on Screening ECG (mean of triplicate recordings) 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
66
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting
CC-90011
15. Subject has other clinically significant heart disease such as congestive heart failure 
requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg).
16. Subject is a pregnant or nursing female.  
17. Subject has known HIV infection. 
18. Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection.

Subjects who are seropositive due to HBV vaccination are eligible

Subjects who have no active viral infection and are under adequate prophylaxis
against HBV re-activation are eligible  

Subjects with HCC and NEHCC are exempt from the above criteria (applies to 
subjects in Part A only)
19. Subject with ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, 
warfarin, low molecular weight heparin, Factor Xa inhibitors, thrombin antagonist). Low 
dose low molecular weight heparin for catheter maintenance and for short-term 
prophylaxis for subjects with prior PE and DVT are permitted under careful consideration 
by the Investigator.
20. Subject has a history of concurrent second cancers requiring active, ongoing systemic 
treatment.
21. Subject has any significant medical condition (eg, active or uncontrolled infection or 
renal disease), laboratory abnormality, or psychiatric illness that would prevent the 
subject from participating (or compromise compliance) in the study or would place the 
subject at unacceptable risk if he/she were to participate in the study.
22. Subjects with poor bone marrow reserve as assessed by Investigator such as in the 
following conditions of (Part B only):

Having received extensive bone radiotherapy

Having experienced several episodes of bone marrow aplasia in previous treatments

Confirmed histological bone marrow cancer infiltration

Requiring regular hematopoietic support (blood transfusion, erythropoietin, GCSF)
23. Subject has any condition that confounds the ability to interpret data from the study.
24. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 
20 days for severe/critical illness prior to C1D1. 
Acute symptoms must have resolved and based on investigator assessment in 
consultation with the Sponsor’s study physician, there are no sequelae that would place 
the subject at a higher risk of receiving study treatment.
25. Previous SARS-CoV-2 vaccine within 14 days of C1D1 (Parts A and B) or Day 1 (Parts 
C and D). For vaccines requiring more than one dose, the full series (e.g. both doses of a 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
67
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
two-dose series) should be completed prior to enrollment when feasible and when a delay 
in enrollment would not put the study subject at risk. The administration of live SARS-
CoV-2 vaccine is prohibited up to 14 days prior to initiation of treatment.
26. Subject has a past history or current diagnosis of platelet disorder, bleeding disorder, or 
clotting disorder regardless of the clinical significance (Parts C and D only).
27. Subject has used any strong or moderate CYP3A enzyme or P-gp/BCRP transporter 
inhibitors or inducers within 15 days or 4-5 half-lives before the first dose of IP. The 
following link should be used to determine strong or moderate inhibitors and/or inducers 
of metabolic enzymes: http://medicine.iupui.edu/clinpharm/ddis/table/aspx. The 
following link should be used to determine inhibitors of P-gp/ BCRP: 
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-
interactions-table-substrates-inhibitors-and-inducers#transporter
The Sponsor’s study physician should be contacted for questions about potential DDIs 
and exclusions/prohibitions when necessary (Parts C and D only).
28. Subject is allergic to or hypersensitive to any of the drugs used in the DDI evaluation part 
of the study in which the subject will participate (Parts C and D only).
29. Subjects with known hypersensitivity or previous adverse events associated with azole 
antifungals (Parts C and D only)
30. Subject has used St. Johnˈs wort within 7 days; or grapefruit, grapefruit products, Seville 
oranges or starfruit within 3 days of the first dose of IP and during the conduct of DDI 
evaluation (Parts C and D only).
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
68
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
5.
TABLE OF EVENTS (PART A AND PART B AND CC-90011 TREATMENT PERIOD FOR 
PART C AND PART D)
For a detailed description of the procedures listed, please refer to Section 6. For details regarding study drug administration, please 
refer to Section 7.
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)r
Study Entry (Section 6.1)
Informed consent 
X
Contraceptive counseling for 
FCBP and malesl
X
X
X
X
X
Informed consent for optional 
exploratory analyses
X
Inclusion/ exclusion criteria
X
Medical/ oncologic history and 
therapiesq
X
Demographics
X
IRT registration
X
X
Day 1 of every Cycle. Please refer to IRT instruction manual.
X
Prior/concomitant medications 
& procedures
X
X
Xp
Xp
X
X
X
X
X
X
X
X
X
X
X
Study Drug (Section 7)
Administer oral CC-90011 per 
assigned dosing schedule
(Section 7.2.1)
Weekly
Note: Alternative dosing schedules may be implemented based on SRC decisions.   
Provide/review of diary card
X
X
X
X
X
X
X
X
X
X
X
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
69
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D) (Continued)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)
IP accountability
X
X
X
X
Safety Assessments (Section 6)
Adverse Event Evaluation 
(Section 6.2.2)
X
X
Xp
Xp
X
X
X
X
X
X
X
X
X
X
X
Height
X
Weight
X
X
X
X
X
X
X (C2 
only)
X
X (C2 
only)
X
X
Vital Signs (Section 6.2.4)
X
X
X
X
X
X
X (C2 
only)
X
X (C2 
only)
X
X
Physical Examination 
(Section 6.2.5)
X
X
X
X
X
ECOG PS (Appendix D)
X
X
X
X
X
B Symptoms Assessment (only 
NHL; Section 6.2.6)
X
As clinically indicated
12-lead ECG (single or 
triplicate; Section 6.2.7)d,s
X
(≥72 hours 
prior to D1)
X
X
X
X
X
X
X
LVEF (ECHO/MUGA; 
Section 6.2.8)
X
As clinically indicated
Pregnancy Testing (FCBP only; 
Section 6.2.9) n
X
X
X
X
X
Hematology laboratory 
(Section 6.2.10)
X
(D-14 to -1)  
X
Xp
X
X
X
X
X (C2 
only)
X
X (C2 
only)
X
X
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
70
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D) (Continued)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)
Chemistry laboratory with LDH 
& uric acid tests 
(Section 6.2.10)
X
(D-14 to -1)
X
X
X
X
X
X (C2 
only)
X
X (C2 
only)
X
X
HbA1C
(Section 6.2.10)
X (pre-
dose)
X (odd 
cycles 
only 
from 
Cycle 
3)
X (odd 
cycles 
only 
from 
Cycle 
7)
Xk
Cholesterol and HDL
X
X
X
X
X
PT (or INR), APTT
X
(D-14 to -1)
As clinically indicated
X
Amylase, lipase, T-cell subsets 
(CD4+ and CD8+), TSH
X
X (odd 
cycles 
only 
from 
Cycle 
3)
X (odd 
cycles 
only 
from 
Cycle 
7)
X
Urinalysis (Section 6.2.10)
X 
(D-14 to -1)  
X
X
X
X
(Part A only)
Hepatitis viral assessment for 
subjects with HCC and NEHCC 
(HBV only)
X
X (odd 
cycles 
only 
from 
cycle 
3)
X (odd 
cycles 
only 
from 
cycle 
7)
Xk
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
71
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D) (Continued)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)
Tumor markers (for any 
subjects with PC and NEPC and 
HCC and NEHCC and other 
tumors, if relevant)
X
X
X
X
Xe
PK & PD Assessments (Section 6.5 & 0)
Blood, PK (Parts A and B only)
Refer to Table 7 for a detailed collection schedule
Blood (whole), PD (Parts A and 
B only)
Refer to Section 0 for a detailed collection schedule
NEPD markers
Blood PD (G2NEN/NET, 
SCLC, and other NEC)
X
X
X
X
X
Xe
Tumor Biopsyf  (Parts A and B 
only)
X (D-28 to  D1 
predose)
X
(D16 or D17)f
Xf
Archival Tumor Tissue (FFPE)  
Xg
SARS-CoV-2 serologyo
X
Serum collected every 6 months during study treatment (eg, C6D1, C12D1, etc.) and approximately 4 
weeks after a documented or suspected SARS-CoV-2 infection
X
Efficacy (Section 6.4)
Solid tumor/NHL 
assessments:  CT/MRI imagingh
X
X 
(D28 
±7d; 
C2 & 
C4)
X (D28 ± 7d in 
C6, then q3 
cycles, ie, end 
of C9, C12, etc)
Xe
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
72
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D) (Continued)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)
Additionally, Subjects with 
known or suspected cerebral 
involvement and all 
neurologically symptomatic 
NEPC subjects, brain scan (CT 
or MRI)
X
NHL-specific: bone marrow 
evaluation if known or 
suspected bone marrow 
involvement 
Xi
X, only when 
confirming CR
X, only
when 
confir
ming 
CR
NHL-specific: FDG PET or 
PET/CT scan (not required if 
tumor is FDG-negative)
X
X, when 
confirming CR 
X, only
when 
confir
ming 
CR
(Part A only)
MTC subjects, isotope bone 
scan
Xm
X 
(D28 
±7d; 
C2 & 
C4)m
X (D28 ± 7d in 
C6, then q3 
cycles, ie, end 
of C9, C12, etcm
X e,m
(Part A only)
For MTC subjects, liver MRI or 
triple phase CT, also MRI or CT 
scan of the neck (only if known 
lesions) should be done
X
X 
(D28 
±7d; 
C2 & 
C4)
X (D28 ± 7d in 
C6, then q3 
cycles, ie, end 
of C9, C12, etc
Xe
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
73
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 5:
Table of Events (Part A and Part B and CC-90011 Treatment Period for Part C and Part D) (Continued)
Treatment Period
Follow-up Perioda
Cycle 1
Cycles 2-5
Cycles 6+
Long
Screening
WK1
WK2
WK3
WK4
WK1
WK2
WK3
WK4
WK1
WK3
EOT
Safety
Term
Eventsb
D-28 to -1
D1
D2
D3
D8
D15
D22
D1
D8j
D15
D22j
D1
D15c
≤ 28 
days
28 days 
(±3 days)
q3 mo 
(±2 wks)
For PC (Part A only) and 
NEPC, 99mTc-methylene 
diphosphonate radionuclide 
bone scan
X
X 
(D28 
±7d; 
C2 & 
C4)
X (D28 ± 7d in 
C6, then q3 
cycles, ie, end 
of C9, C12, etc
Xe
(Part A only)
For HCC and NEHCC subjects 
a contrast enhanced triple phase 
CT/MRI scans of the abdomen
X
X 
(D28 
±7d; 
C2 & 
C4)
X (D28 ± 7d in 
C6, then q3 
cycles, ie, end 
of C9, C12, etc
Xe
Additional Follow-up (Section 6.3)
Follow-up anticancer therapies
X
X
AE/SAE follow-up
X
Survival follow-up
X
Abbreviations: AFP = alpha fetoprotein; anti-HBc = Hepatitis B core antibody; anti-HCV = Hepatitis C surface antibody; anti-HBS = Hepatitis B surface 
antibody; APTT = activated partial thromboplastin time; β - hCG = beta human chorionic gonadotropin; C = cycle; CBC = complete blood count; CR = complete 
response; CT = computed tomography; D = day(s); ECHO = echocardiogram; ECOG Eastern Cooperative Oncology Group; FCBP = females of child bearing 
potential; FDG PET = 18-Fluoro-deoxyglucose positron emission tomography; FFPE = formalin-fixed, paraffin embedded; HBsAg; Hepatitis B Surface Antigen; 
HCC = hepatocellular carcinoma; HDL = High density lipoprotein; INR = international normalized ratio; IRT = interactive response technology; LVEF = left 
ventricular ejection fraction; mo = months; MUGA = multi-gated acquisition scan; NHL = Non-Hodgkin’s lymphoma; PD = pharmacodynamics; PK = 
pharmacokinetics; PS = performance status; PT = prothrombin time; q = every; SAE = serious adverse event; SARs-CoV-2 = severe acute respiratory syndrome 
coronavirus 2; TSH = thyroid-stimulating hormone; WK(s) = week.
a This Safety follow-up assessment may be by telephone (refer to Section 6.3.1).  Long Term survival follow-up for up to 2 years or until death, lost to 
follow-up, or End of Trial, whichever occurs first. May be conducted by record review.
b From Cycle 2 onwards all study visits/procedures will have a ± 3 days window and all laboratory blood samples should be drawn predose, unless otherwise 
specified in this table or Section 6.  If the visit is delayed the dose is also delayed. NE markers must be collected predose at D1 of subsequent cycles, so if visit 
is delayed the intake is delayed too.
c At Cycle 6 on and onwards only Day 1 required.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
74
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
d Triplicate ECGs must be performed  prior to dosing on Day 1. Site will also take the standard 12 lead ECG as per Table of Events. The ECG at screening will 
be assessed by PI and shared with Sponsor’s study physician for eligibility.  
e Unless PD has been previously documented.
f Paired tumor biopsies will be collected for Part A and Part B unless an exemption is granted by the Sponsor’s study physician in exceptional circumstances. 
The Screening biopsy (D-28 to D1 predose) should be obtained after all inclusion/exclusion criteria have been fulfilled. The Cycle 1 biopsy may be obtained on 
Day 16 or 17 (+ 7-day window) provided that 2 consecutive CC-90011 doses have been administered. The EOT biopsy is optional. No fresh biopsies will be 
collected in Parts C and D.
g Mandatory only if fresh biopsy is not collected during Screening unless an exemption is granted by the Sponsor’s study physician in exceptional circumstances.
In Parts C and D, archival tumor tissue will be collected whenever feasible.
h All subjects who discontinue treatment for reasons other than disease progression, start of a new anticancer therapy, or withdrawal of consent from the entire 
study will be followed according to the specified tumor assessment schedule until progression and/or initiation of new systemic anticancer therapies.
I May be omitted if results were normal on the subject’s most recent historical bone marrow biopsy. Additionally, this analysis may be omitted if a prior analysis 
was performed within 90 days before Cycle 1 Day 1. Historical results will be recorded in the eCRF.
j Day 8 and 22 visits may be omitted from Cycle 3 onwards
k May be omitted if it was performed in the previous 28 days
l Fertility counseling including sperm banking for males, if appropriate. 
m If screening baseline isotope scan suggestive of bone metastases an X ray, CT or MRI of the bone lesion should be performed at BL and the same technique 
repeated at each scheduled efficacy assessment.
n Contraception counselling must be recorded over 45 days in females and 105 days in males post last dose.
o Serum collected at Screening or predose on Cycle 1 Day 1. Serum collected approximately every 6 months during study treatment to be used for potential 
future measurements of anti-SARS-CoV-2 serology (anti-SARS-CoV-2 total or IgG). Serum should also be collected approximately 4 weeks after a 
documented or suspected SARS-CoV-2 infection. At EOT, serum will be collected to be used for potential future measurements of anti-SARS-CoV-2 serology 
(anti-SARS-CoV-2 total or IgG). See Section 6.6.2
p Not applicable for Parts C and D
q Medical history will also include COVID-19 vaccines, toxicities of prior treatments, and known allergies.
r Not applicable to those subjects who discontinue during DDI evaluation
s In Parts C and D, ECGs will be performed only at screening and if clinically indicated.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
75
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 6:
Table of Events for DDI Evaluation Period (Part C and Part D)
DDI Evaluation Period
Period 1
Period 2
Events
D1
D8
D15
D18
D21
D22
D29
D36
Study Drugs (Section 7)
Administer CC-90011
X
Xb
Xa
Administer Rifampicin (Part C only)
From D15 to D35
Administer Itraconazole (Part D only)
From D15 to D31
Diary card
X
Xc
Safety Assessments (Section 6)
Adverse Event Evaluation
X
X
X
Xb
Xa
X
X
Prior/Concomitant medications and 
procedures
X
X
X
Xb
Xa
X
X
Weight
X
X
X
Xb
Xa
X
X
Vital Signs
X
X
X
Xb
Xa
X
X
Physical Examination
X
X
X
Xb
Xa
X
X
ECOG Performance Status
X
X
X
Xb
Xa
X
X
12-lead ECG
If clinically indicated
LVEF (ECHO/MUGA)
If clinically indicated
Pregnancy Testing
X
Hematology laboratory
X
X
X
Xb
Xa
X
X
Chemistry laboratory with LDH & uric 
acid tests
X
X
X
Xb
Xa
X
X
HbA1C
X
Xb
Xa
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
76
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 6:
Table of Events for DDI Evaluation Period (Part C and Part D) (Continued)
DDI Evaluation Period
Period 1
Period 2
Events
D1
D8
D15
D18
D21
D22
D29
D36
Cholesterol and HDL
X
Xb
Xa
PT (or INR), APTT
As clinically indicated
Amylase, lipase, T-cell subsets (CD4+ 
and CD8+), TSH
X
Xb
Xa
Urinalysis
X
Xb
Xa
Efficaly Assessment (Section 6.4)
Solid tumor assessments:  CT/MRI 
imaging
Xd
PK Assessments (Section 6.5)
Blood, PK, metabolites
Refer to Table 8 (Part C) and Table 9 (Part D) for a detailed collection schedule
Urine, PK, metabolites
Refer to Error! Reference source not found. for a detailed collection schedule
a Only Part C.
b Only Part D
c Patient diary must be returned at the end of the DDI Evaluation Period.
d CT Scan/MRI must be done at the end of the DDI Evaluation Period, before starting CC-90011 treatment.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
77
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
6.
PROCEDURES
Any questions regarding the protocol should be directed to the Sponsor’s study physician or 
designee. The procedures conducted for each subject enrolled in Parts A and B of the study are 
outlined in Table 5. For subjects enrolled in Part C and Part D, procedures to be conducted 
during the DDI evaluation period are outlined in Table 6, except screening procedures that will 
follow Table 5. After completion of the DDI evaluation period, once subjects start the CC-90011 
Treatment period, will follow procedures shown in Table 5.
All study visits will have a ± 3 days window unless otherwise specified below or in the Table of 
Events (refer to Table 5). Please note that this applies only after Cycle 2. During Cycle 1, this 
window is not allowed as PK/PD must be collected. During DDI evaluation period in Part C and 
Part D, this window is not allowed either. In Parts C and D, the start of the CC-90011 treatment 
period might be delayed until 3 days (40 + 3).
All laboratory blood samples should be drawn predose unless otherwise specified (eg, PK 
samples).
The study procedures should be recorded in the source document and the electronic case report 
forms (eCRF). In the event subjects fail Screening, minimal information will be documented on 
the eCRFs, per database instructions.
6.1.
Screening Period
The Screening window starts 28 days (± 3 days) prior to the first dose of CC-90011. Refer to
Table 5, this section, and Section 6.2 for detailed information on procedures performed and the 
schedule for all study parts. 
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
Safety laboratory analyses will be performed locally. Screening laboratory values must 
demonstrate subject eligibility, but may be repeated within the screening window, if necessary.
The ICF will be administered at the Screening visit to all subjects by qualified study staff.  It 
must be signed and dated by the subject and the administering staff prior to the start of any other 
study procedures and its completion documented in source documents and in the eCRF.  All 
screening tests and procedures must be completed within 28 days (± 3 days) prior to the first 
dose of CC-90011 according to the schedule shown in Table 5.
The following will be performed at Screening, after informed consent has been obtained:

Inclusion and exclusion criteria will be assessed at Screening and recorded in the 
source documents and the eCRF.

Contraceptive counseling:  qualified healthcare professionals will be trained by 
Celgene, or designee, in the requirements specific to contraceptive counseling of 
subjects.  Once trained the healthcare staff will counsel subjects prior to the 
administration of CC-90011 to ensure that the subject has complied with all 
requirements including use of birth control and that the subject understands the risks 
associated with CC-90011. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
78
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Fertility counseling for men: Subjects will be informed that the effects of CC-90011 
on spermatogenesis are unknown and they will be encouraged to collect and bank 
sperm if appropriate, prior to taking CC-90011.

Medical, oncologic, and surgical history, and demographic data (including each 
subject’s date of birth, sex, race, and ethnicity) will be collected during Screening as 
consistent with local regulations.  Oncologic history will include a detailed history of 
the primary diagnosis and date, therapies, and responses. Medical history will also 
include Covid-19 vaccines, toxicities of prior treatments, and known allergies.

Information on prior and concomitant medications and procedures will be collected
(refer to Section 6.2.1).

Registration in the interactive response technology system (IRT)

Adverse event monitoring (refer to Section 10)

Height and weight measured

Vital signs assessed (refer to Section 6.2.4)

Physical examination (source documented only) and ECOG performance status (refer 
to Section 6.2.5 and Appendix D)

For subjects with NHL, measurements of lymph nodes and documentation of any 
enlargement of the spleen and/or liver will be documented radiographically and
recorded in the source document and in the eCRF (Part A and B only)

The B symptom assessment:  B symptoms are fever (> 100.5oF or 38°C) for 2 or 
more weeks without other evidence of infection, night sweats for more than 1 month 
without evidence of infection, and weight loss greater than 10% within the prior 6 
months (Part A and B only)

A 12-lead ECG in triplicate (refer to Section 6.2.7) will be performed prior to the first 
dose of CC-90011 Site will also take the standard 12 lead ECG as per Table of Events 
which will be assessed by PI and shared with the Sponsor Study Physician for 
eligibility. 

Left Ventricular Ejection Fraction (LVEF) assessment (refer to Section 6.2.8)

Pregnancy testing (refer to Section 6.2.9) for all females of childbearing potential
(FCBP). Appropriate methods of contraception and potential risks of fetal exposure 
will be discussed with FCBP and male subjects during Screening.  Double 
contraceptive methods (one of which must be a barrier method) for females of 
childbearing potential (eg, oral, injectable, or implantable hormonal contraceptive; 
intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) 
and a single contraceptive method for males (a condom) must be used from the time 
the ICF is signed, throughout the study (including dose interruptions), and for 45 days
in females and 105 days in males after the last dose of CC-90011 (and for 1 week 
after the last dose of rifampicin and for 2 months after last dose of itraconazole in 
Parts C and D).  This will be documented in source documents.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
79
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Clinical laboratory tests (refer to Section 6.2.10) are to be completed within 14 days 
prior to the first dose of CC-90011

Efficacy/tumor assessments (refer to Section 6.4)

Tumor markers such as PSA for PC (Part A only) and NEPC, Alpha fetoprotein 
(AFP) for HCC (Part A only) and NEHCC (Part A only), CEA for MTC, or 
CA125 for ovarian/NE ovarian cancer (Part A only) will be measured at baseline.

Fresh tumor biopsy (Part A and B only)

Archival tumor tissue (FFPE) collection is mandatory only if a fresh biopsy is not 
collected during Screening but can be omitted under exceptional circumstances 
after agreement with the Sponsor’s study physician. In Parts C and D, archival 
tumor tissue will be collected whenever feasible.

For HCC and NEHCC subjects only (applies only to Part A): 

AFP.

HBsAg, anti-HBS, anti-HBc, and anti-HCV (screening only). 

Measurement of hepatitis B viral load (HBV DNA quantitative by PCR) if 
HBsAg, HBcAb total, and/or HBcAb IgM is/are positive. 

Measurement of Hepatitis C viral load (HCV RNA quantitative by PCR) if HCV 
antibody is positive (only applies to HCC).

Confirmation of antiviral therapy with an appropriate antiviral agent for HBV is 
required in subjects with positive hepatitis B surface antigen, HBcAb IgM, and/or 
viral load - appropriate first line agents include entecavir, tenofovir, and 
lamivudine (note that lamivudine has higher resistance rates). 

Confirmation of antiviral therapy with an appropriate antiviral agent for HCV is 
required in subjects with positive hepatitis C viral load.

Subjects with a positive HBV viral load, HBcAb IgM, and/or HBs Ag or positive 
HCV viral load should be referred to a hepatologist if not already under the care 
of a hepatologist.

SARS-CoV-2 serology (Screening or Predose on Cycle 1 Day 1 [Parts A and B] or 
Predose Day 1 [Parts C and D]) 

Testing for asymptomatic SARS-CoV-2 infection by RT-PCR or viral antigen is not 
required. However, some subjects may develop suspected or confirmed symptomatic 
SARS-CoV-2 infection, or be discovered to have asymptomatic SARS-CoV-2 
infection during the screening period. In such cases, subjects may be considered 
eligible for the study after meeting all inclusion/exclusion criteria related to active 
infection, and after meeting the following criteria: 

At least 10 days (20 days for severe/critical illness) have passed since symptoms 
first appeared or positive RT-PCR or viral antigen test result, and
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
80
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

At least 24 hours have passed since last fever without the use of fever-reducing 
medications, and

Acute symptoms (e.g. cough, shortness of breath) have resolved and 

In the opinion of the investigator, there are no COVID-19 sequelae that may place 
the participant at a higher risk of receiving investigational treatment

In the instance of a SARS-CoV-2 infection during screening, the screening period 
may be extended beyond the protocol-specified timeframe with Sponsor’s study 
physician approval.   

Any screening tests already performed which could potentially be affected by the 
SARS-CoV-2 infection or its complications on an individual basis and agreed upon 
with the Sponsor’s study physician (e.g. safety labs, SpO2, chest CT scan) should be 
repeated within 7 days prior to cycle 1 Day 1.
6.2.
Treatment Period
Visits and assessments are shown in Table 5 and in Table 6 for DDI evaluation period in Part C 
and Part D. Subjects completing 6 cycles of treatment and continuing on study drug are only 
required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent 
cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated. This is applicable 
beyond Cycle 2.  If the visit is delayed the dose is also delayed. NE markers must be collected 
predose at D1 of subsequent cycles, so if visit is delayed the intake is delayed too.
6.2.1.
Concomitant Medication and Procedures
All concomitant medications and procedures taken or conducted beginning when the subject 
signs the ICF throughout the study, and until 28 days after the last dose of CC-90011 will be 
recorded in the source documents and eCRF.
6.2.2.
Adverse Event Monitoring
Adverse events and serious adverse events (SAEs) will be recorded from the time since the
subject signs the ICF until 28 days after the last dose of CC-90011.  
Subjects experiencing AEs will be monitored with relevant clinical assessments and laboratory 
tests, as determined by the Investigator. Every attempt will be made to document resolution dates 
for ongoing AEs. The AEs will be recorded on the AE page of the eCRF and in the subject’s 
source documents. Photographs of skin rashes should be obtained whenever possible, 
anonymized, and stored appropriately for future retrieval.
6.2.3.
Weight 
The subject’s weight will be recorded in the source document and eCRF at the visits listed in 
Table 5.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
81
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
6.2.4.
Vital Signs
Vital signs include body temperature, blood pressure and pulse rate will be recorded during the 
study at various time points for safety monitoring as described in Table 5 and in Table 6 for DDI 
evaluation period in Part C and Part D.
Recorded measurements will be captured in the source document and eCRF.
6.2.5.
Physical Examination and ECOG Performance Status
Complete physical examination and Eastern Cooperative Oncology Group Performance Status 
(ECOG PS; refer to Appendix D) will be performed at the visits listed in Table 5 and in Table 6
for DDI evaluation period in Part C and Part D. Results for both will be recorded in the source 
document.  Results for the ECOG PS will also be collected on the eCRF. 
Physical examination findings will be classified as either normal or abnormal.  If abnormal, a 
description of the abnormality and clinical importance will be provided in the source documents.  
Clinically significant changes from baseline will be recorded in the AE section of the eCRF.
6.2.6.
B Symptom Assessment (NHL Subjects only)
For subjects with NHL, B symptom assessments will be performed at the visits listed in Table 5
and results recorded in the source documents and on the eCRF.
B symptoms are fever (> 100.5oF or 38°C) for 2 or more weeks without other evidence of 
infection, night sweats for more than 1 month without evidence of infection, and weight loss 
greater than 10% within the prior 6 months.
6.2.7.
12-Lead-Electrocardiograms
Triplicate or single standard 12-lead electrocardiograms (ECGs) will be recorded at the visits 
listed in Table 5. In Part C and Part D, ECGs will be performed only at screening and 
subsequently only if clinically indicated as described in Table 6 for the DDI evaluation period
and in Table 5 for the CC-90011 treatment period. The 12-lead ECG should be collected prior to 
any blood draws if both are scheduled for the same nominal time. The 12-lead ECGs (12-lead at 
25 mm/sec reporting rhythm, ventricular rate, PR interval, QRS complex, QT interval, and QTcF
interval) will be performed after the subject has been in the supine position for at least 5 minutes.  
Triplicate ECGs (3 recordings within 2 ± 1 minute intervals) will be performed at:

Screening 

Cycle 1 

Day 1:  predose (within 30 minutes prior to dosing) and 2, 4, 8, 24 hours (± 10 
minutes) postdose. In Part B: predose (within 30 minutes prior to dosing) and 2 
hours postdose.

Days 8, 15 and 22: predose (within 30 minutes prior to dosing) and 4 hours (± 10 
minutes) postdose. In Part B: predose (within 30 minutes prior to dosing) and 2 
hours postdose.

Cycles 2 and higher
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
82
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Day 1:  predose (within 30 minutes prior to dosing).
A single ECG will be performed at the EOT visit (only Parts A and B). 
For alternative dosing schedules, the Cycle 1 Day 15 ECGs will be performed on the last day of 
CC-90011 dosing in Cycle 1.
Investigators will make immediate clinical decisions based on their interpretation of the ECG 
results and provide their overall assessment of the ECG in the eCRF. Clinically significant 
changes from baseline will be recorded in the AE section of the eCRF.  
The ECG outputs will also be uploaded to the central ECG laboratory for definitive analysis and 
interpretation.
6.2.8.
Left Ventricular Ejection Fraction
Left ventricular ejection fraction (LVEF), (multiple gated acquisition scan [MUGA], or 
echocardiogram [ECHO]) will be conducted at Screening in all subjects.  Follow-up assessments 
should be performed as clinically indicated. Follow up assessments should use the same 
procedure used at the screening assessment.  A clinically significant reduction is defined as 
either a ≥ 20% absolute reduction in LVEF or drop to below 45%.
6.2.9.
Pregnancy Test
A female of childbearing potential (FCBP) is defined as a sexually mature woman who has: 

Not undergone a hysterectomy or bilateral oophorectomy, and 

Not been naturally postmenopausal (amenorrhea following cancer therapy does not 
rule out childbearing potential) for at least 24 consecutive months (eg, has had 
menses at any time in the preceding 24 consecutive months).  
The Investigator will classify a female subject as a FCBP according to this definition.  Pregnancy 
testing is not required for non-FCBP subjects but justification must be recorded in the eCRF and 
the source document.  Pregnancy testing will be conducted by the local laboratory.
For a FCBP, pregnancy testing will be conducted at the visits listed in Table 5 and in Table 6 for 
DDI evaluation period in Part C and Part D.

A serum pregnancy test with sensitivity of at least 25 mIU/mL is to be obtained at 
Screening and serum or urine pregnancy test within 72 hours prior to Cycle 1 Day 1
of study treatment.  The subject may not receive CC-90011 until the Investigator has 
verified the two screening pregnancy tests to be negative. 

A serum or urine pregnancy test (based on Investigator’s discretion and minimum test 
sensitivity [25 mIU/mL]) should be done within 72 hours prior to Day 1 of every 
cycle and at the end of treatment (EOT) visit.  The subject may not receive CC-90011
until the Investigator has verified the pregnancy test to be negative.

A FCBP or a male subject whose partner is a FCBP must avoid activities that could 
lead to conception while receiving CC-90011 and for 45 days after the last dose of 
CC-90011.  Practice of true abstinence from sexual activity will be monitored 
monthly and source documented.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
83
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Contraception counselling must be recorded over 45 days in females and 105 days in 
males post last dose.
Results for pregnancy tests will be recorded in the source document and eCRF.  
6.2.10.
Clinical Laboratory Tests
The following laboratory assessments will be performed during the study at the time points as 
described in Table 5 and in Table 6 for DDI evaluation period in Part C and Part D.
All samples should be drawn predose unless otherwise specified.  Laboratory assessments will be 
recorded in the source document and eCRF and are the following: 

Hematology:  Complete blood counts including hemoglobin, hematocrit, WBC count 
with absolute counts for WBC parameters and platelet count.

On Cycle 1, Day 1, the complete blood counts with absolute counts should be 
performed and results checked against entry criteria before drug administration.

Serum chemistry:  albumin, total protein, magnesium, phosphorus, calcium, 
creatinine, urea/BUN, glucose, potassium, sodium, chloride, total bilirubin 
(fractionate if outside normal range), alkaline phosphatase, AST or serum glutamic 
oxaloacetic transaminase (SGOT), ALT or serum glutamate pyruvic transaminase 
(SGPT), LDH, and uric acid.

HbA1c at C1D1 pre-dose, each odd numbered cycle starting from C3D1 and EOT 
(unless performed in previous 28 days).

High density lipoprotein (HDL) and cholesterol.

Special chemistry:  amylase, lipase, T-cell subsets (CD4+ and CD8+), thyroid-
stimulating hormone (TSH; if abnormal reflex to free T4).

During screening, then pre-dose each odd numbered cycle starting from C3D1 
and EOT.

Coagulation: PT (or INR), and APTT (as clinically indicated for Parts C and D).

Urinalysis: dipstick (protein and blood assessment at a minimum).

microscopy and urinary albumin to creatinine ratio in the event of first appearance 
of 2+ or greater protein.

Measured glomerular filtration rate (GFR) determination using an exogenous 
filtration marker such as iohexol, inulin, 51Cr EDTA or 125I iothalamate required at 
Screening to fulfill inclusion criteria if serum creatinine > 1.5 x ULN (refer to 
Section 4.2).

For HCC and NEHCC subjects Part A only:

AFP (if elevated at baseline).

Hepatitis B viral DNA quantitative in subjects with positive hepatitis B viral load 
at baseline and/or positive HBsAg, HBcAb total, and/or HBcAb IgM (odd cycles 
only starting with Cycle 3 or more frequently at investigator’s discretion) and at 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
84
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
EOT (unless performed in previous 28 days). Hepatitis C viral RNA quantitative 
in subjects (applies to HCC only) with positive hepatitis C viral load at baseline 
(odd cycles only starting with Cycle 3 or more frequently at investigator’s 
discretion) and at EOT (unless performed in previous 28 days).

For all G2 NENs/NETs, SCLC, and NEC subjects Pro-GRP, Cg-A and calcitonin 
will be followed at: C1D1, predose, C1D3, C1D8 pre-dose and D1 of each cycle 
and EOT, unless disease progression documented previously. 

Tumor markers such as PSA for PC (Part A only) and NEPC, AFP for HCC (Part A 
only) and NEHCC (Part A only), CEA for MTC (Part A only), or CA125 for 
ovarian/NE ovarian cancer (Part A only) will be measured as appropriate at Day 1 of 
every cycle and EOT, unless disease progression documented previously.
6.2.11.
End of Treatment (EOT)
An EOT evaluation (refer to Table 5 for procedures) should be performed for subjects who are 
withdrawn from treatment for any reason as soon as possible (≤ 28 days) after the decision to 
permanently discontinue treatment has been made. 
6.3.
Follow-up Period 
6.3.1.
Safety Follow-up
All subjects will be followed for 28 days after the last dose of CC-90011 in Parts A and B (or 28 
days after last dose of CC-90011, rifampicin or itraconazole, whichever is the latest, in Part C 
and Part D), for AE reporting and concomitant medication information. The 28-day (±3 days) 
safety follow-up contact may be by telephone. In addition, any SAEs made known to the 
Investigator at any time thereafter that are suspected of being related to CC-90011 will be 
reported as described in Section 10.1.
6.3.2.
Survival Follow-up
After the Safety Follow-up visit, all subjects will be followed every subsequent 3 months (± 2 
weeks) for survival follow-up for up to 2 years or until death, lost to follow-up, or the End of 
Trial, whichever occurs first. New disease therapies should be collected at the same time 
schedule. This does not apply to subjects who discontinue during the DDI evaluation period in 
Part C and Part D.
Survival follow-up may be conducted by record review (including public records) and/or 
telephone contact with the subject, family, or the subject’s treating physician.
6.4.
Efficacy Assessment 
Tumor assessments will be performed at Screening and will include CTs of the chest, abdomen 
and pelvis, and a brain scan (CT or MRI) for subjects with known or suspected cerebral 
involvement and all neurologically symptomatic subjects with NEPC (Part A only).  After 
Screening, radiologic tumor assessments will be performed at the end (Day 28 ± 7 days) of 
Cycles 2, 4, and 6, and then every 3 cycles thereafter, using the same CT/MRI scanning 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
85
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
modalities used at Screening. An EOT scan does not need to be obtained if the prior scan was 
within 28 days.  

Additionally, for R/R NHL subjects, a Screening FDG PET or FDG PET/CT scan 
will be performed unless the tumors are known not to be FDG-avid. A subsequent 
scan will only be obtained to confirm a CR (Parts A and B only). 

For R/R NHL subjects with known or suspected bone marrow involvement, a bone 
marrow evaluation with flow immunophenotyping will be performed at Screening, 
and to confirm a complete response (CR). For NHL subjects, the size of the spleen 
and/or liver should be measured radiologically. For NHL subjects, to document a CR 
the normal radiologic size of the spleen and/or liver should be recorded in the source 
document and in the eCRF (unless splenic enlargement due to another documented 
reason) (Parts A and B only).

For MTC subjects (Part A only) a screening isotope bone scan will be performed at 
baseline. If this is suggestive of bone metastases an X ray, CT or MRI of the bone 
lesion should be performed at BL and the same technique repeated at each scheduled 
efficacy assessment.

For MTC subjects (Part A only) a liver MRI should be performed or if not available, 
a contrast enhanced triple phase CT scan. Also an MRI or CT scan of neck should be 
performed if neck lesions are known or suspected. These should be performed at
baseline and as stipulated above. 

For PC (Part A only) and NEPC subjects, a 99mTc-methylene diphosphonate 
radionuclide bone scan should be performed at screening and subsequently only if 
progressive disease in the bone is suspected.  

For HCC and NEHCC subjects (Part A only), a contrast enhanced triple phase 
CT/MRI scan of the abdomen   should be performed at screening and all subsequent 
efficacy assessments.
In Parts C and D, a CT/MRI will be performed at the end of the DDI evaluation period, before 
starting the CC-90011 treatment period, to be considered as the baseline.
All subjects who discontinue treatment for reasons other than disease progression, start of a new 
anticancer therapy, or withdrawal of consent from the entire study will be followed according to 
the specified tumor assessment schedule until progression and/or initiation of new systemic 
anticancer therapies. This does not apply to subjects who discontinue during the DDI evaluation 
period in Part C and Part D.
Tumor response at each post-screening assessment will be determined by the Investigator, based 
on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 as described in Appendix B
for solid tumors, the Lugano Classification in Appendix C for NHL, PCWG3 (Scher, 2016) for 
PC, and NEPC (Appendix J) and mRECIST for HCC and NEHCC (Appendix I).
Tumor markers ie, PSA for PC (Part A only) and NEPC and AFP for HCC and NEHCC (Part A 
only) at screening, Day 1 of every cycle and EOT unless disease progression documented 
previously.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
86
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
6.4.1.
Neuroendocrine Pharmacodynamic Markers
Neuroendocrine pharmacodynamic (NEPD) markers will be performed at the visits listed in 
Table 5. For all G2 NENs/NETs, SCLC (Part A only), and NEC subjects Pro-GRP, Cg-A and
calcitonin (in Part A only) will be measured centrally at C1D1 (pre-dose) and followed at C1D3, 
C1D8 (pre-dose) and D1 of each cycle and EOT, unless disease progression documented 
previously.
The results from any neuroendocrine pharmacodynamic (NEPD) markers analysis performed at 
local laboratories at the visits listed above or at any unscheduled visit, should be recorded in the 
source documents and on the CRF.
6.5.
Pharmacokinetics 
The PK assessments for Part A and Part B are described below. 
For evaluation of PK of CC-90011 in plasma, blood samples will be collected from all subjects 
at the time points listed in Table 7. The actual time of each sample collection will be recorded in 
the source documents and on the electronic case report forms (eCRFs). An exploratory analysis 
of CC-90011 metabolites in plasma may be performed utilizing the plasma samples collected for 
PK evaluation.
Table 7:
Blood Pharmacokinetic sampling Schedule for Part A and Part B, Cycle 1
Time in Hours 
Relative to 
CC-90011 
Dose
Collection 
Window
Day 1
Day 8
Day 15
Day 22
0 (predose)
Within 30 min 
prior
X
X
X
X
1
± 5 min
X
X
2
± 10 min
X
X
4
± 10 min
X
X
6
± 10 min
X
X
8
± 10 min
X
X
11
± 1 hour
X
X
24
± 1 hour
X
X
48
± 1 hour
X
X
72
± 2 hours
X
X
96
± 2 hours
X
X
The Sponsor may conduct additional analyses on the PK samples and collect extra PK samples in 
order to follow up the safety of the study treatment or to better understand the progression of the 
disease or the disease’s response to the study treatment.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
87
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
See the Laboratory Manual and Appendix G for sample collection, handling, and processing 
instructions.
In Part C and Part D, during the DDI evaluation period, blood samples will be collected for the 
evaluation of PK of CC-90011 in plasma, at the timepoints listed in Table 8 (for Part C) and
Table 9 (for Part D). In addition, urine samples will be collected for exploratory measurements 
of parent drug and metabolites, according to Error! Reference source not found. for both Part 
C and Part D. During the first 24 hours, due to the frequency of PK sampling, overnight stay for 
subjects can be arranged or subjects can be hospitalized at any time point, without this 
constituting a serious adverse event (SAE), if the treating physician considers this appropriate for 
an individual subject. The actual time of each sample collection will be recorded in the source 
documents and on the electronic case report forms (eCRFs).
Importantly, for subjects enrolled in Part C or Part D, PK samples should only be collected 
during the DDI evaluation period, and not during the CC-90011 Treatment period.
Table 8:
Blood Pharmacokinetic Sampling Schedule for CC-90011 and metabolites for 
Part C
Study Day
Time with respect to CC-
90011 dose administration 
on D1 or D22
Allowed PK Window
Period 1
Period 2
D1
D22
Predose, and 0.5, 1, 2, 3, 4, 
6, 8, 12 hr post dose
Predose: Within 60 
minutes prior to dosing
0.5 to 4 hours post 
dose: ± 5 minutes
6 to 12 hours post dose: 
± 10 minutes
D2
D23
24 hr post dose
± 60 minutes
D3
D24
48 hr post dose
± 60 minutes
D4
D25
72 hr post dose
± 60 minutes
D6
D27
120 hr post dose
± 120 minutes
D8
D29
168 hr post dose
± 120 minutes
D10
D31
216 hr post dose
± 180 minutes
D12
D33
264 hr post dose
± 180 minutes
D15
D36
336 hr post dose
± 180 minutes
D40
432 hr post dose
± 180 minutes
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
88
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 9:
Blood Pharmacokinetic Sampling Schedule for CC-90011 and metabolites for 
Part D
Study Day
Time with respect to CC-
90011 dose administration 
on D1 or D18
Allowed PK Window
Period 1
Period 2
D1
D18
Predose, and 0.5, 1, 2, 3, 4, 
6, 8, 12 hr post dose
Predose: Within 60 
minutes prior to dosing
0.5 to 4 hours post 
dose: ± 5 minutes
6 to 12 hours post dose: 
± 10 minutes
D2
D19
24 hr post dose
± 60 minutes
D3
D20
48 hr post dose
± 60 minutes
D4
D21
72 hr post dose
± 60 minutes
D6
D23
120 hr post dose
± 120 minutes
D8
D25
168 hr post dose
± 120 minutes
D10
D27
216 hr post dose
± 180 minutes
D12
D29
264 hr post dose
± 180 minutes
D15
D32
336 hr post dose
± 180 minutes
D36
432 hr post dose
± 180 minutes
D40
528 hr post dose
± 180 minutes
Table 10:
Urine Sampling Schedule for CC-90011 and metabolites for Parts C and D
Study Day
Urine Collection Interval
Collected by
Period 1
D1
0 (predose)
Site
D1
0 to 6 hr
Site
D1
6 to 12 hr
Site
D2
12 to 24 hr
Site
D3
24 to 48 hr
Site
D4
48 to 72 hr
Site
D5
72 to 96 hr
Nursing Service
D6
96 to 120 hr
Site
D7
120 to 144 hr
Nursing Service
D8
144 to 168 hr
Site
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
89
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Study Day
Urine Collection Interval
Collected by
Period 1
D9
168 to 192 hr
Nursing Service
D10
192 to 216 hr
Site
D11
216 to 240 hr
Nursing Service
D12
240 to 264 hr
Site
D13
264 to 288 hr
Nursing Service
D14
288 to 312 hr
Nursing Service
D15
312 to 336 hr
Site
6.6.
Biomarkers and Pharmacodynamics
6.6.1.
Pharmacodynamic and Predictive Biomarkers (only Parts A and B)
The schedules for pharmacodynamic biomarkers are provided below:

Whole blood for PD biomarker studies  

Cycle 1 Day 1: predose (≤ 3 hours)

Cycle 1 Day 3

Cycle 1 Day 5

Cycle 1 Day 8: predose (≤ 3 hours)

Cycle 1 Day 24

Tumor tissue for PD biomarker studies

Screening:  Day -28 to Day 1 predose (after all inclusion and exclusion criteria are 
fulfilled)

Cycle 1 Day 16 or 17 (+ 7 days)

Optional, any other time until EOT visit.
The Sponsor may conduct additional analyses on the PD samples in order to follow up the safety 
of the study treatment or to better understand the progression of the disease or the disease’s 
response to the study treatment.
6.6.2.
Whole Blood samples for Anti-SARS-CoV-2 Serology
Serum and plasma samples may be assessed by enzyme-linked immunosorbent assay, seromics, 
ctDNA measurements, metabolomics, and/or other relevant multiplex-based protein assay 
methods for immune-related factors that may be associated with efficacy or AEs; such factors 
may include, but are not limited to, assessments of cytokines, chemokines, inflammatory factors, 
SARS-CoV-2 serologic status, and ctDNA.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
90
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 11:
Biomarker Sampling schedule for Anti-SARS-CoV-2-Serology
Study Day of Sample Collection
Anti-SARS-CoV-2-Serology
Screening or Predose Cycle 1 Day 1 (Parts A and 
B) or Predose Day 1 (Parts C and D)
X
On-treatment Collection
Approximately every 6 months (e.g. C6D1, 
C12D1 etc.)
X
Approximately 4 weeks after confirmed or 
suspected SARS-CoV-2 infection
X
End of Treatment visit
X
Abbreviations: C = cycle; D = day(s); SARs-CoV-2 = severe acute respiratory syndrome coronavirus 2
During Screening or pre-dose on Day 1, serum will be collected to be used for potential future 
measurements of anti-SARS-CoV-2 serology (anti-SARS-CoV-2 total or IgG). Serum will also 
be collected approximately every 6 months during study treatment to be used for potential future 
measurements of anti-SARS-CoV-2 serology (anti-SARS-CoV-2 total or IgG). Serum should 
also be collected approximately 4 weeks after a documented or suspected SARS-CoV-2 
infection. At EOT, serum will be collected to be used for potential future measurements of anti-
SARS-CoV-2 serology (anti-SARS-CoV-2 total or IgG).
6.6.3.
Tumor Biopsies
Tumor biopsies will be collected whenever safe and feasible in Part A and during expansion 
(Part B), unless an exception is granted by the Sponsor’s study physician in exceptional 
circumstances. No fresh tumor biopsies will be collected in Part C and Part D. The biopsy is 
collected by either surgical biopsy (preferred) or core needle (at least 3 passages, if possible) at 
Screening and in Cycle 1 on Day 16 or 17 (+ 7 days). If study drug treatment is interrupted or 
reduced before this time, the biopsy should be delayed until 1 to 2 days (+7 days) after the 
subject has received two consecutive planned doses of CC-90011. An archival tumor sample 
must be provided if a fresh biopsy is not collected during Screening. In Parts C and D, archival 
tumor sample will be collected whenever feasible. Fine needle aspiration is not sufficient as a 
source of tumor biopsy material.  Samples should be processed as formalin-fixed paraffin-
embedded (FFPE). Optimally, the tumor tissue samples (Screening and on-treatment) will be 
obtained from the same tumor site. 
Additionally, an optional tumor biopsy may be obtained in both Part A and Part B, during later 
treatment cycles or following treatment discontinuation (any time during the 28-day follow-up 
period), to elucidate effects of long-term treatment or resistance mechanisms, respectively.  
See the Laboratory Manual for sample collection, handling, and processing instruction.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
91
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.
DESCRIPTION OF STUDY TREATMENTS
7.1.
Description of Investigational Product(s)
7.1.1.
CC-90011
CC-90011 is a besylate salt with a molecular weight of 609.65.  It is a white to pale yellow solid.
Part A and Part B
CC-90011 will be supplied to the clinic by Celgene Corporation (Celgene) as opaque Swedish 
orange/Grey capsules containing only the active pharmaceutical ingredient at dosage strengths of 
0.50 mg, 0.75 mg, 2.00 mg, 5.00 mg, and 15 mg. The capsules will be supplied in HDPE bottles 
with child-resistant caps, labeled appropriately for investigational use as per the regulations of 
the relevant country health authorities.
Part C and Part D
Celgene Corporation (Celgene) will supply the IP, CC-90011 capsules [available as Blend in 
Capsule (BIC, Gen 2) with 20 mg, 40 mg and 60 mg strengths] for oral administration.
Mechanistic PBPK modeling conducted using validated with clinical data GastroPlus software 
(internal data) predicted that AIC and BIC (Gen2) formulations provide comparable exposures 
over 20 mg to 60 mg dose range. Given the exposure of CC-90011 is approximately dose-
proportional over a wide range of 5 - 80 mg, the formulation is not expected to be a factor in the 
assessment of the extent of DDI on CC-90011 exposure. 
Gen 2 formulation is a step closer to the proposed Phase 3 formulation (Gen 3 tablet) in terms of 
composition and therefore preferred over the AIC formulation for DDI evaluation. The outcome 
of the DDI evaluation will inform the future Phase 3 studies.
In addition, CC-90011 capsules (BIC, Gen 2) with 20 mg, 40 mg or 60 mg strengths for oral 
administration are more convenient to take for subjects as for Part C only 1 capsule of 60 mg 
CC-90011 will be required and for Part D only 1 capsule of 20 mg CC-90011 will be required. 
For the CC-90011 treatment period only 1 capsule of 60 mg CC-90011 will be given QW for the 
convenience of the subjects and to avoid potential dosing errors.
7.1.2.
Rifampicin and Itraconazole
Subjects enrolled in countries where Rifampicin and Itraconazole is commercially available
(Spain) may obtain commercial product through the local hospital pharmacy at the sites or 
licensed distributor. 
The study drugs supplied by Celgene will be labeled appropriately for investigational use as per 
the regulations of the relevant health authorities.
Please refer to local prescribing information for more details on formulations, storage conditions 
(eg, refrigeration), known precautions, warnings, and adverse reactions for these drugs (see 
current version of SmPC). 
The dosing schedules to be followed for this study are described in Section 7.2.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
92
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.2.
Treatment Administration and Schedule
7.2.1.
CC-90011 Administration
Part A, Part B, and CC-90011 treatment period of Part C and Part D
Subjects will administer CC-90011 orally once weekly in each 4-week (28 day) Cycle.
Alternative dosing schedules may be implemented based on the review of clinical safety and 
laboratory data by the SRC. CC-90011 will be administered with at least 240 mL of water.  
Subjects should fast for a minimum of 4 hours in both Parts A and B prior to CC-90011 
administration and refrain from any food intake for up to 1 hour after dosing.  
CC-90011 will be administered in the clinic after any predose assessments are completed (refer
to Section 7.6).
Study treatment may be discontinued if there is evidence of clinically significant disease 
progression, unacceptable toxicity or subject/physician decision to withdraw (refer to   
Section 11).  
If patient vomits after study drug intake and there is no certainty drug has been digested, study 
drug will not be made up to. No further study drug will be administered for that weekly visit. 
Only in cases when study drug is vomited completely and once the vomiting event has settled, 
patient may be challenged to take oral drug again. Otherwise, no further attempts will be made
and study drug will be missed until next weekly administration.
7.2.1.1.
CC-90011, Rifampicin and Itraconazole Administration during DDI evaluation 
period in Part C and Part D
CC-90011, rifampicin and itraconazole will be administered orally with at least 240 mL of water 
in fasting condition at least 4 hours prior to dosing. Subjects should fast for a minimum of 4 
hours prior to CC-90011 administration and should abstain from food or other medication intake 
for ≥ 2 hour after CC-90011 dosing. Additional water may be given to facilitate the swallowing 
of the dose(s). Those days that subject will receive CC-90011 and rifampicin or itraconazole, 
both drugs should be taken as close to the intake of each one as possible. All subjects will 
receive the following oral doses of IPs:
Part C (CC-90011 and Rifampicin):

Period 1 Day 1: 1 × 60-mg CC-90011 capsule

Period 2 Days 15 to 35 (inclusive): 2 × 300-mg rifampicin tablets (equivalent to 600-
mg rifampicin) once daily

Period 2 Day 22: 1 × 60-mg CC-90011 capsule
Part D (CC-90011 and Itraconazole):

Period 1 Day 1: 1 × 20-mg CC-90011 capsule.

Period 2 Days 15 to 31 (inclusive): 2 × 100-mg itraconazole capsules (equivalent to 
200-mg itraconazole) once daily

Period 2 Day 18: 1 × 20-mg CC-90011 capsule
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
93
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.2.2.
Dose Escalation Process (Part A)
For the purposes of dose escalation decisions, at least 3 subjects will be enrolled in successive 
cohorts. The first cohort will be treated with the starting dose of 1.25 mg once weekly.  Subjects 
must complete a minimum of 1 cycle of treatment with the minimum safety evaluation and drug 
exposure or have had a DLT within the first cycle of treatment to be considered evaluable for 
dose escalation decisions. Dose escalation decisions will occur when the cohort of subjects has 
met these criteria. Dose escalation decisions will be made by the SRC. Decisions will be based 
on a synthesis of all relevant data available from all dose levels evaluated in the ongoing study 
including safety information, DLTs, all treatment related CTCAE grade ≥ 2 toxicity data during 
Cycle 1, and PK data from evaluable subjects. PK data from subjects will be made available on 
an on-going basis throughout the study and dosing will be adapted accordingly. The 
recommended dose for the next cohort of subjects will be guided by the BLRM with EWOC 
principle.
The adaptive Bayesian methodology provides an estimate of the dose levels of CC-90011 that do 
not exceed the MTD and incorporates all DLT information at all dose levels for this estimation. 
In general, the next recommended dose will have the highest chance that the DLT rate will fall in 
the target interval (the true DLT rate lying in 16-33%) and will always satisfy the EWOC 
principle. Per EWOC it should be unlikely (<25% posterior probability) that the DLT rate at the 
next dose will exceed 0.33. In all cases, the recommended dose for the next cohort will not 
exceed a 100% increase from the previous dose. Smaller increases in dose may be recommended 
by the SRC upon consideration of all of the available clinical data.
The procedure for subject accrual in each dose cohort and provisions for dose 
escalation/de-escalation decisions for the study is as follows:
1. This study will begin by evaluating CC-90011 in cohorts of at least 3 evaluable subjects
at each dose level. Initially, the dosing increments between cohorts will be 100%. When a 
single subject experiences a DLT, or 2 subjects experience grade ≥ 2 treatment-related
toxicity, which fall under the adverse event terms of thrombocytopenia/platelet count 
decrease, anaemia/red blood cell count decrease, neutropenia/white blood cell count 
decrease, and/or gastrointestinal tract toxicities, the cohort size may be increased to 6 
evaluable subjects for the current and subsequent cohorts. The increase in CC-90011 dose 
will be ≤ 50% for each subsequent dose escalation cohort. Once 2 subjects experience 
grade ≥ 2 treatment-related toxicity, which fall under the adverse event terms of 
thrombocytopenia/platelet count decrease, anaemia/red blood cell count decrease, 
neutropenia/white blood cell count decrease and/or gastrointestinal tract toxicities, the 
enrollment will be restricted to subjects with G2 NENs/NETs, SCLC, and other NECs
who may secrete Pro-GRP, CgA, or calcitonin.
2. Following completion of Cycle 1 for all evaluable subjects in a cohort, the two-parameter 
BLRM with EWOC principle will be used to make recommendations to the SRC for the 
next dose level with the following exceptions:

If the first 2 subjects in a cohort experience DLTs, no additional subjects will be 
enrolled into that cohort until the Bayesian model has been updated with this new 
information. Likewise, the model will be re-evaluated if 2 subjects in a cohort 
experience DLTs before the enrollment of any additional subject.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
94
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
3. After each cohort, the SRC will meet and review data from the BLRM assessment and 
available safety (ie, DLT and non-DLT data), PK, PD, and preliminary efficacy 
information. The final dose escalation decisions will be made by the SRC.
After repeating the above steps, a CC-90011 dose can be declared the MTD after meeting the 
following conditions: 

at least 6 evaluable subjects have been treated at the dose, 

the posterior probability that the DLT rate lying in the target interval (16-33%) at the 
dose exceeds 60% or a sufficient number of subjects have been entered into the study 
to ensure the precision of the MTD estimate, as the posterior probability approaches 
but fails to exceed 60%, and

the dose is recommended according to the BLRM and the SRC approves it.
Dose escalation may be terminated by SRC at any time based on emerging safety concerns 
without establishing the MTD. At the discretion of the SRC to better understand the safety, 
tolerability and PK of CC-90011, additional cohorts of subjects may be enrolled at prior dose 
levels or to intermediate dose levels before or while proceeding with further dose escalation.
7.2.3.
Dose Escalation Decisions (Part A)
Provisional dose levels to be assigned to separate cohorts of subjects are described in 
Section 9.9.1. Dose decisions during escalation are however not limited to these doses. Based on
the recommendation of the BLRM regarding the highest dose that may not be exceeded at any 
decision point during escalation and the maximum increase in dose allowed by the protocol, 
intermediate doses may be administered to subsequent new cohorts of subjects. 
The decision to evaluate additional subjects within a dose cohort, a higher dose cohort, 
intermediate dose cohorts, smaller dose increments, alternative dosing schedules, or declare an 
MTD will also be determined by the SRC, based on their review of clinical and laboratory safety 
data.
7.2.4.
Definition of a Subject Evaluable for DLT (Part A)
All subjects who receive at least one dose of CC-90011 will be evaluable for safety.
After the first dose is administered in any cohort during dose escalation, subjects in each cohort 
are observed for 28 days (Cycle 1, DLT window) before the next dose cohort can begin. A 
subject evaluable for DLT is defined as one that: 

Has received ≥ 75% of the total planned dose amount of CC-90011 during Cycle 1 
without experiencing a DLT,
or

Experienced a DLT after receiving at least one dose of CC-90011.  
Subjects not evaluable for DLT will be replaced. Additional subjects within any dose cohort may 
be enrolled at the discretion of the SRC. Intra-subject dose escalation will not be allowed during 
the DLT assessment period.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
95
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.2.5.
Definition of Maximum Tolerated Dose (MTD) (Part A)
The MTD is the highest dose at which less than 33% of the population (not sample of the 
population) treated with CC-90011 suffer a DLT in the first cycle and at least 6 evaluable 
subjects have been treated at this dose. The estimation of MTD is described in Section 7.2.2.
A variable dose cohort (eg, less frequent dosing or more frequent dosing at a lower dose) may be 
evaluated to accurately determine the MTD at the discretion of the SRC.
7.2.6.
Definition of Dose-Limiting Toxicity (DLT) (Part A)
During dose escalation, the DLT assessment period is Cycle 1 (28 days).
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4.03 are used as a guide for the grading of severity of adverse events.  A DLT is defined 
as any of the following toxicities occurring within the DLT assessment unless the event can 
clearly be determined to be unrelated to CC-90011. Dose-limiting toxicities are described below:

Any Grade 4 non-hematologic toxicity of any duration 

Any non-hematologic toxicity Grade ≥ 3 EXCEPT for: 

Grade 3 diarrhea, nausea, or vomiting of ≤ 3 days duration (with optimal medical 
management).

Grade 3 rash of the acneiform, pustular or maculopapular type which resolves to 
Grade ≤ 2 within 7 days of study drug interruption and does not recur at the same 
level with resumption of study drug at the same dose (with optimal medical 
management).

Grade 3 fatigue which resolves to Grade ≤ 2 within 7 days of study drug 
interruption and does not recur at the same level with resumption of study drug at 
the same dose (with optimal medical management).

Hematological toxicities as follows:

Febrile neutropenia.  

Grade 4 neutropenia lasting > 7 days.

Grade 4 thrombocytopenia lasting > 7 days, Grade ≥3 thrombocytopenia with 
clinically significant bleeding.

Any AE, unless clearly determined to be unrelated to study drug, necessitating 
dose-level reduction during Cycle 1.

Any other toxicity at any time during the trial that the safety committee deem dose 
limiting.
Isolated laboratory changes without associated clinical signs or symptoms (eg, hypomagnesemia, 
hypermagnesemia, hypoalbuminemia, hypophosphatemia, lymphocyte count increased or 
decreased) may not be included in this definition. These findings will be discussed and reviewed 
by the SRC.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
96
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.2.7.
Criteria for Dose Escalation in the Next Cohort of Subjects (Part A)
During Part A, the dose escalation criteria are described in Section 7.2.2 and Section 7.3. 
7.2.8.
Permitted Study Drug Adjustments
Dose reductions are permitted in any cycle, including Cycle 1.  Dose reductions that occur in 
Cycle 1 during dose escalation will constitute DLT as outlined in Section 7.2.6, but subjects will 
be allowed to continue on CC-90011 at a reduced dose.  
When a dose adjustment is indicated, the dose frequency will be adjusted first.  Dose omission 
and reduction are allowed after consultation with the Sponsor’s study physician. Once the dose 
has been reduced, it can be escalated when toxicity reaches Grade ≤ 1.  If toxicity recurs at the 
higher dose, the dose will be reduced a second time, but no re-escalation is then permitted. If any 
subject continues to experience unacceptable toxicity after two dose reductions (one for the dose 
level), CC-90011 will be discontinued permanently.
Intra-subject dose escalation will not be allowed during the DLT assessment period. Refer to 
Section 7.2.10 for additional information on possible dose increases.
Dose modifications or interruptions are not allowed during the DDI evaluation period unless 
discussed and agreed upon by the Study Sponsor Physician and only for safety reasons. 
During the CC-90011 Treatment period:
CC-90011 will be given orally at the RP2D of 60 mg QW in 28-day cycles. Dose modifications 
or interruptions are allowed, after discussion and agreement by the Study Sponsor Physician.
7.2.9.
Criteria for Dose Reduction
Any AE meeting the definition of DLT will require dose frequency adjustment and subsequent 
dose interruption if no recovery.  Subjects with Grade ≥ 2 thrombocytopenia should not be dosed 
until recovery of thrombocytopenia to Grade ≤1, with the exception of subjects with R/R NHL 
with G2 thrombocytopenia who may be dosed if no other safety concerns occur and with a 
weekly hematology follow up.  Once the thrombocytopenia has resolved to Grade ≤ 1, treatment 
can be resumed (discussion with the Sponsor’s study physician is highly recommended).
Treatment related Grade ≥ 3 toxicity or chronic Grade 2 toxicity may warrant dose reduction of 
CC-90011. Subjects with R/R NHL with G2 thrombocytopenia may be dosed at the same dose 
with weekly hematology follow up if no other safety concerns occur. Such cases should be 
discussed with the Sponsor’s study physician before dosing changes are made.
In Part C and Part D (DDI cohorts), treatment related Grade ≥ 3 toxicity or chronic Grade 2 
toxicity may warrant dose reduction of CC-90011. Investigators are encouraged to discuss such 
cases with the Sponsor’s study physician.
Rifampicin and itraconazole dosing regimens are not intended to be altered. If the second CC-
90011 dose in Period 2 cannot be administered as planned, then the Sponsor may decide to stop 
the concomitant doses of rifampicin or itraconazole, in which case the subject will be considered 
DDI non-evaluable.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
97
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.2.10.
Criteria for Dose Increase
Intra-subject dose escalation will not be allowed during the DLT assessment period, however, in 
Cycles ≥ 3, subjects without evidence of disease progression who are tolerating their assigned 
dose of CC-90011 may (at the Investigator’s discretion and in consultation and agreement with 
the Sponsor’s study physician) escalate to the highest dose level shown to be adequately 
tolerated by at least one cohort of subjects in this study (ie, ≤ 33% of evaluable subjects having 
experienced a DLT at that dose level).
In Part B (expansion phase), no dose escalation beyond the MTD is allowed.
In Part C and Part D (DDI cohorts), no dose escalation beyond the pre-specified doses for DDI 
evaluation and treatment periods is allowed.
7.2.11.
Treatment Interruption for Adverse Events
Treatment may be interrupted up to 4 weeks until toxicity (excluding alopecia) reaches either 
Grade ≤ 1 or baseline levels.  Treatment may restart either at the same, or a reduced dose, at the 
Investigator’s discretion or as described in Section 7.2. Any such treatment interruptions must be 
discussed with the Sponsor´s study physician. 
In the DLT assessment period of the dose escalation phase, a treatment interruption with > 1
missed dose of CC-90011 for reasons other than DLT will make a subject non-evaluable for 
DLT and necessitate replacement of that subject in the dosing cohort. Any such treatment 
interruptions must be discussed with the Sponsor´s study physician.
In Part C and Part D (DDI cohorts), treatment related toxicity may warrant dose interruptions of 
CC-90011. Such cases should be discussed with the Sponsor’s study physician before dosing 
interval changes are made. In case of safety concerns, the physician may interrupt treatments to 
protect the safety of the subject. Such subjects will become non-evaluable for DDI assessment 
and will need to be replaced.
Subjects with confirmed SARS-CoV-2 infection following initiation study treatment with 
CC-90011 must have treatment interrupted. Subjects with confirmed SARS-CoV-2 infection 
may resume treatment after 1) at least 10 days (20 days for severe/critical illness) have passed 
since symptoms first appeared,  positive RT-PCR test result, or positive viral antigen test result, 
2) resolution of acute symptoms (including at least 24 hours has passed since last fever without 
fever reducing medications), 3) evaluation by the Investigator with confirmation that there are no 
sequelae that would place the subject at a higher risk of receiving investigational treatment, and 
4) consultation by the Sponsor’s study physician. For suspected cases, treatment may also 
resume if SARS-CoV-2 infection is ruled-out and other criteria to resume treatment are met.
Prior to re-initiating on-study treatment in a subject with a dosing delay lasting > 4 weeks due to 
SARS-CoV-2 infection, the Sponsor’s study physician /designee must be consulted.
7.2.12.
Management of Select Adverse Events
7.2.12.1.
Neutropenia, Thrombocytopenia, and Anemia
Hematopoietic growth factors or other hematologic support, such as erythropoietin, darbepoetin, 
granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
98
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
factor (GM CSF), and RBC- or platelet- transfusions are allowed in the study with therapeutic 
intent. Therapeutic use of G-CSF is allowed at any time for subjects experiencing Grade 3/4 
neutropenia or any grade febrile neutropenia. Prophylactic use of granulocyte (or granulocyte-
macrophage) growth factors is not allowed during Cycle 1.
Subjects with Grade 3 or 4 neutropenia and/or Grade ≥ 2 thrombocytopenia should be monitored 
frequently with laboratory tests until resolution to Grade ≤ 1. Antimicrobial, antifungal, and 
antiviral prophylaxis should be considered, as appropriate.
As of 11 Sep 2020, 50 subjects were enrolled in Part A of the study and received escalating oral 
doses of CC-90011 QW at 9 dose levels from 1.25 mg to 120 mg/dose and 16 subjects 
(14 subjects with low/intermediate-grade lung NETs [typical and atypical carcinoid], 2 subjects 
with prostate NEC and 1 subject with MZL) were enrolled in Part B of the study and received 
oral CC-90011 QW at 60 mg. The Part A of the study has been completed and the primary 
objectives were met. The NTD was determined to be 120 mg, the MTD was 80 mg, and the 
RP2D was 60 mg, QW of 28-day cycles. Thrombocytopenia, an on-target effect, was the only 
dose-limiting toxicity (DLT); these events occurred mainly at the highest dose levels and were 
successfully managed with dose interruption for a week and/or dose reduction. CC-90011 has 
been generally well tolerated with the majority of treatment-emergent adverse events (TEAEs)
being reversible and manageable by dose adjustments and/or supportive treatments.
Subjects with Grade ≥ 2 thrombocytopenia should not be dosed until recovery of 
thrombocytopenia to Grade ≤1, with the exception of subjects with R/R NHL with G2 
thrombocytopenia who may be dosed if no other safety concerns occur and with a weekly 
hematology follow up. Once the thrombocytopenia has resolved to Grade ≤ 1, treatment can be 
resumed (discussion with the Sponsor’s study physician is highly recommended).
7.2.12.2.
Pain
Tumor pain or treatment-induced pain can be controlled with opioid and opioid-related 
analgesics, such as codeine, meperidine, propoxyphene or morphine, administered at the 
clinician’s discretion, and as dictated by medical need. The risk of bleeding, especially in the 
setting of thrombocytopenia, should be considered prior to use of non-steroidal anti-
inflammatory drugs (NSAIDs) and aspirin. NSAIDS and aspirins should be avoided if possible 
and paracetamol should be administered instead.
7.2.12.3.
Gastrointestinal Effects
Mucosa coating agents for protection of esophageal/gastric mucosa are recommended at the 
discretion of the Investigator as well as monitoring subjects for GI bleeding. However, proton 
pump inhibitors may affect the neuroendocrine markers in NEN/NET/SCLC and other NEC
subjects, so histamine (H2) receptor antagonists should be administered preferentially if 
appropriate in these subjects. Subjects will be encouraged to report all episodes of GI discomfort 
or pain, appetite loss, change of stool, or blood in stool.
It is recommended that subjects experiencing diarrhea be managed according to the guideline 
provided in Appendix F. Anti-diarrheal medication, such as loperamide, should be initiated at the 
earliest onset of Grade 1-2 diarrhea. Anti-diarrheal medication may be administered as 
prophylaxis and for treatment of diarrhea.  Dehydration and electrolyte disturbances should be 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
99
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
rapidly corrected. General measures to improve diarrhea, such as a low-fiber diet and increased
liquid consumption, should be considered and weight should be closely monitored.
7.2.13.
Definition of Overdose
Overdose, as defined for this protocol, refers to CC-90011 dosing only. In Part C and Part D, 
overdose refers to CC-90011, rifampicin or itraconazole. On a per dose basis, an overdose is 
defined as the following amount over the protocol-specified dose of CC-90011, rifampicin or 
itraconazole assigned to a given subject, regardless of any associated adverse events or sequelae:

PO any amount over the protocol-specified dose
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.  
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form. Refer to 
Section 10 for the reporting of adverse events associated with overdose.
7.3.
Method of Treatment Assignment
Eligible subjects will be enrolled sequentially in Part A (dose escalation). Enrollment in Part B 
(dose expansion) will be stratified by disease cohort and dosing schedule, as applicable. In Part C 
and Part D, subjects will be alternatively enrolled: first subject will be assigned to Part C and the 
following subject to Part D, etcetera.
An Interactive Response Technology (IRT) system will be used to track subject assignments to 
the dose levels in Part A and tumor cohorts in Part B.
7.4.
Packaging and Labeling
The label(s) for CC-90011 will include, but not limited to, sponsor name, address and telephone 
number, the protocol number, CC-90011, dosage form and strength (where applicable), amount 
of CC-90011 per container, lot number, expiry date (where applicable), medication 
identification/kit number, dosing instructions, storage conditions, and required caution 
statements and/or regulatory statements as applicable. Additional information may be included 
on the label as applicable per local regulations.
The labels for rifampicin and itraconazole contain information found on the commercial label(s) 
for these products.
7.5.
Investigational Product Accountability and Disposal 
Celgene (or designee) will review with the Investigator and relevant site personnel the 
procedures for documenting receipt of investigational products, as well as the procedures for 
counting, reconciling investigational products, and documenting this process. Celgene (or 
designee) will also review with the Investigator and relevant site personnel the process for 
investigational products return, disposal, and/or destruction including responsibilities for the site 
vs. Celgene (or designee).
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
100
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
7.6.
Investigational Product Compliance
Only the pharmacist or the Investigator’s designee will dispense investigational products.  A 
record of the number of dosing units of the investigational products dispensed to and taken by 
each subject must be maintained. The pharmacist or the Investigator’s designee will document 
the doses dispensed/administered in the appropriate study records.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
101
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
8.
CONCOMITANT MEDICATIONS AND PROCEDURES
All medications (excluding prior cancer therapy for the tumor under evaluation) taken beginning 
when the subject signs the ICF and all concomitant therapy during the study until 28 days after 
treatment discontinuation, together with dose, dose frequency and reasons for therapy use will be 
documented in the source documents and on the concomitant medication eCRF.  
All prior chemotherapy (biologic, immunologic, or radiation therapy) and anticancer surgery 
prior to the administration of study drug, will be recorded in the appropriate section of the eCRF.
The Investigator will instruct subjects to notify the study staff about any new medications taken 
after signing the ICF.  All medications and significant non-drug therapies (herbal medicines, 
physical therapy, etc.) and any changes in dosing with existing medications will be documented 
on the eCRFs.
8.1.
Permitted Concomitant Medications and Procedures
Subject to the precautions described in Section 8.2, the use of any concomitant 
medication/therapies deemed necessary for the care of the subject should be used.  Repeat PK 
evaluations may be conducted if changes are made to concomitant medications suspected of 
affecting drug absorption or metabolism. The following are permitted concomitant medications 
and procedures:

Subjects with ≥ Grade 1 diarrhea should promptly initiate treatment with 
diphenyoxylate/atropine (Lomotil), or loperamide (Imodium) or an alternative over-
the-counter remedy for diarrhea.  Premedication with antidiarrheal medication for 
subsequent doses of CC-90011 may be appropriate and should be discussed with 
Sponsor’s study physician.

Subjects may receive prophylactic anti-emetics at the discretion of the Investigator, 
including dexamethasone.  

Prophylactic mucosa protective agents may be appropriate at the discretion of the 
Investigator. However, proton pump inhibitors may affect the neuroendocrine 
markers in G2 NENs/NETs, SCLC, and other NEC subjects, so histamine (H2) 
receptor antagonists should be administered preferentially in such subjects if 
appropriate.

Antiviral therapy with an appropriate antiviral agent for HBV is required in HCC and 
NEHCC subjects with positive hepatitis B surface antigen, HBcAb IgM, and/or viral 
load appropriate first line agents include entecavir, tenofovir, and lamivudine (note 
that lamivudine has higher resistance rates). Confirmation of antiviral therapy with an 
appropriate antiviral agent for HCV is required in subjects with positive hepatitis C 
viral load.  Regimens appropriate for the treatment of HCV should not be interrupted 
when administering CC-90011.  

Therapeutic use of granulocyte growth factors is allowed at any time for subjects 
experiencing febrile neutropenia or Grade 3/4 neutropenia. Routine prophylaxis with 
granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating 
factor is allowed at Investigator discretion starting with Cycle 2 and beyond.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
102
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Subjects receiving stable doses of recombinant erythropoietin or darbepoetin alfa for 
at least 4 weeks prior to starting the CC-90011 may continue their pretreatment doses 
throughout the study.  Subjects may initiate de novo treatment with erythropoietin 
stimulating agents (ESAs) beginning in Cycle 2 for hypoproliferative anemias 
secondary to prior chemotherapy exposure provided there is no clinical suspicion of a 
concurrent cause for the anemia (eg, CC-90011-induced).

Parenteral flu vaccination is permitted.  

Routine infectious disease prophylaxis is not required.  However, antibiotic, antiviral, 
anti-pneumocystis, antifungal, or other prophylaxis may be implemented during the 
study at the discretion of the Investigator.  

Treatment with bisphosphonates (eg, pamidronate, zolendronate) or other agents (eg, 
denosumab) is permitted to prevent or delay progression of bone metastases.  
Maintenance of a stable dosing regimen throughout the study is recommended.

Focal palliative radiotherapy for treatment of cancer-related symptoms (eg, localized 
bone pain) is allowed during study treatment at the discretion of the investigator, 
provided this is not indicative of disease progression, in which case the subject should 
be discontinued.

Subjects may receive physiologic replacement doses of glucocorticoids (up to the 
equivalent of 10 mg daily prednisone) as maintenance therapy.

Maintenance hormonal therapies are allowed in subjects with a history of breast or 
prostate cancer.

Somatostatin analogs (SSA) may be used for symptom control as appropriate.

As a precautionary measure, it is recommended that subjects avoid prolonged 
exposure to ultraviolet (UV) light, wear protective clothing and sunglasses, and use 
UV-blocking topical preparations while taking CC-90011.

Subjects may receive authorized or approved SARS-CoV-2 vaccines while 
continuing on study treatment at the discretion of the Investigator.

Treatment of active SARS-CoV-2 infections or high risk exposures, including use of 
investigational therapies, is allowed and should be discussed with the Sponsor’s study 
physician.
8.2.
Prohibited Concomitant Medications and Procedures
Other investigational therapies must not be used while the subject is on the study.
Anticancer therapy (chemotherapy, biologic or investigational therapy, and surgery) other than 
the study treatments must not be given to subjects while the subject is on the study.  If such 
treatment is required the subject must be discontinued from the study. Treatment with 
immunosuppressive agents is not allowed while the subject is on the study.  If such treatment is 
required the subject must be discontinued from the study.
Treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular 
weight heparin, Factor Xa inhibitors, thrombin antagonists) is not allowed.  Short-term, 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
103
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
prophylactic dosing of anticoagulants may be considered in subjects if medically indicated (eg, 
hospitalized subjects, post-operatively) under careful consideration by the Investigator.
Since drug-drug interactions have not been investigated in clinical studies; and in vitro studies 
have shown that CC-90011 is primarily metabolized by CYP3A4/5, drugs that are known strong 
inducers or inhibitors of these enzymes should not be co-administered with CC-90011.  If use of 
one of these drugs is necessary, the risks and benefits should be discussed with the Sponsor’s 
study physician prior to its concomitant use with CC-90011. Grapefruit juice and St. John’s Wort 
should also be avoided during study treatment.
Examples of these drugs are (not inclusive):

CYP3A4/5 inhibitors:  atazanavir, clarithromycin, indinavir, itraconazole (allowed 
during DDI evaluation period in Part D), ketoconazole, nefazodone, nelfinavir,
posaconazole, ritonavir, saquinavir, telithromycin and voriconazole.

CYP3A4/5 inducers: rifampicin (allowed during DDI evaluation period in Part C), 
apalutamide, carbamazepine, enzalutamide and phenytoin.
A more exhaustive list of CYP inhibitors and inducers of potential clinical relevance is provided 
at the following link: 
https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-
table-substrates-inhibitors-and-inducers#transporter.
Administration of investigational SARS-CoV-2 vaccines is not allowed during the study. Live 
vaccines are prohibited during the study treatment. In addition, the administration of live SARS-
CoV-2 vaccine is prohibited up to 14 days prior to initiation of treatment.
Treatment of active SARS-CoV-2 infections or high risk exposures, including use of 
investigational therapies, is allowed and should be discussed with the Sponsor’s study physician.
8.2.1.
Medications to be used with caution
Proton pump inhibitors should be avoided, if possible, in the G2 NENs/NETs, SCLC, and other
NEC subjects due to a possible effect on the biomarkers. If clinically appropriate, subjects should
be changed to a H2 antagonist at least 7 days prior to the first dose.
In view of the potential for thrombocytopenia, NSAIDS and aspirins should be avoided. Based 
on the experience from part A, there has not been any noticeable interference/safety concern with 
the concomitant use of Omeprazole, NSAID or aspirin when clinically indicated. If use of one of 
these drugs is necessary, the risks and benefits should be discussed with the Sponsor’s study 
physician prior to its concomitant use with CC-90011. If possible and paracetamol should be 
administered instead of NSAIDS and aspirins.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
104
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
9.
STATISTICAL CONSIDERATIONS
9.1.
Overview
Part A and Part B
The primary objectives of this study are to determine the safety, tolerability, and MTD of 
CC- 90011 when administered orally once a week for 4 weeks (28-day Cycle) to adult subjects 
with advanced unresectable R/R solid tumors (including G2 NENs/NETs, SCLC, and other 
NECs) and R/R NHL.  The secondary objectives are to make a preliminary assessment of the 
antitumor activity of CC-90011, and to determine its PK characteristics.
Part C and Part D
The primary objectives of the DDI evaluation periods are:

To evaluate the effect of rifampicin, a strong cytochrome P450 (CYP) 3A and P-
glycoprotein (P-gp) inducer, on the PK of CC-90011 (Part C) and,

To evaluate the effect of itraconazole, a strong CYP3A and P-gp inhibitor on the PK 
of CC-90011 (Part D). 
The secondary objectives of the DDI evaluation periods are:

To characterize the PK parameters of a single dose of CC-90011 alone and in
combination with rifampicin (Part C) or itraconazole (Part D) and,

To assess the safety and tolerability of a single dose of CC-90011 alone and in 
combination with rifampicin (Part C) or itraconazole (Part D)
Data summaries/statistical analyses will be performed by study part (Part A or B), dose schedule, 
dose level (Part A), tumor cohort (Part B), and study period (DDI period/CC-90011 treatment 
period) in Part C and Part D as applicable.
9.2.
Study Population Definitions
The study population definitions are as follows: 

Enrolled Population – All subjects who meet inclusion/exclusion criteria.

Treated Population – All subjects who enroll and receive at least one dose of 
CC-90011.

Efficacy Evaluable (EE) Population – All subjects who enroll in the study, meet 
eligibility criteria, complete at least one cycle of CC-90011 (taking at least 75% of 
assigned doses), and have baseline and at least one valid post-baseline tumor 
assessment.

Pharmacokinetic (PK) Evaluable Population – all subjects who enroll and receive at 
least one dose of CC-90011 and have at least one measurable concentration of 
CC-90011.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
105
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

DDI Evaluable Population (only Parts C and D) – all subjects who enroll and 
complete both periods in Parts C or D, and have adequate number of blood samples 
collected for assessment of primary PK endpoints.

Biomarker Evaluable (BE) Population – all subjects who enroll, receive at least one 
dose of study drug, and have at least one biomarker assessment, excluding 
disqualified assessments.
9.3.
Sample Size and Power Considerations
During Part A of the study an adaptive Bayesian logistic regression (BLR) model (with 2 
parameters) guided by the escalation with overdose control (EWOC) principle will be for dose 
escalation as described in Section 7.2.2. No formal statistical power calculations to determine 
sample size were performed for this study. The actual number of subjects will depend on the 
number of dose levels/cohorts that are tested. However, the anticipated number of subjects will 
be approximately 55.
After the MTD/RP2D is determined from Part A, Part B will enroll 3 selected cohorts of 
advanced low/intermediate-grade lung NETs, NEPCs and R/R NHL (MZL, including EMZL, 
SMZL, NMZL and histologic transformation of MZL) with up to 10-20 evaluable subjects for 
each cohort.  
For Part B, sample sizes are not determined based on power calculation but rather on clinical, 
empirical and practical considerations traditionally used for exploratory studies of this kind. 
During the Part B dose expansion, at least 10-14 efficacy evaluable subjects for each tumor 
cohort will initially be accrued. The tumor cohort will be expanded to approximately 10-20 
subjects if a responder or SD of 4 months or longer is observed.
Parts C and D
The sample size estimation is based on the observed dose- response association of CC-90011 
with thrombocytopenia, an on-target, completely reversible and clinically manageable DLT. In 
the CC-90011-SCLC-001 study in 1 L ES SCLC patients, a 40 mg QW dose of CC-90011 in 
combination with chemotherapy (Cisplatin/Etoposide) was identified as the RP2D based on the 
incidence of thrombocytopenia, thus providing a 2-fold no-effect boundary to the 20 mg dose of 
CC-90011 selected for Part D (itraconazole DDI).
In the preliminary population pharmacokinetic (PPK) analysis of study ST-001 Part A data, 
residual variability was estimated to be ~30%. Also, a preliminary PBPK model was developed 
for prediction of CC-90011 DDI with itraconazole, which predicted a geometric mean ratio 
(GMR) of 4.7 for AUC0-∞parameter between treatments (“CC-90011+ itraconazole”/ “CC-
90011”). Using a conservative intra-subject SD of 0.5 and model predicted GMR of 4.7 for 
AUC0-∞, a sample size of 6 and 8 DDI evaluable subjects in Part D would achieve 81% and 92% 
power, respectively, to reject null hypothesis that the geometric mean ratio is less than or equal 
to 2.  The calculation used a 1-sided paired t-test at significance level of 0.05. Based on these 
calculations, sample size of 6 to 8 DDI evaluable subjects is considered adequate (>80% power)
for Cohort D.
Six (6) to 8 DDI evaluable subjects enrolled in Part C (rifampicin DDI) are also expected to
provide adequate precision in the comparison of PK parameters. The precision is calculated for 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
106
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
different estimates of intra-subject standard deviation (SD) on the natural log scale and sample 
size (Table 12). The precision represents the width of the 90% CI of the geometric mean ratios 
on the original scale. 
The subjects for Parts C and D will be replaced if not DDI evaluable.
Table 12:
Precision and Intrasubject Standard Deviation
Sample Size
Precision
Intra-SD = 
0.2
Intra-SD = 
0.3
Intra-SD = 
0.4
Intra-SD = 
0.5
Intra-SD = 
0.6
n = 6
26.2%
41.8%
59.3%
78.9%
101.0%
n = 7
23.1%
36.6%
51.5%
68.1%
86.5%
n = 8
20.9 %
32.9 %
46.1 %
60.6 %
76.5 %
n = 10
17.8 %
27.9 %
38.8 %
50.7 %
63.5 %
n = 12
15.8 %
24.6 %
34.1 %
44.3 %
55.3 %
n = 14
14.3 %
22.2 %
30.7 %
39.7 %
49.4 %
n = 16
13.2 %
20.4 %
28.1 %
36.3 %
45.0%
Abbreviations: n = number of subjects; SD = standard deviation.
Although the target sample size of 8 DDI evaluable subjects is planned for each of the Cohorts C 
and D, the enrollment may be stopped when a sample size of 6 DDI evaluable subjects is reached
for each cohort.
9.4.
Background and Demographic Characteristics
The baseline characteristics of subjects will be summarized by study part (Part A or B), dose 
schedule, dose level (Part A), tumor cohort (Part B), and study period (DDI period/CC-90011 
treatment period) in Part C and Part D as applicable. The age, weight, height and other 
continuous demographic and baseline variables will be summarized using descriptive statistics.  
Performance status, gender, race and other categorical variables will be summarized with 
frequency tabulations. Medical history data will be summarized using frequency tabulations by 
system organ class and preferred term.
9.5.
Subject Disposition
Subject disposition (analysis population allocation, on-going, discontinued, along with primary 
reason) from treatment and study will be summarized using frequency and percent.  A summary 
of subjects enrolled by site will be provided. Protocol violations will be summarized using 
frequency tabulations. Supportive corresponding subject listings will also be provided.
9.6.
Efficacy Analysis
Efficacy analyses will be based on the treated population by dose cohort in Part A, tumor type in 
Part B, and CC-90011 treatment period in Parts C and D and include summaries of clinical 
benefit rate (CBR), objective response rate (ORR), duration of response or stable disease, 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
107
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
progression-free survival (PFS), and OS by dose cohort and dosing schedule (Part A) or tumor 
type and dosing schedule (Part B), and treatment period in Parts C and D.  Tumor response (CR, 
PR, SD, PD, or inevaluable) will be assessed by investigators according to Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.1, mRECIST for HCC and NEHCC, PCWG3 for 
PC and NEPC and the Lugano Classification criteria for NHL. The CBR is defined as tumor 
responses (as assessed by the Investigators) of CR, PR and durable SD (SD of ≥ 4 months 
duration).  The ORR is defined as the percent of subjects whose best response is CR or PR.  
When SD is the best response, it must be documented radiographically at least once after study 
entry after a minimal interval of 8 weeks from first dose (ie, coincident with the first post 
baseline response assessment time point minus assessment window). If the minimal time for a 
best response of SD is not met, the subject’s best response will depend on the outcome of 
subsequent assessments. For example, a subject who exhibits SD at first assessment (where the 
first assessment does not meet minimal duration criteria for SD) and PD at the second 
assessment, would be classified as having a best response of PD. A subject lost to follow-up after 
the first SD assessment would be considered non-evaluable, if the minimal duration criteria for 
SD were not met. 
Two-sided 95% Clopper-Pearson exact confidence intervals will be provided for ORR and CBR
estimates. Similar analyses will be performed to include those subjects with confirmed responses 
as well as for the Efficacy Evaluable population.
For subjects with best response of CR or PR, duration of response is measured from the time 
when criteria for CR/PR are first met (whichever is first recorded) until the first date at which 
progressive disease is objectively documented. For subjects with best response of SD, duration 
of SD is measured from the first dose date until the criteria for progression are met.  If 
progression is not documented prior to CC-90011 discontinuation, duration of overall response, 
and duration of SD will be censored at the date of the last adequate tumor assessment. 
Duration of response/SD based on investigators’ assessments will be summarized by descriptive 
statistics (mean, standard deviation, median, minimum and maximum) for the treated population. 
Except for medians, which will be calculated based on both observed and censored values using 
the Kaplan-Meier method, all other statistics (mean, standard deviation, minimum and 
maximum) will be calculated based on observed values only.
Progression-Free Survival (PFS) is defined as the time from the first dose of CC-90011 to the 
first occurrence of disease progression or death from any cause.  Subjects who neither progress 
nor die at a data cutoff date will be censored at the date of their last adequate tumor assessment. 
The PFS will be summarized using descriptive statistics (mean, standard deviation, median, 
minimum and maximum) for the treated population. Except for the median, which will be 
calculated based on both observed and censored values using the Kaplan-Meier method, all other 
statistics (mean, standard deviation, minimum and maximum) will be calculated based on 
observed values only. 
Overall Survival (OS) is measured as the time from the first dose of CC-90011 to death due to 
any cause and will be analyzed in a manner similar to that described for PFS.
The assessments of serum neuroendocrine markers over time in neuroendocrine subjects will be 
summarized.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
108
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
9.7.
Safety Analysis
Adverse events, including treatment-emergent adverse events (TEAEs), laboratory assessments, 
vital signs, ECG results, ECOG performance status, LVEF assessments, physical examinations, 
vital signs, exposure to study treatment, assessment of concomitant medications, and pregnancy 
testing for females of childbearing potential will be summarized for the treated population by 
dose cohort in Part A, tumor type in Part B and study period (DDI period/CC-90011 treatment 
period) in Part C and Part D.
Adverse events observed will be classified using the Medical Dictionary for Regulatory 
Activities (MedDRA), Version 18.1 or higher, system organ class (SOC) and preferred term 
(PT).  In the by-subject analysis, a subject having the same AE more than once will be counted 
only once.  All adverse events will also be summarized by SOC, PT, and NCI CTCAE grade 
(Version 4.03).  Adverse events leading to discontinuation of study treatment, those classified as
Grade 3 or 4, study drug-related AEs, and SAEs (including deaths) will be tabulated separately. 
By-subject listings of all AEs, TEAEs, SAEs (including deaths), and their attribution will be 
provided. 
Clinical laboratory results will be summarized descriptively by dose cohort (Part A) or tumor 
type (Part B), study period (Part C and Part D) and visit, which will also include a display of 
change from baseline. Shift tables demonstrating the changes (low/normal/high) from baseline to 
worst post-baseline laboratory value will be displayed in cross-tabulations by dose cohort (Part 
A). tumor type (Part B) or study period (Part C and Part D). Similar shift tables demonstrating 
the change of NCI CTCAE grades from baseline to the worst post-baseline severity grade during 
the treatment period will also be presented by dose cohort (Part A), tumor type (Part B) or study 
period (Part C and Part D) for applicable analytes. Listings of abnormal clinical laboratory data 
according to NCI CTCAE severity grades (if applicable), abnormal flags (low or high) and 
clinical significance of the latter will be provided.
Graphical displays (eg, “spaghetti” plots or box plots) will be provided for key laboratory 
analytes.
Descriptive statistics for vital signs, both observed values and changes from baseline, will be 
summarized by dose cohort (Part A), tumor type (Part B) or study period (Part C and Part D) and 
visit.  Shift tables demonstrating the changes from baseline to the worst post-baseline value will 
be displayed in cross-tabulations by dose cohort (Part A), tumor type (Part B) or study period 
(Part C and Part D). Vital sign measurements will be listed by subject and by visit. 
ECG parameters and changes from baseline will be summarized by dose cohort (Part A) or 
tumor type (Part B) and visit using descriptive statistics. Post-baseline abnormal QTc (both 
QTcF and QTcB) values will be summarized using frequency tabulations for the following 5 
categories:  

QTc > 450 msec 

QTc > 480 msec 

QTc > 500 msec 

QTc increase from baseline > 30 msec 

QTc increase from baseline > 60 msec 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
109
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Shift from baseline to worst post-baseline qualitative assessment of abnormality (ie, ‘Normal’, 
‘Abnormal, not clinically significant’, and ‘Abnormal, clinically significant’ or ‘Normal’ and 
‘Abnormal’) will be displayed in cross–tabulations by dose cohort (Part A) , tumor type (Part B)
or study period (Part C and Part D).  A listing of ECG parameters by subject, by visit will be 
provided.
9.8.
Interim Analysis
No formal interim analysis is planned. Data will be reviewed by the SRC on an on-going basis.
9.9.
Other Topics
9.9.1.
Statistical Method for Dose Escalation (Part A only)
An adaptive BLRM guided by the escalation with EWOC principle will be used to make dose 
recommendations and estimate the MTD during the escalation phase of the study (refer to 
Appendix E for additional details).
The DLT relationship in the escalation part of the study will be described by the following 
Bayesian logistic regression model:
where pj’s are DLT rates at dose, dj’s are dose levels, d*=30 mg reference dose, α is odds of 
DLT at d*.
Prior Specifications
Prior for (log(α), log(β)):
A vague bivariate normal prior for the model parameters (log(α), log(β)) is elicited based on 
prior estimates (medians) from preclinical data and wide confidence intervals for the 
probabilities of a DLT at each dose. Prior MTD is assumed to be 30 mg based on preclinical 
data. The probability of DLT for the first dose is assumed to be low. The parameters of the prior 
distributions of model parameters are selected based on the method to construct weakly 
informative prior as described in Neuenschwander et al (2015) and are provided in Table 13. 
Figure 6 illustrates the resulting prior distribution of DLT rate derived from the prior parameters
given in Table 13 .
Table 13:
Prior Parameters for Bivariate Normal Distribution of Model Parameters
Parameters
Means
Standard Deviation
Correlation
log(α),log(β)
(-0.693, 0.205)
(2, 0.75)
0
0
,0
,
log
log
1
log
*






















d
d
p
p
j
j
j
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
110
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Figure 6:
Probability of DLT According to Prior Distribution
Dose Recommendation
The provisional dose levels are: 1.25 mg, 2.5 mg, 5 mg, 10 mg, 15 mg,
22.5 mg, 30 mg, and 
37.5 mg.
It is however possible that the actual dose levels selected for the trial may be different from the 
provisional dose levels, based on emerging safety information.
After each cohort of subjects, the posterior distributions for the probabilities of a DLT rates at 
different dose levels are obtained. The results of this analysis are summarized in terms of the 
estimated probabilities that the true rate of DLT at each dose-level will have of lying in each of 
the following intervals:

[0, 0.16) under-dosing

[0.16, 0.33) targeted toxicity

[0.33, 1.00] excessive toxicity
Following the principle of escalation with EWOC, after each cohort of subjects the 
recommended dose is the one with the highest posterior probability of the DLT rate falling in the 
target interval [16%, 33%) among the doses fulfilling EWOC, ie, it is unlikely (<25% posterior 
probability) that the DLT rate at the dose falls in the excessive toxicity interval.
Note that the dose that maximizes the posterior probability of targeted toxicity is the best 
estimate of the MTD, but it may not be an admissible dose according to the overdose criterion if 
the amount of data is insufficient. If vague prior information is used for the probabilities of DLT, 
in the early stages of the study this escalation procedure will reflect a conservative strategy.
0.0
0.2
0.4
0.6
0.8
1.0
P(DLT)
Doses
1.25
5
10
15
22.5
30
37.5
2.5%
Median
97.5%
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
111
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
The dose recommended by the adaptive Bayesian logistic model may be regarded as guidance 
and information to be integrated with a clinical assessment of the toxicity profiles observed at the 
time of the analysis in determining the next dose level to be investigated.
Details of the dose escalation and determination of the MTD are provided in Section 7.2.
9.9.2.
Assessment of Pharmacokinetics
Parts A and B
Plasma PK parameters such as AUC, Cmax, Tmax, t1/2, CL/F, and Vz/F of CC-90011 will be 
calculated by the noncompartmental analysis method from the plasma concentration-time 
profiles of CC-90011. Other PK parameters may be calculated as appropriate.
Summary statistics including number of subjects (N), mean, standard deviation (SD), coefficient 
of variation (CV%), geometric mean, geometric CV%, median, minimum, and maximum will be 
provided for CC-90011 concentration by nominal time point, study day, and dose cohort.  Mean 
and individual plots of plasma concentrations will be presented in both original and semi-
logarithmic scales.  Summary statistics will also be provided for CC-90011 PK parameters by 
study day and dose cohort and be presented in tabular form.
A population PK analysis for CC-90011 may be conducted to explore the inter-individual 
variability of plasma drug exposure and the contributing factors (covariates).  The relationship 
between CC-90011 dose, plasma exposures, and selected clinical endpoints (eg., measures of 
toxicities, effectiveness, and/or biomarkers) will be explored. The population PK model, in 
combination with the knowledge on exposure-response, may be used to assist identification of 
the dosing regimen for Part B or Phase 2 studies.
Parts C and D
Plasma CC-90011 concentration will be listed and summarized descriptively (N, mean, SD, 
coefficient of variation [CV%], geometric mean, geometric CV%, minimum, median, and 
maximum) by Part and Period for both PK evaluable and DDI evaluable subjects. Individual 
plots of plasma CC-90011 concentration vs. time will be provided for all PK evaluable subjects 
and mean plots of CC-90011 plasma concentration vs. time will be provided for both PK 
evaluable and DDI evaluable subjects by Part and Period.
Plasma CC-90011 PK parameters will be calculated using noncompartmental methods. The 
following PK parameters will be estimated for CC-90011 in Parts C and D:

Cmax

Time to Cmax (Tmax)

Area under the plasma concentration-time curve (AUC) from time zero to the last
quantifiable concentration (AUC0-t)

AUC from time zero extrapolated to infinity (AUC0-∞)

AUC from time 0 to 168 hours postdose (AUC0-168)

Terminal elimination half-life (t1/2)

Apparent total plasma clearance after oral administration (CL/F)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
112
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Apparent total volume of distribution when dosed orally (Vz/F), based on the 
terminal phase
The PK parameters will be listed and summarized descriptively (N, mean, SD, coefficient of 
variation [CV%], geometric mean, geometric CV%, minimum, median, and maximum) by Part 
and Period for both PK evaluable and DDI evaluable subjects.
Statistical analyses will be conducted using DDI evaluable subjects. To compare PK parameters, 
an ANOVA model with treatment as a fixed effect and subject as a random effect will be 
performed separately for each Part on the natural log transformed Cmax and AUC. The 
geometric means along with ratios of the geometric means (expressed as a percentage) and 
associated 90% CIs will be presented for the following PK parameter comparisons.

Part C: CC-90011 plus rifampicin (test) versus CC-90011 alone (reference)

Part D: CC-90011 plus itraconazole (test) versus CC-90011 alone (reference)
For Tmax, Wilcoxon signed-rank test, Hodges-Lehmann estimate, and its 90% CI will be
calculated for the median difference between treatments.
Additionally, exploratory assessments will be conducted to (1) Identify metabolites of CC-90011 
in urine, as well as to determine the urinary excretion of CC-90011 (Period 1 of Parts C and D), 
and (2) To explore the plasma PK of metabolite CC7108272 (M1) and possibly other metabolites 
after administration of CC-90011 on D1 (Parts C and D) and on D22 (Part C) and on D18 (Part 
D). Results of all exploratory PK assessments will be reported separately from this CSR.
9.9.3.
Assessment of Pharmacodynamics
Descriptive statistics (N, mean, SD, median, min, and max) will be provided for baseline, post-
baseline values, and changes from baseline or percent change from baseline for biomarkers 
including neuroendocrine markers by dose cohort (Part A) or tumor type (Part B) and visit.  
Subjects’ biomarker results over time will be plotted.  Comparison of biomarker levels before 
and during treatment will be performed by Wilcoxon signed rank test. If sufficient and valid 
results from biomarker assays can be obtained, the relationship between percent changes in 
biomarker levels and clinical endpoints including ORR and CBR will be explored. The 
population PK model, in combination with the knowledge on exposure-response, may be used to 
assist in identification of the dosing regimen for Part B or Phase 2 studies.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
113
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
10.
ADVERSE EVENTS
10.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria in Section 10.3), regardless of etiology. Any 
worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be 
reported on the overdose CRF. (See Section 7.2.13 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported 
on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for CC-90011 overdose. 
Actual treatment should depend on the severity of the clinical situation and the judgment and 
experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 28 days after the last dose of CC-90011 as well as those SAEs made known to the 
Investigator at any time thereafter that are suspected of being related to CC-90011. For Part C 
and Part D, all AEs will be recorded by the Investigator from the time the subject signs informed 
consent until 28 days after the last dose of CC-90011, or rifampicin or itraconazole as well as 
those SAEs made known to the Investigator at any time thereafter that are suspected of being 
related to CC-90011, or to rifampicin or itraconazole. All AEs and SAEs will be recorded on the 
AE page of the CRF and in the subject’s source documents. Refer to Section 10.5 for instructions 
on how to report SAEs to Drug Safety.
Subjects will be followed for all SAEs and all AEs (SAEs and non-serious AEs) associated with 
confirmed or suspected SARS-CoV-2 infection until resolution, the condition stabilizes, the 
event is otherwise explained, the event is deemed irreversible, the participant is lost to follow-up 
(as defined in Section 6.3), or for suspected cases, until SARS-CoV-2 infection is ruled-out.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
114
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
10.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
10.2.1.
Seriousness 
An SAE is any AE occurring at any dose that:

Results in death;

Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires subject hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as subject admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);

Is a congenital anomaly/birth defect;

Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life-
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:

a standard procedure for protocol therapy administration. However, hospitalization or 
prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.

routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.

the administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.

a procedure for protocol/disease-related investigations (eg, surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling). However, hospitalization or 
prolonged hospitalization for a complication of such procedures remains a reportable 
SAE.

hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.

a procedure that is planned (ie, planned prior to start of treatment on study); must be 
documented in the source document and the CRF. Hospitalization or prolonged 
hospitalization for a complication remains a reportable SAE.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
115
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

an elective treatment of or an elective procedure for a pre-existing condition,
unrelated to the studied indication, that has not worsened from baseline. 

emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to the IP, action taken regarding the IP, and outcome.
10.2.2.
Severity/Intensity
For both AEs and SAEs, the Investigator must assess the severity/ intensity of the event. 
The severity/intensity of AEs will be graded based upon the subject’s symptoms according to the 
current active minor version of the Common Terminology Criteria for Adverse Events (CTCAE, 
Version 4.03); http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
ctc.htm#ctc_40
AEs that are not defined in the CTCAE should be evaluated for severity/intensity according to 
the following scale:

Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required

Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required

Grade 3 = Severe – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible

Grade 4 = Life-threatening – extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable

Grade 5 = Death - the event results in death]
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
116
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
10.2.3.
Causality
The Investigator must determine the relationship between the administration of the IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
a causal relationship of the adverse event to IP administration is 
unlikely or remote, or other medications, therapeutic 
interventions, or underlying conditions provide a sufficient 
explanation for the observed event.
Suspected:
there is a reasonable possibility that the administration of IP 
caused the adverse event.  ‘Reasonable possibility’ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
Causality should be assessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional 
CC-90011 that has not been manufactured or provided by Celgene, please provide the name of 
the manufacturer when reporting the event.
10.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
10.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or dose reduction of IP, as appropriate) and report if 
concomitant and/or additional treatments were given for the event. 
10.2.6.
Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE).
10.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

results in discontinuation from the study;

requires treatment, modification/ interruption of CC-90011 dose, or any other 
therapeutic intervention; or
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
117
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).
10.4.
Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject of childbearing 
potential or partner of childbearing potential of a male subject are immediately reportable events.  
The exposure of any pregnant female (eg, caregiver, pharmacist, study coordinator or monitor) to 
CC-90011 is also an immediately reportable event.
10.4.1.
Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including elevated β-hCG or positive pregnancy test in a 
female subject of childbearing potential regardless of disease state) occurring while the subject is 
on study treatment, or within 45 days of the subject’s last dose of CC-90011(or within 45 days of 
the last dose of CC-90011,within 1 week of last dose of rifampicin or within 2 months of the last 
dose of itraconazole, whichever is latest, in Part C and Part D), are considered immediately 
reportable events. Investigational product is to be discontinued immediately. The pregnancy, 
suspected pregnancy, or positive pregnancy test must be reported to Celgene Drug Safety 
immediately by email, phone or facsimile, or other appropriate method, using the Pregnancy 
Initial Report Form, or approved equivalent form.  
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling. The Investigator will 
follow the female subject until completion of the pregnancy, and must notify Celgene Drug 
Safety immediately about the outcome of the pregnancy (either normal or abnormal outcome) 
using the Pregnancy Follow-up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the CC-90011 should also be reported to Celgene Drug Safety 
by facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.  
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
118
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
10.4.2.
Male Subjects
If a female partner of a male subject taking CC-90011, rifampicin or itraconazole becomes 
pregnant, the male subject taking IP should notify the Investigator, and the pregnant female 
partner should be advised to call her healthcare provider immediately. This includes pregnancies 
occurring within 105 days of the male subject’s last dose of CC-90011 and within 1 week after 
last dose of rifampicin or itraconazole. Where applicable, the CC-90011 may need to be 
discontinued in the male subject, but may be resumed later at the discretion of the Investigator 
and Sponsor’s study physician.
10.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion requires reporting as an SAE within 24 hours of the 
Investigator’s knowledge of the event. This instruction pertains to initial SAE reports as well as 
any follow-up reports.
This requirement applies to all SAEs (regardless of relationship to CC-90011, rifampicin or 
itraconazole) that occur during the study (from the time the subject signs informed consent until 
28 days after the last dose of CC-90011, rifampicin or itraconazole, whichever is the latest) or 
any SAE made known to the Investigator at any time thereafter that are suspected of being 
related to study treatment.  Serious adverse events occurring prior to treatment (after signing the
ICF) will be captured.
The SAE is reported directly to Celgene Drug Safety by facsimile, or other appropriate method 
using the SAE Report Form or approved equivalent form. The SAE report should provide a 
detailed description of the SAE and include a concise summary of hospital records and other 
relevant documents.  If a subject died and an autopsy has been performed, results of the autopsy 
report and/or death certificate are to be sent to Celgene Drug Safety as soon as these become 
available.  Any follow-up data should be detailed in a subsequent SAE Report Form, or approved 
equivalent form, and sent to Celgene Drug Safety. Queries pertaining to SAEs will be 
communicated from Celgene Drug Safety to the site via facsimile or electronic mail.  Urgent 
queries (eg, missing causality assessment) may be handled by phone.
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant 
initial and follow-up information about the event. The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.
10.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail. The response time is expected to be no more than five (5) business 
days. Urgent queries (eg, missing causality assessment) may be handled by phone.
10.5.2.
Death Reports
Deaths due to progressive disease will not be reported as an SAE unless considered related to IP 
(if assessed as lack of efficacy by the investigator). Any sign, symptom, or manifestation of 
progressive disease that meet any of the seriousness criteria and result in death will be reported 
as individual SAEs. Any other AEs leading to death should be reported as an SAE.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
119
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
10.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to CC-90011 based on the Investigator Brochure.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
For the purpose of regulatory reporting in the EEA, Celgene Drug Safety will determine the 
expectedness of events suspected of being related to rifampicin or itraconazole, based on the 
summary of product characteristics (SmPC).
Celgene or its authorized representative shall notify the Investigator of the following 
information:

Any AE suspected of being related to the use of CC-90011 in this study or in other 
studies that is both serious and unexpected (eg, SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC (refer to Section 14.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pregnancy Report Form Completion Guidelines.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
120
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
11.
DISCONTINUATIONS
11.1.
Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product(s):

Adverse Event

Withdrawal by subject

Lack of efficacy

Physician decision

Protocol violation

Progressive disease

Death

Lost to follow-up

Other (to be specified on the CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.  In case of treatment discontinuation following an adverse event, every effort will be 
made to follow subjects for 28 days after the last dose of CC-90011.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor.  However, prior to discontinuing 
a subject, the Investigator may contact the Sponsor’s study physician and forward appropriate 
supporting documents for review and discussion.
Note: Any laboratory result, such as neutropenia, thrombocytopenia, other abnormalities, etc., 
which are felt to be clinically significant should be followed until return to baseline or Grade 1.
11.2.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Screen failure

Withdrawal by subject

Lack of efficacy

Physician decision

Protocol violation

Progressive disease

Death

Lost to follow-up
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
121
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

Other (to be specified on the CRF)
The reason for study discontinuation should be recorded in the CRF and in the source 
documents.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
122
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
12.
EMERGENCY PROCEDURES
12.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Sponsor’s study 
physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Sponsor’s study physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contacting the on-call Celgene/contract 
research organization Sponsor’s study physician, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Sponsor’s study physician(s) or Medical Monitor or designee for emergency 
calls. 
12.2.
Emergency Identification of Investigational Products
This is an open-label study; therefore, CC-90011 will be identified on the package labeling.
Subjects enrolled in this study will be issued an identification card showing the name of this 
study and an emergency contact number. This can be used by health care professionals seeking 
emergency information about a subject’s participation in the study.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
123
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
13.
REGULATORY CONSIDERATIONS
13.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative,
and Investigator abide by Good Clinical Practice (GCP), as described in International Council for
Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined 
in the Declaration of Helsinki. The study will receive approval from an IRB/EC prior to 
commencement. The Investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
13.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations. Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, 
including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
form (ICF) and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information. Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigator’s or their institution’s website) without express written 
approval from Celgene. Information proposed for posting on the Investigator’s or their 
institution’s website must be submitted to Celgene for review and approval, providing at least 5 
business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay person. The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
124
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
13.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subject’s legal representative 
prior to any study related procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subject’s entry into the study, must be maintained 
in the Investigator’s study files and a copy given to the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the treatment phase of the study when the amended protocol is 
implemented must be re-consented with the revised version of the ICF.  Only substantial 
protocol amendments will require revision of the ICF and re-consenting of subjects in active 
treatment. Once a subject has been discontinued from study drug and is undergoing follow up, 
re-consenting of subjects should be sought but if the subject declines or is unable to sign, this 
shall not constitute a deviation from protocol, especially if the amendment(s) contain no safety 
implication for the particular subject. The revised ICF signed and dated by the study subject and 
by the person consenting the study subject must be maintained in the Investigator’s study files 
and a copy given to the study subject.
13.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate individual.
13.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Sponsor’s study physician/Medical 
Monitor.  Amendments will be submitted to the IRB/EC for written approval. Written approval 
must be obtained before implementation of the amended version occurs.  The written signed 
approval from the IRB/EC should specifically reference the Investigator name, protocol number, 
study title and amendment number(s) that is applicable. Amendments that are administrative in 
nature do not require IRB/IEC approval but will be submitted to the IRB/IEC for information 
purposes.
In the event of a substantial amendment in the study, the corresponding amendment will be 
submitted to the Competent Regulatory Authority in each country and will not be implemented 
until it has been approved.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
125
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
13.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
Celgene or its authorized representative. This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a committee member. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
13.7.
Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.
13.8.
Termination of the Study
Celgene reserves the right to terminate this study prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
126
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment

GCP noncompliance

Inaccurate or incomplete data collection

Falsification of records

Failure to adhere to the study protocol
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
127
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
14.
DATA HANDLING AND RECORDKEEPING
14.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
photographs of clinical lesions; laboratory notes; memoranda; subject’s diaries or evaluation 
checklists; dispensing records; recorded data from automated instruments; copies or 
transcriptions certified after verification as being accurate copies; microfiche; x-ray film and 
reports; and records kept at the pharmacy, and the laboratories, as well as copies of CRFs or CD-
ROM.
14.2.
Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This 
data will be electronically verified through use of programmed edit checks specified by the 
clinical team.  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the 
database.  An audit trail within the system will track all changes made to the data.
14.3.
Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined 
in the clinical trial agreement. The Investigator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:

Signed ICFs for all subjects

Subject identification code list, screening log (if applicable), and enrollment log

Record of all communications between the Investigator and the IRB/EC

Composition of the IRB/EC

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s)

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures

Copies of CRFs (if paper) and of documentation of corrections for all subjects

IP accountability records

Record of any body fluids or tissue samples retained

All other source documents (subject records, hospital records, laboratory records, 
etc.)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
128
CC-90011-ST-001 Amendment 10 Final: 05 November 2021

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial)
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
Investigator or institution should take measures to prevent accidental or premature destruction of 
these documents.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
129
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
15.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative
for compliance with applicable government regulations with respect to current GCP and SOPs.
15.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are reviewed with the Investigator and the staff at a study 
initiation visit and/or at an Investigators’ Meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol, CRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  
Monitoring details describing strategy, including definition of study critical data items and 
processes (eg, risk-based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques (central, 
remote, or on-site monitoring) are provided in the monitoring plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified. Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
15.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene. Representatives of this unit will conduct audits of clinical research
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/ECs, regulatory authorities (eg, FDA, EMA, Health Canada) and 
company authorized representatives. The Investigator should make every effort to be available 
for the audits and/or inspections.  If the Investigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
15.3.
Product Quality Complaint
Issues that call into question IMP safety, purity, potency, quality and identity (e.g., evidence of 
suspected tampering of product) must be reported as soon as possible to your study Clinical Trial 
Monitor and/or Clinical Trial Manager or designee. Report an issue or concern with all BMS 
supplied IMP, NIMP or AxMP suspected to have occurred before the product was transferred to 
the responsibility of the investigational site (e.g., during manufacturing, packaging and labeling, 
storage, and/or distribution). 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
130
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
This includes suspected quality issues of components co-packaged with the drug, labelling, and 
IMP device/drug combination products, and medical devices. 
In the event of a suspected product quality issue, the immediate action to be taken by site is to 
quarantine the affected product. Do not dispose of the product unless retention presents a risk to 
personnel (e.g., cytotoxic, risk of injury from broken glass or sharps). When reporting, provide as 
much product information as possible. Suspected IMP quality issues will be investigated and a 
response will be provided back to the investigational site.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
131
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
16.
PUBLICATIONS
As described in Section 13.2, all protocol- and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications. Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review 
and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development 
programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes. Additionally, this study and its results may be 
submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations. 
Eligibility for external authorship, as well as selection of first authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
132
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
17.
REFERENCES
Adamo A, Sese B, Boue S, Castano J, Paramonov I, Barrero M, et al. LSD1 regulates the balance 
between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol.
2011;13:652–659.
Ambrosio S, Amente S, Saccà CD, Capasso M, Calogero RA, Lania L, et al. LSD1 mediates 
MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor 
NDRG1 gene. Oncotarget. 2017 Jan 17;8(3):3854-3869. 
Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV, Majello B, et al. LSD1-mediated 
demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene 
2010;29:3691-3702.
Amente S, Lania L, Barbara M. The histone LSD1 demethylase in stemness and cancer 
transcription programs. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 
2013; 1829 (10):981–986.
Barski A, Cuddapah C, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of 
histone methylations in the human genome. Cell 2007;129:823-837. 
Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key 
oncogene in B cell lymphomagenesis. Adv Immunol. 2010;105:193-210. Review.
Benson AB, Ajani JA, Catalano RB, Engkeling C, Kornblau SM, Martenson JA Jr, et al.  
Recommended guidelines for the treatment of cancer treatment-induced diarrhea.  J Clin Oncol 
2004; 22(14):2918-26.
Brambilla E, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 
2015;63-68. IARC
Cancer Research UK www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/lung-cancer/incidence#heading-Zero)
Campbell AM, Campling B, Algazy K, El-Deiry W. Clinical and Molecular Features of Small 
cell Lung Cancer. Cancer Biology & Therapy 2002;1(2):105-112.
Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European 
Neuroendocrine Tumor Society expert consensus and recommendations for best practice for 
typical and atypical pulmonary carcinoid. Ann Oncol. 2015;26:1604–1620.
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, et al. Rationally designed 
BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest. 2016 Sep 
1;126(9):3351-62.
Chen C, Ge J, Lu Q, Ping G, Yang C, Fang X. Expression of Lysine-specific demethylase 1 in 
human epithelial ovarian cancer. J Ovarian Res. 2015; 8: 28.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations 
for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin 
Lymphoma: The Lugano Classification. J. Clin Oncol. 2014;32(27):3059-68
Chi P, David Allis C, Wang GG. Covalent histone modifications –miswritten, misinterpreted and 
mis-erased in human cancers. Nat. Rev. Cancer 2010; 10(7):457-469.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
133
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine Tumors. Front Oncol. 
2016 Apr 14;6:94. eCollection 2016. Review.
Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold A 1997a Analysis of 
the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours. Clinical 
Endocrinology 47 523–528.
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, 
Orlefors H, Sigurd M. Temozolomide as monotherapy is effective in treatment of advanced 
malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986–2991.
Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) Inducers on 
Exposure of P-gp Substrates: Review of Clinical Drug–Drug Interaction Studies. Clin 
Pharmacokinet. 2020; 59(6): 699–714
European Medicines Agency (EMA) Guideline on the investigation of drug interactions 
(CPMP/EWP/560/Rev.1 Corr.2**, 21 June 2012)
European Medicines Agency (EMA) Committee for Medicinal Products for Human Use 
(CHMP) Guideline on Clinical Trials in small populations.  CHMP/EWP/83561/2005/Corr. 
London, 2006.
Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. Cancers (Basel). 
2012;4:777–798.
Flossbach L, Antoneag E, Buck M, Siebert R, Mattfeldt T, Möller P, Barth TF. BCL6 gene 
rearrangement and protein expression are associated with large cell presentation of extranodal 
marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Int J Cancer. 2011 Jul 
1;129(1):70-7. Food and Drug Administration/CDER. Guidance for industry: clinical drug 
interaction studies –cytochrome P450 enzyme- and transporter mediated drug interactions. Jan 
2020.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary 
neuroendocrine tumors. Cancer. 2008;113:5–21.
Haines RR, Barwick BG, Scharer CD, Majumder P, Randall TD, Boss JM. The Histone 
Demethylase LSD1 Regulates B Cell Proliferation and Plasmablast Differentiation. J Immunol. 
2018 Nov 1;201(9):2799-2811.
Haines RR, Scharer CD, Lobby JL, Boss JM. LSD1 Cooperates with Noncanonical NF-κB 
Signaling to Regulate Marginal Zone B Cell Development. J Immunol. 2019 Sep 6. 
Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y. The Histone Demethylase 
KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells. Cancer Cell 
2012;21:473–487.
Hatzi K, Maria Nieves CV, Cerchietti L, Melnick A. The Histone Demethylase LSD1 Acts As a 
BCL6 Corepressor In Germinal Center B Cells[abstract]. 55th ASH Meeting 2013 Abstracts:
abstract 781.
Hatzi K, Geng H, Doane AS, Meydan C, LaRiviere R, Cardenas M, et al.. Histone demethylase 
LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nat 
Immunol. 2019 Jan;20(1):86-96. 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
134
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of 
LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. 
Int. J. Cancer 2011;128:574–586.
Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. The role of histone 
demethylases in cancer. Molecular Oncology 2012;6:683-703.
Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. p53 is regulated by the 
lysine demethylase LSD1. Nature 2007;449:105-180. 
Itraconazole [Summary of Product Characteristics]. Available from: 
https://www.medicines.org.uk/emc/product/5914/smpc#gref
Jotatsu T, Yagishita S, Tajima K, Takahashi F, Mogushi K, Hidayat M, et al. LSD1/KDM1 
isoform LSD1+8a contributes to neural differentiation in small cell lung cancer. Biochem 
Biophys Rep. 2016 Dec 1;9:86-94. doi: 10.1016/j.bbrep.2016.11.015. eCollection 2017 Mar.
Jin Y, Huo B, Fu X, Hao T, Zhang Y, Guo Y, Hu X. LSD1 collaborates with EZH2 to regulate 
expression of interferon-stimulated genes. Biomed Pharmacother. 2017 Apr;88:728-737. 
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor 
coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 
predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341-11347.
Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, et al. Role of 
androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in 
localized and advanced human bladder cancer. Mol. Carcinogen. 2011;50:931–944.
Klimstra D.S. Neuroendocrine neoplasms of the pancreas. WHO Classification of Tumours of 
the Digestive System IARC 2010:322-326.
Koch LK, Zhou H, Ellinger J, Biermann K, Holler T, von Rucker A, et al. Stem cell marker 
expression in small cell lung carcinoma and developing lung tissue. Human pathology 2008; 
39(11):1597-1605.
Laga AC, Lai CY, Zhan Q, Huang SJ, Velazquez EF, Yang Q, et al. Expression of The 
Embryonic Stem Cell Transcription Factor SOX2 in Human Skin. Relevance to Melanocyte and 
Merkel Cell Biology. Am J Pathol. 2010; 176(2): 903–913.
Lencioni R, et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. 
Semin. Liver Dis. 2010;30:52-60
Llovet JM, et al. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin 
Liver Dis1999; 19:329-338.
Li Y, Wang Z, Shi H, Li H, Li L, Fang R, et al. HBXIP and LSD1 Scaffolded by lncRNA Hotair 
Mediate Transcriptional Activation by c-Myc. Cancer Res. 2016 Jan 15;76(2):293-304.
Lim S, Janzer A, Becker A, Zimmer A, Schule R,  Buettner R, Kirfel J. Lysine-specific 
demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker 
predicting aggressive biology. Carcinogenesis 2010;31(3):512-520.
Liu L, et al. Best Practices for the Use of Itraconazole as a Replacement for Ketoconazole in 
Drug–Drug Interaction Studies. J Clin Pharmacol. 2016;56(2):143-151
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
135
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Lv T, Yuan D, Miao X, et al. Over-expression of LSD1 promotes proliferation, migration and 
invasion in non-small cell lung cancer. PLoS ONE 2012;7:e35065.
Lynch, JT, Harris, WJ, and Somervaille, TC (2012). LSD1 inhibition: a therapeutic strategy in 
cancer? Expert Opin. Ther. Targets 16, 1239–1249.
Maes T, et al. Activity of highly selective LSD1 inhibitors in HCT-116 xenograft mice. Journal 
of Clinical Oncology, ASCO Annual Meeting Abstracts 2010; 28 (15): e13663.
Maes T, et al., ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment 
of Acute Leukemia. Cancer Cell 2018; 33, 1–17.  https://doi.org/10.1016/j.ccell.2018.02.002
Magerl C, Elliger J, Braunschweig T, Kremmer E, Koch LK, Holler T,  et al.  H3K4 
dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and 
gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the 
demethylase LSD1.Hum Pathol. 2010 Feb;41(2):181-189.
McDonald O, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming 
during epithelial to mesenchymal transition. Nat Struct Mol Biol. 2011;18(8): 867–874.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 
Feb 15;97(4):934-59.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. 
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. 
Mohammad HP, Smitheman C, Damat C, Johnson N, Hann C, Kruger R. A DNA 
Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer 
Cell. 2015;28(1):57-69.
Nagasaka M, Tsuzuki K, Ozeki Y, Tokugawa M, Ohoka N, Inoue Y, et al. Lysine-Specific 
Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc. Biol Pharm Bull. 
2019;42(3):481-488. doi: 10.1248/bpb.b18-00892.
Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and 
Molecular Aspects. Genes (Basel). 2017 Apr 5;8(4). 
Niebel D, et al. Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms 
Blood 2014 124:151-152.
Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic 
tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of 
Oncology 2012;23 (Supplement 7): vii124–vii130.
Oberg K, Hellman P, Ferrolla P, Papotti M. Neuroendocrine Bronchial and Thymic Tumours: 
ESMO Clinical Practice Guidelines Annals of Oncology 2012; 23 (Suppl 7): vii120-vii123.
Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am 
J Clin Oncol. 1982; Dec;5(6):649-55.
Park KS, Liang MC, Reiser D, Zamponi R, Roach R, Curtis S, et al. Characterization of the cell 
of origin for small cell lung cancer. Cell Cycle. 2011;10:2806–2815.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
136
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Patta A, Fakih M. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine 
tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res. 2011 
Mar;31(3):975-8
Peifer M, Fernandez-Cuesta, Sos M, George J, Seidel D, Kasper LH, et al. Integrative genome 
analyses identify key somatic driver mutations of small-cell lung cancer Nat. Genet. 
2012;44(10):1104–1110.
Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, et al. British Thyroid 
Association Guidelines for the Management of Thyroid Cancer. Clinical Endocrinology 
2014;81(1) Chap 17:69-75
Poirier JT, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and 
correlates with high expression of EZH2. Oncogene 2015;34:5869-5878. 
Pugh RN, et al. Transection of the oesophagus for bleeding oesophageal varices.  British Journal 
of Surgery.  1973; 60(8): 646–649.
Ray S, et al. CtBP and Associated LSD1 Are Required for Transcriptional Activation by 
NeuroD1 in Gastrointestinal Endocrine Cells. Mol Cell Biol. 2014; 34(12): 2308-2317.
Rechtman N. Neuroendocrine Tumors of the Lung. An Update. Arch Pathol Lab Med. 
2010;134:1628–1638.
Rifampicin [Summary of Product Characteristics]. Available from: 
https://www.medicines.org.uk/emc/product/8789/smpc#gref
Rindi G, et al. Nomenclature and classification of Neuroendocrine neoplasms of the digestive 
system. WHO Classification of Tumors of the Digestive Tract. WHO IARC 2010;13-14.
Rinske van Oorschot, Marten Hansen, Johanna M. Koornneef, Anna E. Marneth, Saskia M. 
Bergevoet, et al. Molecular mechanisms of bleeding disorderassociated GFI1BQ287* mutation 
and its affected pathways in megakaryocytes and platelets.  Haematologica. 2019 Jul; 104(7): 
1460–1472. 
 
Saleque S, et al. Epigenetic regulation of hematopoetic differentiation by Gfi-1 and Gfi-1b is 
mediated by the cofactors CoREST and LSD1. Mol. Cell 2007;27:562-572.
Sankar S, et al. Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional 
Activity and Impedes Ewing Sarcoma Tumor Growth. Clin Cancer Res 2014; 20:4584.
Sarvi S, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic 
and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74:1554.
Scoumane A. The lysine-specific demethylase 1 is required for cell proliferation in both p53-
dependent and -independent manners. J Biol Chem. 2007;282(21):15471-5.
Scher H, et al. Trial design and objectives for castration-resistant prostate cancer: Updated 
recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 
2016;34:1402-1418.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
137
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Schulte JH, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated 
neuroblastoma: implications for therapy. Cancer Res 2009;69:2065-71.
Sequist LV, et al. Genotypic and histologic evolution of lung cancers acquiring resistance to 
EGFR inhibitors. Sci. Transl. Med. 2011;3:75ra26.
Serce N, et al (2012). Elevated expression of LSD1 (lysine-specific demethylase 1) during 
tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin. 
Pathol.2012; 12:13.
Shi Y, et.al. Coordinated histone modifications mediated by a CtBP co-repressor complex. 
Nature 2003; 422:735–738. 10.1038/nature01550
Shi Y, et al.  Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 
2004;119:941-953.
Sholl LM, et al. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. 
Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):55-61.
Somervaille T, Salamero O, Montesinos P, Willekens C, Perez Simon JA, Pigneux A, et al. 
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Activity in Acute Leukemia of 
Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A 
(LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study [abstract]. Presented at: 
The 58th Annual Meeting of the American Society of Hematology (ASH) and Exposition. 2016 
Dec 3-6; San Diego, CA; USA: Abstract 4060.
Sprussel A, et al. Lysine-specific demethylase 1 restricts hematopoetic progenitor proliferation 
and is essential for terminal differentiation. Leukemia 2012;26:2039-2051.
Srinivas NR. Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous 
Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. 
Drugs R D. 2016;16:141-148
Stewart CA, et al. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells 
via LSD1 Inhibition. Cancer Cell 2015;28(1):4-6.
Sutherland KD, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in 
distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754–764.
Takagi S, Ishikawa Y, Mizutani A, Iwasaki S, Matsumoto S, Kamada Y, et al.LSD1 Inhibitor T-
3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain 
Proteins INSM1 and GFI1B. Cancer Res. 2017 Sep 1;77(17):4652-4662. 
Thiagalingam A, et al. RREB-1, a novel zinc finger protein, is involved in the differentiation 
response to ras in human medullary thyroid carcinomas. Mol. Cell. Biol. 1996;16:5335–5345.
Thiesen ER, et al.  Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor 
strategy for poorly differentiated endometrial carcinoma. BMC Cancer 2014;14:752.
Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 
2015;63-72. IARC
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
138
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Van Cutsem E.2013 
http://oncologypro.esmo.org/content/download/53285/983285/file/Preceptorship-NETs-
Epidemiology-clinical-presentation-NETs-Van-Cutsem.pdf
Von Pawel J, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the 
treatment of recurrent small-cell lung cancer. JCO 1999;17(2):658-667.
Wang J, et al Opposing LSD1 complexes function in developmental gene activation and 
repression programmes. Nature 2007;446, 882-887.
Wang J, et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global 
DNA methylation. Nat Genet 2009; 41: 125–129.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular 
endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of 
depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 
10;26(8):1316-23. 
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after 
"carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases 
in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. 
Yao JC, Voi M, Rouyrre N, Singh S. Everolimus for thetreatment of advanced, non-functional 
neuroendocrinetumours of the lung or gastrointestinal tract (RADIANT4):a randomised, 
placebo-controlled, phase 3 study. Lancet. 2016;387:968–977.
Yashiro T, Fulton N, Hara H, Yasuda K, Montag A, Yashiro N, Straus F, II, Ito K, Aiyoshi Y & 
Kaplan EL 1993 Comparison of mutations of ras oncogene in human pancreatic exocrine and 
endocrine tumors. Surgery 114 758–763.
Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S & Itakura M 1992 Role of p53 mutations 
in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand 
conformation polymorphism. Cancer Research 52 5061–5064.
Yu HA, et al. Analysis of tumor specimens at the time of acquired resistence to EGFR-TKI 
therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240 -2247.
Yu X, et al. SOX2 expression in the developing, adult, as well as diseased prostate. Prostate 
Cancer Prostatic Disease 2014;17(4):301-309. 
Zakowski MF, et al. EGFR mutations in small-cell lung cancers in patients who have never 
smoked. New Engl. J. Med 2006;355:213-215
Zhang Z, et al. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. 
Cell Death and Disease 2013;4:e633.
Zhao ZK, et al. Overexpression of lysine specific demethylase 1 predicts worse prognosis in 
primary hepatocellular carcinoma patients. World J Gastroenterol.  2012; 18(45): 6651-6656.
Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al.; ESMO Guidelines 
Committee. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. 
Epub 2019 Dec 4.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
139
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.
APPENDICES
18.1.
Appendix A:  Table of Abbreviations
Table 14:
Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term
Explanation
ADL
Activity of daily life
ADR
Adverse drug reaction 
AE
Adverse event
ALT
Alanine aminotransferase (SGPT)
ANC
Absolute neutrophil count
AST
Aspartate aminotransferase (SGOT)
AUC
Area under the curve
β-hCG
β-subunit of human chorionic gonadotropin
BDC
Bile duct cannulated
BM
Bone Marrow
BSA
Body surface area
BUN
Blood urea nitrogen
CBC
Complete blood count
CgA
Chromogranin A
CL
Clearance
Cmax
Maximum plasma concentration of drug
CNS
Central nervous system
CR
Complete response
CRO
Contract research organization
CRF
Case report form
CRP
Clinical Research Physician
CRS
Clinical Research Scientist
CS
Clinically Significant
CT
Computed tomography
CTCAE
Common Terminology Criteria for Adverse Events
CYP
Cytochrome P450
DCR
Disease control rate
DDI
Drug-Drug Interaction
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
140
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 14:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
DLT
Dose-limiting toxicity
DMC
Data Monitoring Committee
DOR
Duration of response
EC
Ethics Committee
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
EEA
European Economic Area
EMA
European Medicines Agency
EMZL
Extranodal Marginal Zone Lymphoma
EOT
End of treatment
FCBP
Females of childbearing potential
FDA
Food and Drug Administration
FDG
Fluorodeoxyglucose
FFPE
Formalin-Fixed, Paraffin Embedded
GCP
Good Clinical Practice
GLP
Good Laboratory Practice
GMR
Geometric Mean Ratio
HBS
Hepatitis B Surface
HDL
High Density Lipoprotein
HIV
Human immunodeficiency virus
HNSTD
Highest Non-Severely Toxic Dose
IB
Investigator’s Brochure
ICF
Informed consent form
ICH
International Council for Harmonisation
IHC
Immunohistochemistry
IND
Investigational New Drug
IP
Investigational Product
IRB
Institutional Review Board
IRT
Interactive Response Technology
IV
Intravenous
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
141
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 14:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
LDH
Lactate dehydrogenase
LSD
Lysine-Specific Demethylase
LVEF
Left ventricular ejection fraction
MedDRA
Medical Dictionary for Regulatory Activities
MRI
Magnetic resonance imaging
MTD
Maximum tolerated dose
MRP2
Multidrug resistance-associated protein 2
MUGA
Multi-gated acquisition
MZL
Marginal Zone Lymphoma
NCI
National Cancer Institute
NEC
Neuroendocrine carcinoma
NEN
Neuroendocrine neoplasia
NEPC
Neuroendocrine prostate cancer
NET
Neuroendocrine tumor
NMZL
Nodal Marginal Zone Lymphoma
NSE
Neuron specific enolase
ORR
Overall response rate
OS
Overall survival
PCR
Polymerase Chain Reaction
PCWG3
Prostate Cancer Clinical Trials Working Group 3
PD
Progressive disease
PET
Positron emission tomography
PFS
Progression-free survival
P-gp
P-glycoprotein
PK
Pharmacokinetics
PPK
Population Pharmacokinetic
PR
Partial response
Pro-GRP
Pro-gastrin-releasing peptide
PSA
Prostate-specific antigen
QW
Every week
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
142
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 14:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
RBC
Red blood cell count
RECIST
Response Evaluation Criteria in Solid Tumors
RP2D
Recommended phase 2 dose
R/R
Relapsed and/or refractory
RT-PCR
Reverse Transcription Polymerase Chain Reaction
SAE
Serious adverse event
SAP
Statistical analysis plan
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SC
Steering committee
SD 
Stable disease/Standard deviation
SGOT
Serum glutamic oxaloacetic transaminase 
SGPT
Serum glutamic pyruvic transaminase
SmPC
Summary of Product Characteristics
SMZL
Splenic Marginal Zone Lymphoma
SOP
Standard operating procedure
sqNSCLC
Squamous non-small cell lung cancer
SRC
Safety review committee
STD10
Severely Toxic Dose in 10% of the animals
SUSAR
Suspected unexpected serious adverse reaction
SYP
Synaptophysin
t1/2
Half-life
TEAE
Treatment-emergent adverse event
TK
Toxicokinetics 
UGT
UDP-glucuronyltransferases 
ULN
Upper limit of normal
USA
United States of America
USP
United States Pharmacopeia
Vss
Volume of distribution
WBC
White blood cell count
WHO
World Health Organization
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
143
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.2.
Appendix B:  RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009, New Response 
Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (Version 1.1). Please refer to 
the primary reference for further information.
Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or non-measurable.
Measurable Disease
Tumor Lesions.  Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:

10 mm by CT scan (CT scan slice thickness no greater than 5 mm)

10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)

20 mm by chest X-ray
Malignant Lymph Nodes.  To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed.
Non-measurable Disease
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes 
with ≥ 10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions considered 
truly non-measurable include: leptomeningeal disease, ascites, pleural or pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses/abdominal organomegaly identified by physical exam that is not measurable by 
reproducible imaging techniques.
Tumor Response Evaluation
Target lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. Note that pathological nodes must meet the measurable 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis ≥ 10 mm but 
< 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes:  overall 
maximum of 5) is to be recorded.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
144
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
After baseline, a value should be provided on the eCRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately 
measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.
Non-target lesions
All non-measurable lesions (or sites of disease) plus any measurable lesions over and above 
those listed as target lesions are considered non-target lesions. Measurements are not required 
but these lesions should be noted at baseline and should be followed as “present,” “absent,” or 
“unequivocal progression.”
Response Criteria
Target and non-target lesions are evaluated for response separately, and then the tumor burden as 
a whole is evaluated as the overall response.
Target Lesion Response
Target lesions will be assessed as follows:

Complete Response (CR).  Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to 
< 10 mm.

Partial Response (PR).  At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD).  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance 
of one or more new lesions is also considered progression).

Stable Disease (SD).  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
Non-target Lesion Response
Non-target lesions will be assessed as follows:

Complete Response (CR).  Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm 
short axis).

Non-CR/Non-PD.  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.

Progressive Disease (PD).  Unequivocal progression (see comments below) of 
existing non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
When the Subject Also Has Measurable Disease:  In this setting, to achieve “unequivocal 
progression” on the basis of the non-target disease, there must be an overall level of substantial 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
145
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
“increase” in the size of one or more non-target lesions is usually not sufficient to quality for 
unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare. 
When the Subject Has Only Non-measurable Disease:  This circumstance arises in some 
Phase 3 trials when it is not a criterion of study entry to have measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease 
burden. Because worsening in non-target disease cannot be easily quantified (by definition:  if all 
lesions are truly non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in “volume” (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large,” 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as “sufficient to require a change in therapy.” If “unequivocal progression” is seen, the 
subject should be considered to have had overall PD at that point. While it would be ideal to 
have objective criteria to apply to non-measurable disease, the very nature of that disease makes 
it impossible to do so: therefore, the increase must be substantial.
Overall Response
Overall response should be assessed according to Table 15 for subjects with target lesions, and 
Table 16 for subjects with only non-target lesions.
Table 15:
Time Point Response: Subjects With Target (± Non-target) Disease
Target Lesions 
Response
Non-target Lesion 
Response
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/ non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = inevaluable.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
146
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 16:
Time Point Response: Subjects With Non-target Disease Only
Nontarget Lesions Response
New Lesions
Overall Response
CR
No
CR
Non-CR/ non-PD
No
Non-CR/ non-PD
a
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NE = inevaluable.
a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is 
not advised.
Symptomatic Deterioration
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‘symptomatic deterioration’. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stopping study therapy. The objective response status of 
such subjects is to be determined by evaluation of target and non-target disease.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
147
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.3.
Appendix C:  The Lugano Classification 
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-
Hodgkin lymphoma: the Lugano Classification (Cheson, 2014) can be accessed online at: 
https://ascopubs.org/doi/10.1200/JCO.2013.54.8800
(click on “manual download for full text PDF of manuscript)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
148
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.4.
Appendix D:  Performance Status Criteria
Table 17:
Eastern Cooperative Oncology Group (ECOG) Performance Status
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  
Up and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or 
chair
5
Dead
(Oken, 1982)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
149
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.5.
Appendix E:  Characteristics of the Bayesian Logistic Regression 
Model
Introduction
An adaptive Bayesian logistic regression model (Neuenschwander, 1998) for dose escalation 
with overdose control (Babb, 1988) will be used to guide dose escalation in this study. The 
BLRM and prior specification are described in Section 9.1.  
The purpose of this appendix is to present performance metrics (operating characteristics) that 
illustrate the precision of the design in estimating the MTD under various dose-toxicity 
relationships through computer simulation. In addition, recommendations of the next dose level 
by BLRM with overdose control principle are provided under various hypothetical outcome 
scenarios in early cohorts (assuming exactly 3 evaluable subjects in each cohort for simplicity) to 
show how it facilitates on-study dose-escalation decisions.
Specifications and results of simulation study
This section presents the operating characteristics that illustrate the precision of the design in 
estimating the MTD under various assumed true dose-toxicity relationships.
Simulations are performed for the BLRM under a total of 5 scenarios of true dose-DLT
relationship (refer to Table 18 and Figure 7):
1. Dose-DLT relationship is a steep curve and MTD is reached at early dose level (SE).
2. Dose-DLT relationship is a steep curve and MTD is reached at middle dose level (SM).
3. Dose-DLT relationship is a steep curve and MTD is reached at late dose level (SL).
4. Dose-DLT relationship is a flat curve and MTD is reached at middle dose level (FM).
5. Dose-DLT relationship is a flat curve and MTD is reached at late dose level (FL).
Table 18:
P(DLT) for Five Simulated Scenarios with Numbers in Grey Indicating 
Doses with True P(DLT) within the Target Toxicity Interval [16%, 33%]
P(DLT) at Different Dose Levels (mg)
Scenario
1.25
2.5
5
10
15
22.5
30
37.5
SE
0.091
0.1699
0.2951
0.4613
0.5655
0.6642
0.7269
0.7702
SM
0.0113
0.031
0.0827
0.2022
0.317
0.4594
0.5663
0.6455
SL
0
0.0002
0.0018
0.0155
0.0522
0.1618
0.3196
0.4836
FM
0.0513
0.0867
0.1428
0.2263
0.289
0.361
0.4165
0.4611
FL
0.0009
0.0033
0.0121
0.0438
0.09
0.176
0.2694
0.3603
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
150
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Figure 7:
Dose Toxicity Curves for Simulation
Operating characteristics are reviewed to investigate overall performance of the BLRM under 
each true scenario. Table 19 summarizes the results from the simulations performed.
Table 19:
Summary Metrics of Simulation for BLRM and Comparison with 3+3
Scenario/
Method
Mean 
Number of 
Subjects
Proportion of 
subjects with 
DLT
Probability of recommending a dose with true 
P(DLT)
0.16-0.33
≥0.33
<0.16
SE, N-CRM
19.75
0.24
0.80
0.06
0.14
SE, 3+3
14.72
0.24
0.63
0.06
0.31
SM, N-CRM
22.50
0.16
0.72
0.06
0.22
SM, 3+3
20.48
0.16
0.55
0.05
0.40
SL, N-CRM
25.55
0.11
0.75
0.08
0.18
SL, 3+3
26.85
0.11
0.68
0.08
0.24
FM, N-CRM
22.24
0.17
0.48
0.08
0.44
FM, 3+3
20.38
0.18
0.37
0.10
0.52
0
10
20
30
40
0.0
0.2
0.4
0.6
0.8
Dose
P(DLT)
o
o
o
o
o
o
o
o
o o
o
o
o
o
o
o
o o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o o
o
o
o
o
o
o
SE
SM
SL
FM
FL
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
151
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 19:
Summary Metrics of Simulation for BLRM and Comparison with 3+3
(Continued)
Scenario/
Method
Mean 
Number of 
Subjects
Proportion of 
subjects with 
DLT
Probability of recommending a dose with true 
P(DLT)
0.16-0.33
≥0.33
<0.16
FL, N-CRM
25.66
0.10
0.57
0.16
0.27
FL, 3+3
26.80
0.11
0.51
0.16
0.33
Overall the BLRM model with specified prior is performing reasonably. With similar or a little 
more sample size, BLRM model can select MTD in the target range with higher probability, 
especially for scenarios 1, 2, and 4.
Hypothetical Dose Escalation Scenarios in Early Cohorts
Aside from the overall operating characteristics studied above, the design should make 
reasonable decisions during a study based on the observed toxicities. After completion of a given 
cohort, the decision to dose escalate and actual dose chosen for the subsequent cohort will 
depend on the recommendation of the BLRM per EWOC principle and medical review of 
available clinical and laboratory data.
Some scenarios to illustrate the dose escalation up to the third dose cohort are listed in Table 20
using the 2-parameter BLRM. It is assumed that each cohort has exactly 3 evaluable subjects. 
Dose escalation again follows the rule listed in Section 7.2.3.
Table 20:
Possible Scenarios Up to the Third Dosing Cohort with Three Subjects per 
Cohort
Scenario
Dose History (mg)
Number of 
DLTs/Number of 
Subjects
Next dose by
N-CRM(mg)
1
1.25
0/3
2.5
2
1.25
2.5
0/3
0/3
2.5
5
3
1.25
2.5
0/3
1/3
2.5
2.5
4
1.25
2.5
0/3
2/3
2.5
1.25
5
1.25
2.5
5
0/3
0/3
0/3
2.5
5
10
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
152
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
Table 20:
Possible Scenarios Up to the Third Dosing Cohort with Three Subjects per 
Cohort (Continued)
Scenario
Dose History (mg)
Number of 
DLTs/Number of 
Subjects
Next dose by
N-CRM(mg)
6
1.25
2.5
5
0/3
0/3
1/3
2.5
5
5
7
1.25
2.5
5
0/3
0/3
2/3
2.5
5
2.5
8
1.25
2.5
2.5
0/3
1/3
1/3
2.5
2.5
2.5
9
1.25
2.5
2.5
0/3
1/3
2/3
2.5
2.5
1.25
10
1.25
2.5
1.25
0/3
2/3
1/3
2.5
1.25
1.25
11
1.25
2.5
1.25
0/3
2/3
0/3
2.5
1.25
2.5
Again the BLRM model is performing reasonably for the hypothetical dose escalation scenarios.
Discussion
The Bayesian Logistic Regression Model enables us to incorporate the pre-clinical information, 
as well as to update the recommended dose based on all safety data in the study.
By reviewing the metrics presented in the table, it can be seen that the model is not sensitive to 
different scenarios of truth. In general, this model is conservative due to the overdose control 
criteria. In all scenarios, the probability of recommending a dose that is excessively toxic with 
true P(DLT) ≥ 33% is much smaller than that of recommending a dose with true P(DLT) 
between 16% and 33% as MTD. On-study recommendations based on the model are consistent 
with the clinical decision making process, and should be considered in conjunction with other 
available clinical information by the Celgene Clinical Trial Team and study investigators in 
deciding the dose levels to be tested in order to determine the MTD.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
153
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.6.
Appendix F:  Recommendations for Management of Treatment-
Induced Diarrhea
The following published guidelines (Benson, 2004) were modified in order to be consistent with 
the study protocol. 
Figure 8:
Recommendations for management of Treatment-Induced Diarrhea
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
154
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.7.
Appendix G:  Management of Biologic Specimens
This is an addendum to the Laboratory Manual.
Sample Handling and Storage
All blood and tissue samples collected for biomarker and genetic research as part of this 
study that are not depleted following analysis will be stored for use in research for up to 5 
years after the study is completed. With subject consent, the storage period will be extended 
to 20 years after the study is completed for use in future research to learn more about cancer 
and other diseases. Samples will be stored in a secure laboratory facility designed for long
term sample storage, with appropriate access control, monitoring and back-up systems.
Sample Coding
All biomarker and genetic research samples will be identified only by a code (subject 
identification number). These samples will not have any other personal information on them.  
The study doctor will keep the code key. The samples and the code key will be kept 
confidential and separate.  Researchers who perform tests on samples will only see the code 
and will not see any information that specifically identifies the subject.
Research on Blood & Tissue Samples
Biomarker and genetic research samples will be tested by the sponsor or by companies 
contracted by the sponsor for use in future research to learn more about cancer and other 
diseases. This includes determining if biomarkers in blood cells or tumor cells demonstrate 
that CC 90011 is biologically active.    
Reporting and Availability of Biomarker and Genetic Results
Biomarker and genetic research sample test results will not be shared with the subject, 
insurance companies nor any other third parties not involved in the sample analysis described 
above. The results will not be filed in the subject’s medical records.  Test results are for 
research purposes only and will not be used to make decisions about a subject’s routine 
medical care.
Names of subjects and identifiers will not be mentioned in publications or reports, thereby 
minimizing the possibility of psychological or social risks that could arise from knowledge of 
this biomarker and genetic information, such as risk for employability or insurability or the 
risk of discrimination.
Mechanism to Request Sample Destruction upon Withdrawal of Consent
If subjects withdraw consent to participate in the study, they may additionally request to have 
their biomarker and genetic research samples destroyed. In such cases, a subject will inform 
the study doctor that consent has been withdrawn and request to have any stored, unused 
samples destroyed. Any unused samples will then be destroyed by the sponsor.  However, if 
samples were analyzed before consent was withdrawn, then the sponsor may still use data 
already available.
If subjects agree to allow biomarker and genetic research samples to be kept 20 years for 
future research, they are also free to reverse just that decision at any time. The subject will 
inform the study doctor that permission has been withdrawn for samples to be used for future 
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
155
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
research. Any unused samples will then be destroyed by the sponsor. However, if samples 
were analyzed before consent was withdrawn, then the sponsor may still use data already 
available.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
156
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.8.
Appendix H: Child-Pugh Classification
18.8.1.
Child-Pugh Classification of Liver Failure
Subjects with a Child-Pugh A classification without hepatic encephalopathy meet this individual 
inclusion criterion for the study.
Table 21:
Child-Pugh Classification
1 point
2 points
3 points
Bilirubin (mg/dL)
< 2
2-3
>3
Albumin (g/L)
>3.5
2.8-3.5
<2.8
Prothrombin time prolonged in seconds 
(INR)
1-4 (<1.7)
4-6 (1.7-2.3)
>6 (>2.3)
Ascites
None
Slight
Moderate
Hepatic encephalopathy
None
Grade 1-2
Grade 3-4
Child A: 5-6 points; Child B: 7-9 points; Child C: ≥ 10 points
INR = international normalized ratio.
Source: Pugh, 1973.
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
157
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.9.
Appendix I: Modified RECIST (mRECIST)
mRECIST criteria (Lencioni, 2010) can be accessed online at: 
https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0030-1247132
(click on “manual download for full text PDF of manuscript)
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
CC-90011
Protocol CC-90011-ST-001
Celgene Corporation
Confidential and Proprietary
158
CC-90011-ST-001 Amendment 10 Final: 05 November 2021
18.10.
Appendix J: Prostate Cancer Clinical Trials Working Group 
(PCWG3)
Recommendations of the PCWG3 on the design and end points of clinical trials for subjects with 
progressive prostate cancer and castrate levels of testosterone (Scher, 2016) can be accessed 
online at:
http://jco.ascopubs.org/content/34/12/1402
Approved
20.0
v
Approved
1.0
v

EDMS Doc. Number: 25877016 - 20921081
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
UserName: 
Title:  
Date: Friday, 05 November 2021, 07:48 AM   Eastern Daylight Time
Meaning: Approved, no changes necessary.
 ================================================
Approved
20.0
v
Approved
1.0
v